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ABSTRACT 
 
PREDICTING THE INFLUENCE OF DRUG SOLUBILIZING AGENTS ON 
COCRYSTAL SOLUBILITY, STABILITY, AND TRANSITION POINTS 
 
by 
Maya Pandit Lipert 
 
Chair:  Naír Rodríguez-Hornedo 
 
 Pharmaceutical cocrystals have emerged as a useful strategy to improve the aqueous 
solubility of inherently poorly soluble drugs to improve their oral absorption and bioavailability.  
Aqueous cocrystal solubility can be orders of magnitude higher than that of the constituent drug.  
Chemical interactions between cocrystal constituents and dissolution media additives are 
critically important for cocrystals to achieve a wide range of solubility and stability 
(Scocrystal/Sdrug) behaviors.  In the presence of drug solubilizing agents, a cocrystal with high 
aqueous Scocrystal/Sdrug can display higher, equal, or lower solubility than the drug, depending on 
the nature and concentration of the additive.  This dissertation explores the mechanisms of 
cocrystal solubilization by solubilizing agents and the impact on cocrystal solubility, 
Scocrystal/Sdrug, and transition points. 
The objectives of this work are to (1) understand the effect of solubilization by 
physiologically relevant solubilizing agents on cocrystal solubility, solubilzation ratio 
(SRcocrystal), and Scocrystal/Sdrug (2) develop models to describe cocrystal solubility, SRcocrystal, and 
 xviii 
 
Scocrystal/Sdrug based on cocrystal dissociation and constituent ionization and micellar 
solubilization solution equilibria, (3) expand these models to consider the effect of multiple 
solubilizing agents, and (4) develop simplified models for the facile estimation of cocrystal 
transition points from commonly reported drug solubility descriptors.  
Cocrystal solubility, SRcocrystal, and Scocrystal/Sdrug, were investigated in fed state simulated 
intestinal fluid (FeSSIF) for seven cocrystals comprised of constituents with a range of ionization 
and micellar solubilization properties.  Mathematical models that predicted cocrystal solubility 
and Scocrystal/Sdrug based on cocrystal dissociation and constituent ionization and micellar 
solubilization were derived and expanded to consider two ideally mixing solubilizing agents 
(FeSSIF and Tween 80). The models were found to be in excellent agreement with the 
experimentally measured values.  SRcocrystal was found to be correlated with the log octanol-water 
distribution coefficient (log D) and models derived to predict SRcocrystal from log D.  Cocrystal 
solubility at the transition point (S*) was found to be independent of solubilizing agent and 
solely depend on drug and cocrystal aqueous solubility and models derived to predict this 
behavior.  The influence of solubilizing agents on the position of cocrystal solubility relative to 
the transition point was predicted by comparing SRdrug with S*. 
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CHAPTER 1  
INTRODUCTION 
 
The absorption of an orally administered drug depends on its permeability through the 
gut wall and its ability to dissolve in gastrointestinal fluids
1
.  Oral absorption can be described 
according to the biopharmaceutics classification system (BCS) which groups drugs based on 
their aqueous solubility and permeability
2
.  For BCS Class II drugs (poorly soluble, highly 
permeable), absorption is dissolution rate-limited, and solubility is a critical physicochemical 
property than can be altered to improve absorption
3
.  A large percentage of newly discovered 
drug candidates have inadequate solubility and consequently limited absorption and 
bioavailability after oral administration
4, 5
.  To improve the solubility and dissolution of a drug 
molecule without changing its chemical structure, and therefore pharmacological effect, a 
number of strategies can be employed.   Various solid forms can be generated such as 
polymorphs, amorphous materials, salts, and cocrystals; additionally, the solution environment 
can be modulated by changing the pH, surfactants, or complexing agents present in solution
3
. 
Cocrystals are of increasing interest to the pharmaceutical industry because of their 
ability to fine-tune the aqueous solubility of inherently insoluble drugs that are otherwise 
difficult to develop.  Cocrystals have several advantages in that (1) they apply to a large number 
of drug molecules since not all drugs are acidic or basic enough to form salts, (2) are crystalline 
in nature, giving them a stability advantage over most amorphous materials, (3) their 
stoichiometry and composition can be designed using crystal engineering principles rather than 
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empirical approaches, and (4) drug delivery can be fine-tuned because of the cocrystal sensitivity 
to molecular interactions in solution
6-8
.  
 Cocrystals are supersaturating drug delivery systems (SDDS) and one of the main 
barriers to their development is rapid conversion to the original drug due to thermodynamic 
instability
7
.  While there are numerous examples of cocrystals that exhibit enhanced aqueous 
solubility and dissolution rate compared to their drug component
9-16
, this improved dissolution 
behavior does not always result in improved bioavailability
17, 18
, which has been attributed to 
rapid conversion to parent drug in vivo
18
.  Additives such as polymers and surfactants have been 
shown to improve the dissolution behavior of cocrystals in aqueous media by inhibiting 
conversion to parent drug
11, 19, 20
.  Cocrystal solubility and stability dependence on micellar 
solubilization is established in the literature, but only confirmed for cocrystals of a nonionizable 
drug in a single surfactant
20-22
.  The influence of solution conditions such as pH and surfactant 
concentration on the solubility of a given drug is different from the influence on the solubility of 
a cocrystal of that drug
20-28
.  This difference in solution behavior underlines the need for 
informed additive selection to capture a cocrystal’s solubility advantage19, 21, 22.   In addition, 
physiologically relevant surfactants composed of bile salts and phospholipids greatly influence 
the solubility of poorly soluble drugs
29-33
; however their effect on the solubility of cocrystals of 
poorly soluble drugs remains to be established.    Knowledge of cocrystal solution behavior in 
physiologically relevant surfactants will aid in understanding cocrystal performance in vivo and 
guide additive selection to meet target solubilities in biorelevant environments.  
 The solubility and dissolution of several cocrystals have been evaluated in 
physiologically relevant solubilizing agents
18, 34
.  These preliminary studies show dissolution 
enhancement compared to parent drug, but a fundamental understanding of how the media 
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affects cocrystal solution interactions is lacking
34
.  Since cocrystal solubility dependence in the 
presence of a single micellar surfactant is profoundly different from the linear dependence of a 
drug
21, 22, 24, 26
, it is not unreasonable to assume that cocrystals may exhibit distinct behavior in 
physiologically relevant surfactants; however, this remains to be established. In addition, oral 
drug products usually contain at least one additive, if not many
35
, and solubility evaluation of 
formulated cocrystals in physiologically relevant surfactants may be more meaningful to predict 
in vivo performance.  Understanding cocrystal-additive solution interactions in these conditions 
is complicated by competing factors such as the nature of additives, diversity of associations of 
cocrystal components in solubilizing agents, and different ionization states
6
.  The ability to 
predict how cocrystal solubility and stability are influenced by formulation additives and 
biorelevant conditions would provide a useful development tool.   
 The solubility of cocrystals in aqueous solution has been described by the solubility 
product (Ksp), in addition to equilibrium constants that describe cocrystal component 
complexation (K11), ionization (Ka), and micellar solubilization (Ks), depending on the 
interactions taking place in solution
13, 21, 23, 36-41
.  Additionally, the critical stabilization 
concentration (CSC), the surfactant concentration above which cocrystal is thermodynamically 
stable and no transformation to parent drug is possible has been described
21, 22
.  Since solution 
conditions influence drug and cocrystal solubility differently
21, 23
, it essential to extend the 
cocrystal solubility model to biorelevant environments since it is unlikely cocrystals will behave 
similarly to drugs.   
 This chapter introduces cocrystals and concepts relevant to micellar solubilization in the 
context of cocrystal design, the current understanding of cocrystal solution chemistry and 
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solubility properties, and fundamentals of micellar solubilization.  This chapter will conclude 
with a statement of research objectives. 
Pharmaceutical Cocrystal Formation and Design 
A pharmaceutical cocrystal is a multicomponent crystal composed of two or more 
different molecules (one of which is a drug molecule) in a defined stoichiometric ratio which are 
solids at room temperature
9, 38, 41-43
.  Molecular recognition events lead to the supramolecular 
self-assembly of cocrystal formers to form molecular complexes in either the solid state through 
noncovalent interactions with energetically favorable geometries
42
.  Both single component and 
multicomponent (cocrystalline) solid complexes can be formed.  The noncovalent interactions 
responsible for cocrystal formation include Van der Waals forces, π-π interactions, and most 
commonly, hydrogen bonds
38, 43, 44
.  
Molecular recognition through hydrogen bonding imparts directional interactions 
between cocrystal components. Based on characterized molecular structures containing multiple 
functional groups capable of hydrogen bonding, three guidelines to predict which hydrogen bond 
interactions lead to molecular assembly have been established
45
: 
1. All acidic hydrogens will be used in hydrogen bonding in the crystal structure of a 
compound. 
2. All good acceptors will be used in hydrogen bonding if there are sufficient hydrogen 
bond donors. 
3. Hydrogen bonds will preferentially form between the best hydrogen bond donor and best 
hydrogen bond acceptor. 
Common noncovalent intermolecular interactions of specified geometries and bonding 
motifs are referred to as synthons. Supramolecular synthons are useful in the design and 
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synthesis of cocrystals of a given drug as they predict successful coformers based on structural 
properties
46
.  Examples of common hydrogen-bonded synthons are shown in Figure 1.1
38, 44
. 
 
Figure 1.1.  Common supramolecular synthons formed between carboxylic acid and amide 
groups
38
. 
Synthons are classified as homosynthons when identical functional moieties interact and as 
heterosynthons when different functional groups interact
38
.  Cocrystal structures can form 
through both hetero and homosynthons, depending on the functional groups interacting.  Using 
synthon design strategies, it is possible to generate many cocrystals of a given drug.  Selection of 
a particular cocrystal to optimize a particular property of the drug, such as solubility or 
dissolution, requires an understanding of cocrystal solution phase interactions.  
Solid form modification is an effective means to change the physicochemical properties 
of a drug substance without changing its chemical structure and therefore pharmacological 
effect.  Additionally, knowledge of the different possible solid forms of a drug is essential to 
ensure quality control and prevent unwanted solid form transformations during processing.  Once 
the thermodynamically stable polymorph has been identified, other single and multicomponent 
solid forms can be explored.  To increase solubility, single component solid forms like higher 
energy (metastable) polymorphs or amorphous phases can be utilized.  However, polymorphs 
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exist in limited chemical space and cannot be rationally designed, and amorphous phases often 
lack the required stability for solid dosage forms
38
.   
Multicomponent options include solvates, salts, and cocrystals.  Solvates are very similar 
to cocrystals, but are composed of the drug molecule and one component that is a liquid at room 
temperature, rather than two solid components.  Salts are formed through an acid-base reaction 
between components, creating an ionic interaction
47
.  Successful salt formation generally 
requires a ΔpKa of 2 or greater between the two salt components41.  Cocrystallization does not 
have this requirement, and can occur with both nonionizable and weakly ionizable drugs.  
Additionally, there are many more possible cocrystal coformers then salt counter ions, resulting 
in an increased ability to fine-tune properties of the drug molecule
6, 38
.   
Cocrystal Solubility and Stability 
The ability of cocrystals to fine-tune drug solubility arises from not only their range of 
lattice properties, but also from their solution phase interactions as a result of their diverse 
molecular properties
6
.  Understanding the effect of solution chemistry on cocrystal components 
is essential to control cocrystal solubility and stability.  Since cocrystals are composed of 
multiple components molecular associations in the solution phase are an important contribution 
to the solubility, as shown in Figure 1.2
6
.  Some of these processes include dissociation, 
complexation, ionization, and micellar solubilization.   
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Figure 1.2.  Cocrystal solution phase interactions and associated equilibria for a cocrystal RHA 
of a nonionizable drug I and weakly acidic coformer (HA) in a micellar solution
6
.   
Modeling Cocrystal Solubility 
 Cocrystal dissociation, complexation, ionization, and micellar solubilization can be 
described by the following equilibrium reactions and associated constants for a cocrystal RHAof 
a nonionizable drug R monoproic and weakly acidic coformer HA
13, 21, 23, 36, 48
: 
spK
solid aq aqRHA R +HA          (1.1) 
aK - +
aq aq aqHA A +H           (1.2) 
R
sK
aq mR +M R           (1.3) 
HA
sK
aq mHA +M HA          (1.4) 
-A
sK- -
aq mA +M A           (1.5) 
And the associated equilibrium constants are: 
The cocrystal solubility product Ksp 
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spK =[R][HA]            (1.6) 
The ionization constant Ka for the monoprotic weakly acidic coformer HA 
- +
aq aq
a
aq
[A ] [H ]
K =
[HA]
          (1.7) 
The micellar solubilization constant Ks
R 
for nonionizable drug R 
R m
s
aq
[R]
K =
[R] [M]
          (1.8) 
The micellar solubilization constants Ks
HA
, and Ks
A 
for weakly acidic coformer HA 
HA m
s
aq
[HA]
K =
[HA] [M]
          (1.9) 
-
-
A m
s -
aq
[A ]
K =
[A ] [M]
          (1.10) 
where the subscripts aq and m refer to aqueous and micellar pseudophases, respectively.  M is 
the micellar surfactant, or the total surfactant minus the critical micellar concentration (CMC). 
Activities are replaced by concentrations assuming dilute solution conditions.  Equations (1.8), 
(1.9), and (1.10) assume the partitioning of R, HA, and A
-
 into micelles is independent
21
.  [M] is 
the micellar surfactant concentration given by total surfactant concentration minus the critical 
micellar concentration (CMC).  Generally, the partitioning of the ionized coformer into micelles 
(equation (1.10)) is negligible and can be ignored
21
.  After the appropriate equilibrium reactions 
are identified for a cocrystal, they can be used to model the cocrystal solubility.  For a 1:1 
cocrystal of nonionizable drug R and weakly acidic coformer HA, the mass balances for each 
component in aqueous solution (no micellar solubilization) are
23
: 
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T aq m[R] =[R] +[R]           (1.11) 
- -
T aq m aq m[A] =[HA] +[HA] +[A ] +[A ]         (1.12) 
By combining equations (1.11), (1.12), and (1.6), and substituting appropriate equilibrium 
constants, an expression for total drug concentration as a function of total coformer concentration 
can be derived: 
sp a
T +
T
K K
[R] = 1+
[A] [H ]
           (1.13) 
Cocrystal solubility is predicted to increase with pH and decrease as coformer solution 
concentration increases, as shown in Figure 1.3
23
. 
 
Figure 1.3.  Dependence of cocrystal solubility or drug concentration [R]T, on coformer 
concentration [A]T, and pH for a 1:1 RHA cocrystal; calculated from equation (1.13) with Ksp = 
1 mM
2
 and coformer pKa  =3.0. Solubility of the drug, SR is represented by the yellow surface 
(SR = 2 mM) and cocrystal by the blue/green surface
6, 23
. 
The cocrystal and drug solubility surfaces intersect at a given pH value and solution 
concentrations of R and A.  At this point, cocrystal and drug are in equilibrium with solution at a 
particular pH, and it is regarded as a pHmax
6
.  
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 Under stoichiometric conditions, when cocrystal is in equilibrium with a solution of 
cocrystal components in stoichiometry equal to that of the cocrystal, the cocrystal solubility will 
equal the total drug or total coformer concentration.  That is, for a 1:1 cocrystal: 
RHA,T T TS =[R] =[A]            (1.14) 
By substituting Scocrystal into equation (1.13), the following equation for the solubility of a 1:1 
cocrystal with a nonionizable drug and a weakly acidic coformer can be derived: 
a
RHA,T sp
K
S K 1
[H ]
 
  
 
         (1.15) 
The cocrystal solubility-pH dependence has been derived for cocrystals of varying 
stoichiometries and ionization properties
23
. 
 When cocrystal is in the presence of a micellar surfactant, equations (1.3)-(1.5) must be 
considered 
21, 23
.  Under stoichiometric conditions, the solubility of RHA is given by: 
  a aR HA ARHA,T sp s s s
K K
S K 1 K [M] 1 K [M] K [M]
[H ] [H ]

 
 
     
 
    (1.16) 
where [M] is the micellar surfactant concentration given by total surfactant concentration minus 
the critical micellar concentration (CMC).  Equation (1.16) assumes that the micellar partitioning 
of drug and coformer is independent and can be used to describe the solubility of a 1:1 cocrystal 
RHA as a function of surfactant concentration.  It is important to note that the nonlinear cocrystal 
solubility dependence on surfactant concentration can lead to an intersection point with the drug 
solubility curve, which is called the critical solubilization concentration (CSC).  The CSC 
defines important stability regions and will be discussed in the stability region.   
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Determining the solubility of a cocrystal can be difficult if the cocrystal is more soluble 
than the drug.  In these instances, the cocrystal can undergo solution-mediated transformation to 
the less soluble drug. Equilibrium eutectic points can be used to describe the cocrystal solubility 
and stability and are described in the next section. 
The cocrystal eutectic point 
The eutectic point is a three-phase equilibrium point between two solid phases (cocrystal 
and drug or coformer) and solution
13, 48
.  At this point, two solid phases, usually cocrystal and 
drug, coexist in equilibrium with solution
6
.  The solution composition of cocrystal components 
([drug]eu and [coformer]eu) is fixed at a given temperature and pH at this equilibrium point.   The 
eutectic constant, Keu, has been introduced for racemic chiral systems and has been applied to 
describe the stability of cocrystals
6, 13, 49, 50
.  Keu is an experimentally accessible parameter for 
both stable and metastable cocrystals that has been shown to be a function of the cocrystal to 
drug solubility ratio and indicate cocrystal stability relative to the drug
48
.  It can also be used to 
estimate stoichiometric cocrystal solubility
13
.  Keu is defined as the activity ratio of coformer to 
drug at the eutectic point, and in dilute conditions, can be calculated from the total cocrystal 
component solution concentrations at the eutectic point where solid cocrystal and solid drug 
coexist in are in equilibrium with solution
6
: 
coformer,eu eu
eu
drug,eu eu
a [coformer]
K
a [drug]
           (1.17) 
To understand how Keu reflects cocrystal stability, consider the following equilibrium reactions 
and constants for 1:1 cocrystal of drug A and coformer B, neglecting any solution phase 
interactions such as ionization, complexation, and micellar solubilization: 
spK
solid soln solnAB A +B           (1.18) 
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spK =[A][B]            (1.19) 
The cocrystal solubility and eutectic constant are given by: 
eu
eu
eu
[B]
K =
[A]
            (1.20) 
cocrystal spS =K             (1.21) 
For drug component A: 
solid solnA A            (1.22) 
A TS =[A] =[A]            (1.23) 
By substituting equations (1.19), (1.21), and (1.23) into (1.20), Keu can be described as a function 
of the cocrystal to drug solubility ratio: 
sp
2
cocrystaleu A
eu
eu A drug
K
S[B] S
K = = =
[A] S S
 
  
 
         (1.24) 
This derivation for Keu is greatly simplified; Keu has been determined to depend on solvent, 
cocrystal stoichiometry, and solution interactions such as complexation, ionization, and micellar 
solubilization
22, 48
.   
 A phase solubility diagram (PSD) that describes the solubility of cocrystal AB and drug 
A can be generated by plotting equations (1.23)and (1.19)
37
.  The drug solubility curve will 
intersect the cocrystal solubility curve when drug A is less soluble than coformer B and the 
cocrystal AB
37
.  An example PSD is shown in Figure 1.4 
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Figure 1.4.  Phase solubility diagram of cocrystal AB (solid red line) and drug A (dashed blue 
line).  Btr is the coformer transition concentration, also called eutectic concentration [B]eu where 
Scocrystal = SA. Adapted from reference 36. 
The eutectic point establishes the thermodynamic stability regions I-IV of the cocrystal as shown 
in Figure 1.4.  At [B]<[B]eu, cocrystal AB is unstable in solution and can transform to less 
soluble drug A.  At [B]>[B]eu, cocrystal is stable in solution.  At the eutectic point, SA = Scc, and 
both solid drug A and solid cocrystal AB will be present in solution.    
The critical stabilization concentration (CSC) 
 The critical stabilization concentration (CSC) is the surfactant concentration at which 
cocrystal solubility is equal to drug solubility
21
.  At the CSC, solid cocrystal and drug phases are 
in equilibrium with solution; thus, it is a eutectic point by definition
6
.  As in the cases of Keu and 
pHmax described above, the CSC marks cocrystal thermodynamic stability regions in solution.  
The ability of a surfactant to stabilize a cocrystal (reduce the cocrystal to drug solubility ratio to 
achieve a critical stabilization concentration, CSC) is dependent on the differential solubilization 
of drug versus coformer.  That is, the greater the drug micellar solubilization Ks
R
 relative to that 
of the coformer, Ks
HA
, the lower the CSC value as shown in Figure 1.5
6, 21
.   
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Figure 1.5.  Differential solubilization of cocrystal components represented by the relative 
values of Ks
HA
 and Ks
R
 leads to nonlinear cocrystal solubility dependence and to intersection of 
the cocrystal and drug solubility curves at the CSC.   CSC refers to the critical stabilization 
concentration, at which both cocrystal and drug are thermodynamically stable
21
. 
In this way, the ability of a cocrystal to be stabilized by a surfactant can be judged.  As coformer 
micellar solubilization approaches that of the drug, the ability of the surfactant to stabilize the 
cocrystal by achieving a CSC is diminished
21
.  At surfactant concentrations > CSC, cocrystal is 
thermodynamically stable relative to the drug.  Below the CSC, drug is the thermodynamically 
stable solid phase.  The dependence of CSC on relevant parameters such as pH, cocrystal 
stoichiometry, cocrystal solubility, and cocrystal ionization properties has been derived and has 
important implications for cocrystal solution phase solubility and stability in the presence of 
surfactants
22, 27
.   
Additives for Solubility and Dissolution Enhancement  
Important additives to examine with regards to cocrystal solubility and dissolution 
include those that are physiologically relevant and have been used to model in vivo conditions.  
Biorelevant media to model the fasted and fed states in the GI tract is composed of bile salts 
alone or in combination with phospholipids, usually lecithin
51
.  Understanding cocrystal solution 
phase behavior in the presence of these physiologically relevant surfactants will give greater 
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understanding and aid in the prediction of cocrystal in vivo performance.  Additionally, additives 
that enhance dissolution through wetting, solubilization, or stabilization are important to enable 
high solubility cocrystals in solution
6, 11
.  Nonionic, and anionic surfactants are often used to 
solubilize or wet poorly soluble drugs
3, 40
, and understanding their impact on cocrystal solubility 
and dissolution is important to optimize these critical properties.  Since a cocrystal of a poorly 
soluble drug formulated with a formulation surfactant will also encounter physiologically 
relevant surfactants in vivo, it is also necessary to understand cocrystal solubility and stability in 
these mixed systems. 
Physiologically relevant surfactants 
Biorelevant media containing physiologically relevant surfactants were first developed 
and standardized in composition in the late 1990’s30, 52.  Since their introduction, the use of 
simulated gastric and intestinal fluids has increased tremendously as an integral part of the 
development and optimization of oral dosage forms
53
.  Updated compositions have since been 
introduced to more accurately mimic in vivo conditions
54
; however, the main components remain 
the same.  The bile salt sodium taurocholate (NaTC) is used in varying concentrations, usually in 
combination with the phospholipid lecithin, to simulate in vivo solution conditions in the fasted 
and fed states
52, 55
.  In some cases, these natural solubilizing components have been replaced with 
sodium lauryl sulfate (SLS) or Triton X synthetic surfactants, but in most cases, NaTC and 
lecithin are used
32, 52, 56
.   
Bile salts are natural surfactants present in the GI tract that have been shown to greatly 
affect the bioavailability of poorly soluble drugs in fed state conditions
31, 32, 51, 52, 55
.  It has been 
suggested that the increased bioavailability is either due to increased solubility of drugs in this 
media compared to aqueous buffer due to micellar solubilization or enhanced dissolution rate 
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due to wetting effects
32, 57
.  It has been observed that more hydrophobic drugs exhibit improved 
dissolution behavior due to micellar solubilization in bile salt/lecithin mixed micelles while more 
hydrophilic drugs exhibit improvement due to wetting phenomena
29, 33
.  Poorly soluble and 
highly permeable drugs are more susceptible to variation in dissolution medium during in vitro 
dissolution testing to be meaningfully evaluated
2, 3, 58
.  Lecithin, a naturally occurring 
phospholipid, forms mixed micelles with NaTC, resulting in an enhanced solubilization capacity 
for NaTC
51, 52, 59
.  Physiologically relevant concentrations of bile salts range between 10-30 mM 
in the fed state and 3-8 mM in the fasted state
51, 54
.  Lecithin is usually present in a 1:2.5 – 1:5 
ratio with NaTC, depending on bile output
52
.  Examples of other bile salts include sodium 
cholate, sodium glycocholate and sodium deoxycholate
40
.  
The mechanism of solubilization is different for bile salts and bile salt/lecithin mixed 
micelles compared to traditional surfactants. Due to their complex mechanism of aggregation 
where they self-associate noncritically, bile salts do not exhibit a distinct CMC
60
.  A range of 
CMC values for these systems is reported in the literature due to variation in experimental 
parameters such as ionic strength, temperature, etc
52
.  At 25°C, 0.1M NaCl, the CMC of NaTC 
was reported to drop from 4.7 to 0.25 mM with addition of lecithin in a 4:1 NaTC/lecithin ratio
30, 
52
.  NaTC/lecithin mixtures which are rich in NaTC (like most biorelevant media) first form 
small aggregates of 2-10 NaTC monomers via hydrophobic interactions
61, 62
.  These small 
“primary micelles” can then interact via hydrogen bonding to form large planar “secondary 
micelles” at higher NaTC concentration61 and are characterized by a gradual increase in 
solubilization
60, 63
.  Figure 1.6 shows the structures of bile salt micelles
61
.   
 17 
 
 
Figure 1.6.  Proposed structures of primary and secondary bile salt micelles
61
.  
The solubilization achieved by bile salts and bile salt/lecithin mixed micelles can be 
analyzed based on the narrow concentration ranges that exhibit linear solubilization of a 
particular drug
30, 55
.   Figure 1.7 shows carbamazepine solubility as a function of bile salt 
(sodium deoxycholate) concentration
63
. 
 
Figure 1.7.  Solubility of carbamazepine (mM) as a function of sodium deoxycholate 
concentration (M) at 37°C
63
.   
Solubility increases linearly with bile salt concentration in the range from 0.01 to 0.10 M, and a 
solubilization constant for carbamazepine can be calculated from the slope of the plot in this 
region.   
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Nonionic Surfactants 
Nonionic surfactants are commonly used in pharmaceutical formulations due to their 
relatively low toxicity, stability, and ability to interact favorably with other common formulation 
additives
3, 40, 62, 64
.  Polysorbate surfactants (common brand name Tween®) are used to wet, 
solubilize, stabilize drugs in oral, topical, ocular and parenteral formulations due to their ability 
to solubilize and emulsify water insoluble substances
40, 64, 65
.  Since they are well-tolerated 
physiologically, polysorbate 20 and 80 can be used up to 10% in oral and topical formulations.  
Other commonly used nonionic formulation surfactants include Myrj®, and Brij®.  Table 1.1 
shows the chemical structures of some commonly used nonionic surfactants. 
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Table 1.1.  Chemical structure, CMC, and use of common nonionic and anionic surfactants.   
Surfactant CMC (M)
a 
Type Use 
NaTC 
 
a
2.5 x 10
-5
 anionic dissolution media 
Tween 80 
 
b
1 x 10
-5
 nonionic formulation 
SLS 
 
 
c
8.2 x 10
-3
 anionic 
formulation 
dissolution media 
(a) From reference55. 
(b) From reference 66. 
(c) From reference67. 
  
Information regarding the solubilization of poorly soluble drugs by nonionic surfactants is 
widely available in the literature.   The solubilization of carbamazepine, indomethacin, and 
piroxicam has been studied in polysorbates and Brij, and Myrj surfactants
68-75
.  In addition, the 
effect of polysorbate 80, Myrj 52, and Brij 99 on the solubility and stability of IND-SAC and 
CBZ-SAC has been investigated in our laboratory
21, 76
.  Results indicate that IND-SAC is 
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stabilized to a greater extent than CBZ-SAC in these surfactants, and that a critical stabilization 
constant (CSC) exists for IND-SAC in these surfactants.   
Relationships between hydrophobicity and micellar solubilization  
 The micellar partitioning of several drugs in different types of surfactants is observed to 
increase with the hydrophobicity (as determined by octanol-water partition coefficient, log P) of 
the drug
55, 77, 78
.  The log micellar equilibrium partition coefficient (log KM
N
) is observed to 
increase linearly with the log P of the drug for several drugs including barbiturates, steroids, and 
benzoic acid derivatives for polysorbate (Tween®) 80 as shown in Figure 1.8
77
.   
 
 
Figure 1.8.  Log Polysorbate 80 molar micelle–water partition coefficient (log KM
N
) versus log P 
of several drugs
77
. 
In this example, KM
N
 is equivalent to Ks as defined in equation 10.  Based on this data set, 
equation (1.25) can be used to calculate the Ks in units of M
-1
 of a drug in polysorbate 80 based 
on its logP
77
: 
 slogK = 0.9201 log P + 0.0690          (1.25) 
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Linear relationships between the solubilization of drugs in the bile salt sodium 
taurocholate (NaTC), and in bile salt/phospholipid mixed micelles (NaTC/lecithin) and their log 
P have also been observed
55, 78
.  In NaTC, a linear relationship was established between the log P 
and the log solubilization ratio (log SR) of nonionizable nonsteroidal and steroidal drugs, shown 
in Figure 1.9
55
.  
 
Figure 1.9.  Log SR in aqueous NaTC as a function of log P for 6 steroidal and 6 non-steroidal 
compounds
55
. 
SR is defined as: 
bile salt
aqueous
SC
SR = 
SC
          (1.26) 
where SCbile salt  is the solubilization capacity of the bile salt for drug and SCaqueous the 
solubilization capacity of water for the drug
55
.  SC is defined as the number of moles of 
solubilizate per mole of micellized surfactant (in case of bile salt) or per mole of water 
(aqueous).  Based on the definition of the solubilization capacities
40, 55
, SR can be related to Ks 
(in units of M
-1
): 
-2
sK = SR(1.8 x10 )           (1.27) 
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The relationship between hydrophobicity and SR of several nonionizable and ionizable 
drugs in the biorelevant media FaSSIF and FeSSIF which contain NaTC/lecithin mixed micelles 
was recently investigated
78
.  In this study, SR was defined as: 
biorelevant media
aqueous buffer
SC
SR=
SC
          (1.28) 
where biorelevant media was either FeSSIF or FaSSIF and aqueous buffer was at the pH of the 
media (6.5 for FaSSIF, 5.0 for FeSSIF).  The log SR was plotted against log P, as shown in 
Figure 1.10, and a weak linear correlation was observed with R
2
 = 0.32
78
.   
 
Figure 1.10.  The solubilization capacity (SR) versus log Poct of FaSSIF (●) and FeSSIF (○) for a 
data set of nonionizable and ionizable drugs; an R
2
 of 0.32 was obtained
78
. 
This weak correlation was expected, as the majority of compounds in the sample set carry a net 
charge at the pHs of FaSSIF (pH=6.5) and FeSSIF (pH=5.0)
78
.  When the log P was exchanged 
for log DpH 6.5 for FaSSIF and log DpH 5.0 for FeSSIF, a stronger linear relationship was observed 
(R
2
 = 0.74), as shown in Figure 1.11.   
 23 
 
   
Figure 1.11.  The solubilization capacity (SR) versus log Doct of FaSSIF (●) and FeSSIF (○) for 
a data set of nonionizable and ionizable drugs; an R
2
 of 0.74 was obtained
78
. 
Since log D (distribution coefficient) values give apparent log P (partition coefficient) values at a 
given pH, they account for both ionized and unionized species in aqueous solution
78
.  This type 
of relationship can be used to investigate whether the differential solubilization of cocrystal 
components can be explained by hydrophobicity differences (either log P for nonionizable 
components, or log D for ionizable components).   
Effect of Temperature, pH and Ionic Strength on Micellar Solubilization 
Micellar solubilization is affected by temperature, pH and ionic strength
62
; therefore, the 
equilibrium solubilization constants (Ks) will vary with these parameters as well.  For nonionic 
surfactants, the extent of solubilization increases with temperature due to the changes in the 
aqueous solubility properties of the solubilizate and changes in the properties of the micelles
62
.  
This trend has been verified for solubilization of poorly soluble drugs by polysorbate 80
79
.  The 
micelle size of nonionic surfactants has been observed to increase and the CMC has been 
reported to decrease with increasing temperature resulting in an overall increase in micellar 
solubilization
3, 40, 62, 80
.  In contrast, ionic surfactants often show reduced solubilization with 
temperature increase
3, 40
.  The CMCs of the ionic surfactants sodium lauryl sulfate (SLS) and 
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cetroimondium bromide (CTAB) have been observed to both increase and decrease slightly with 
temperature
3, 40
.  For SLS, the CMC initially decreases as temperature increases due to 
dehydration of monomers, followed by a sharp increase in CMC due to disruption of water 
around the hydrophobic groups, which opposes micellization
62
.  In addition, it is not uncommon 
for both nonionic and ionic micelles to go from spherically shaped to more asymmetrical at 
higher temperatures and for the size distribution of micelles to become more polydisperse
62
.  The 
CMC of the bile salts sodium taurocholate and sodium taurodeoxycholate are observed to 
increase with increasing temperature above 40°C with little change at lower temperatures
40
. 
The effect of pH on the micellar solubilization of a nonionic surfactant depends solely on 
the ionization properties of the solubilizate
3, 62
.  Unionized solubilizates are expected to partition 
into micelles more favorably than ionized solubilizates
3, 40
.  The effect of pH on the micellar 
solubilization by an ionic surfactant will depend on the pKa of the surfactant and the ionization 
properties of the solubilizate
3, 40
.  As the pH decreases towards the pKa of an ionic surfactant, it 
becomes less soluble resulting in a lowering of its CMC
40
.  At low pH, bile acids are precipitated 
from solution, initially being incorporated or solubilized in existing micelles
62
.  The pH at which 
precipitation/saturation occurs is generally one pH unit higher than the pKa of the bile acid (pKa 
of NaTC = 1.84)
62
. 
Strong electrolytes have been observed to decrease in the CMC of both nonionic and 
ionic surfactants
3, 40, 62
.   For nonionic surfactants, this leads to increased solubilization capacity
3, 
40
.  However, for ionic surfactants, at concentrations in great excess of the CMC, this is not the 
case
62
.  The location of solubilizate in the micelle is important factor in determining the effect of 
electrolyte on solubilization by ionic surfactants.  Addition of electrolyte to an ionic surfactant 
decreases the repulsion between polar head groups, stabilizing the micelle and allowing for 
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denser packing of the surfactant monomers, increasing micelle size
40, 62
.  Addition of a strong 
electrolyte can also influence micelle morphology by changing spherical micelles to more 
asymmetrical forms
62
.  SLS micelles are observed to change from spherical to spherocylindrical 
(rods) with added NaCl
62
.  
Modeling Solubilization in Mixed Surfactants 
 Surfactant mixtures are commonly encountered in pharmaceutical applications
35
.  For 
poorly soluble oral drugs, several formulation surfactants are often used to improve solubility 
and dissolution behavior
3
.  Additionally, formulated oral drugs encounter physiological 
surfactants, such bile salt/lecithin mixed micelles in vivo.  In order to better predict and optimize 
cocrystal in vivo performance, an understanding of cocrystal solubility and stability in the 
presence of physiologically relevant surfactants and formulation surfactants is necessary.  These 
mixed surfactant systems can be theoretically modeled for two cases
81
.  In one case, the two 
surfactants are assumed to either act independently or interact to form micelles identical to those 
of the constituent surfactants; in the other case, the two surfactants interact to some extent to 
form mixed micelles
81
. 
Drug Solubilization in Ideal Surfactant Mixtures 
 If micelle formation is ideal in a binary surfactant mixture, the two surfactants are 
assumed to either form micelles independently of each other 
35, 81
, or form mixed micelles 
identical to those of the constituent surfactants.  In this simplified case of non-interacting 
surfactants, the CMC, Ks, or other relevant property of the mixture can be determined from the 
properties of the pure surfactants comprising the mixture and knowledge of the mixture 
composition
35
.  A similar approach has been used to calculate the hydrophile-lipophile balance 
(HLB) numbers of mixed surfactant systems in emulsion literature
62
.  With regards to 
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solubilization, ideal interaction means that the environment of the solubilizate (incorporation site 
in the micelle) is identical among the mixed surfactants (either a mixture of pure micelles or 
mixed micelles) and the pure micelles of the constituent surfactants.  Clearly, this is an ideal case 
that may not apply to many real-life scenarios.  Binary mixtures of structurally similar nonionic 
surfactants can approach this behavior; however, in most cases, there is some degree of 
nonideality
82
.    The equilibrium partition coefficient of a solubilizate in an ideal mixture of A 
and B can be modeled as: 
AB A B
s A s B slnK =X lnK +X lnK           (1.29) 
where Ks
AB
 is the partition coefficient of the mixture, Ks
A
 and Ks
B
 are the partition coefficients of 
the pure surfactants A and B, and XA and XB are the mole fraction of A and B present in the 
mixture
81
.  Equation (1.29) ignores nonideal surfactant-surfactant and surfactant-solubilizate 
interactions
35, 81, 83, 84
.  While equation 44 for nonsynergistic solubilization represents an ideal 
case, it can still be applied to cocrystal systems as a simplified situation from which to start 
modeling nonideal mixed surfactant systems. 
Mixtures of the anionic surfactant sodium lauryl sulfate (SLS) and the bile salt sodium 
taurodeoxycholate (NaTDC) have been studied assuming ideal mixing.  The CMC of the ideal 
mixture was calculated according to
85, 86
: 
SLS NaTDC
mix,ideal SLS NaTDC
X X1
= +
CMC CMC CMC
         (1.30) 
where XSLS and XNaTDC are the mole fraction of SLS and NaTDC in the mixture.  Experimentally 
measured CMCmix values at for compositions ranging from 1:9 to 1:1 SLS/NaTDC were greater 
than the CMCmix, ideal while compositions ranging from 2:1 to 4:1 SLS/NaTDC were less than the 
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calculated CMCmix, ideal
85
.  This was attributed to a noncompatibility of the bile salt and SLS with 
regard to charge interaction, head group type, and structure of hydrophobic moieties below 50 
mol % SLS
85
.  While the authors were not able to quantitatively predict the CMC of the mixture 
due to nonidealities, the ideal calculations did allow them to draw conclusions about the nature 
of bile salt-anionic surfactant interactions.   
Statement of dissertation research 
The purpose of this dissertation is to explore the mechanisms of cocrystal solubilization 
by solubilizing agents and their impact on cocrystal solubility, Scocrystal/Sdrug, and transition 
points. Cocrystals have been shown to profoundly increase aqueous solubility of poorly soluble 
drugs. However, there remains a significant lack of understanding of the factors that influence 
the solution behavior of cocrystals such as differential solubilization of cocrystal components by 
physiologically relevant and synthetic formulation solubilizing agents. There is a critical need to 
develop mechanism-based strategies to understand and predict cocrystal solution behavior in 
these environments to guide cocrystal development leading to optimized oral delivery.  The 
objective of this work is to develop a theoretical framework that explains cocrystal solution 
behavior in the presence of drug solubilizing agents in terms of experimentally accessible 
thermodynamic parameters.  The following chapters model and explain cocrystal solubility, 
solubilization ratio, and thermodynamic stability by considering appropriate solution phase 
equilibria. 
Chapter 2 investigates the mechanisms of cocrystal solubilization in the presence of 
physiologically relevant surfactants.  Previous work has shown the influence of synthetic 
surfactants on cocrystal solubility in nonionizing conditions, and mechanism based models have 
been derived to predict this behavior.  In physiological environments, drugs are often in ionizing 
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conditions and in solution with physiologically relevant surfactants, such as bile salts and 
phospholipid mixed micelles.  Mathematical models that predict cocrystal solubility and 
cocrystal solubilization ratio (SRcocrystal) are derived based on solution equilibria that consider 
cocrystal dissociation and constituent ionization and micellar solubilization.  SRcocrystal is shown 
to be orders of magnitude less than SRdrug when the drug constituent is preferentially solubilized. 
This chapter discusses and challenges the model’s predictions of SRcocrystal and cocrystal 
solubility with a series of seven cocrystals of diverse properties in fed state simulated intestinal 
fluid (FeSSIF).  Predicted the SRcocrystal and solubility values are in excellent agreement with the 
predictions.   
Chapter 3 investigates the impact of preferential solubilization of drug constituents on 
Scocrystal/Sdrug in the presence of physiologically relevant surfactants.  The objective of this 
chapter is to study the reduction in Scocrystal/Sdrug in physiologically relevant surfactants due to 
preferential solubilization and assess the impact on supersaturation during dissolution in this 
media.  Mechanism-based mathematical models to predict Scocrystal/Sdrug are in good agreement 
with the experimentally measured Scocrsytal/Sdrug values for a diverse series of cocrystals in 
FeSSIF and blank aqueous buffer.  Cocrystals are demonstrated to exhibit significantly lower 
Scocrystal/Sdrug in the solubilizing agent compared to aqueous buffer due to preferential 
solubilization of the drug constituent, with cocrystals of more hydrophobic and highly 
solubilized drugs exhibiting the largest decreases in Scocrystal/Sdrug.  The decreased Scocrystal/Sdrug 
results in sustained supersaturated drug concentrations and slower transformation to drug during 
cocrystal dissolution in physiologically relevant surfactants compared to aqueous buffer. 
Chapter 4 develops models that describe the relationship between log SRcocrystal and log 
SRdrug in the presence of drug solubilizing agents for the purpose of comparing the correlation 
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between log SR and drug hydrophobicity for drugs and cocrystals were derived.  The octanol-
water distribution coefficient (log D) is found to be a good predictor of log SR for drug and 
cocrystals.  The log SRcocrystal is shown to exhibit a weaker dependence on drug log D compared 
to log SRdrug, which is predicted from the derived models.  Log SRcocrystal can be calculated 
simply from knowledge of drug log D if a robust log SRdrug-log D linear regression correlation is 
calculated from experimentally measured SRdrug values.  These models are valuable since SRdrug 
and log P and/or log D are commonly measured and reported drug properties.   
Chapter 5 investigates cocrystal soluiblization in the presence of multiple drug 
solubilizing agents.  This chapter expands on the theoretical framework developed in Chapter 2 
to consider cocrystal solubilization in the presence of two ideally mixing surfactants, where the 
solubilization contributions of the surfactants are assumed to be additive.  Additional 
mathematical equations that predict cocrystal solubility and Scocrystal/Sdrug in two surfactants based 
on cocrystal dissociation and constituent ionization and micellar solubilization are derived for the 
first time.  The solubility and Scocrystal/Sdrug in the presence of FeSSIF and Tween 80 of two 
cocrystals of danazol (DNZ) was quantitatively predicted from relevant equilibrium constants 
based on the presented models.  Preferential solubilization of DNZ is shown to result in a 
dramatic decrease in Scocrystal/Sdrug as Tween 80 concentration increases, but this effect is 
dampened in the presence of FeSSIF, particularly at low Tween 80 concentrations.   
Chapter 6 brings together concepts that are relevant to the solubilization and 
thermodynamic stability in the presence of drug solubilizing agents. Simple equations are 
derived that allow for the facile calculation of SRcocrystal and transition point solubility.  Analysis 
of 10 cocrystals in 6 different solubilizing agents shows that SRcocrystal is quantitatively predicted 
from knowledge of SRdrug.   Drug solubilizing agents are shown to induce cocrystal transition 
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points, where drug and cocrystal solubilities are equal and above which the cocrystal solubility 
advantage over drug is eliminated.   This chapter demonstrates for the first time that cocrystal 
solubility at the transition point can be predicted from the aqueous solubilities of drug and 
cocrystal and is independent of the nature and concentration of the solubilizing agent.  Based on 
the derived models, the concept of a critical transition point solubility S* is developed, where 
drug and cocrystal have equal solubilities in the presence of a solubilizing agent.  Predicted S* 
values are in good agreement with experimentally determined values for cocrystals of 
carbamazepine (CBZ).  Simple equations that relate the cocrystal Scocrystal/Sdrug in aqueous 
solution to SRdrug are derived to predict a cocrystal’s position on a phase diagram relative to its 
transition point.  Predicted transition points are shown to be in good agreement with 
experimentally measured values for cocrystals of pterostilbene (PTB) and DNZ.   
The conclusions of this dissertation and future directions of this research are discussed in 
Chapter 7.  Several of these chapters are currently in preparation for submission for publication.  
Chapter 2 is a manuscript currently under review in the Journal of Pharmaceutical Sciences 
2015.  Chapter 6 is a manuscript currently under review in Molecular Pharmaceutics 2015. 
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CHAPTER 2  
QUANTITATIVE PREDICTION OF COCRYSTAL SOLUBILIZATION BY 
BIORELEVANT MEDIA  
Equation Chapter (Next) Section 1 
Introduction 
Pharmaceutical cocrystals have emerged as a useful strategy to improve the aqueous 
solubility of inherently poorly soluble drugs to improve their oral absorption and bioavailability
1-
6
.  Cocrystal solubility can be orders of magnitude higher than that of the constituent drug in 
aqueous solutions.  In the presence of a solubilizing agent, however, a cocrystal can display 
higher, equal, or lower solubility than the constituent drug, depending on the concentration of the 
additive
7-9
.  The solubility advantage of several carbamazepine cocrystals in buffer was 
eliminated by the presence of sodium lauryl sulfate (SLS)
7-9
. SLS concentrations of 0.5% and 1 
% induced a turning point in the cocrystal solubility enhancement over drug for CBZ-SLC (pH 
3.0) and CBZ-SAC (pH 2.2), respectively.  These cocrystals were 2.5 and 4.5 times more soluble 
than the stable form of carbamazepine (dihydrate) under the aqueous conditions studied and low 
levels of surfactants reduced the cocrystal solubility enhancement to zero (Scocrystal = Sdrug) and/or 
to negative values (Scocrystal < Sdrug)
7, 8
.    
The underlying mechanism for this behavior is the preferential solubilization of the drug 
constituent over the coformer
7-9
.  Generally, coformers are much more hydrophilic than the 
constituent drugs and therefore preferential drug solubilization is often observed with 
solubilizing agents in aqueous media
7-11
.   This behavior leads to a nonlinear dependence of 
  37 
cocrystal solubilization on solubilizing agent concentration.  The characteristic behavior for 1:1 
cocrystal and its constituent drug is illustrated in Figure 2.1.    
 
Figure 2.1.  Transition point (S* and CSC) for a 1:1 cocrystal (
_____
) and its constituent drug 
(
_____
) in the presence of a solubilizing agent.  The curves represent the theoretical cocrystal and 
drug solubility dependence on solubilizing agent concentration
7
. S* = (Scocrystal,aq)
2
/(Sdrug,aq). 
Cocrystals have a square-root dependence on solubilizing agent concentration, whereas the drug 
has a linear dependence.  The cocrystal solubility can therefore reach a point at which it is equal 
to the drug solubility, and above which the cocrystal solubility is lower than the drug solubility.  
The cocrystal transition point is described by a solubilizing agent concentration (CSC, or critical 
stabilization concentration) and a solubility at which both drug and cocrystal are in equilibrium 
(S*)
12
.    Not knowing such behavior will lead to variability in cocrystal performance and 
associated risks for cocrystal selection and formulation. 
Cocrystal solubility is therefore more than just "one number" that describes how soluble 
the cocrystal is compared to the constituent drug.   There is a multi-dimensional set of variables 
and solution conditions that all work in concert to change/tune cocrystal solubility and thus its 
performance.   Solubilizing agents and pH, for instance, can impart order of magnitude changes 
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to cocrystal solubility and its relationship to parent drug solubility.  The central hypothesis of the 
research presented here is that physiological surfactants such as those encountered in intestinal 
fluids will solubilize cocrystals to a lesser extent than drugs when the drug (not the coformer) is 
preferentially solubilized in biorelevant media.    This has huge implications as cocrystals may 
mitigate food effects and could in concert with formulation additives become less soluble than 
the drug. 
Mechanism-based models that describe cocrystal solubility dependence on solubilizing 
agent have been established in the literature, but only confirmed for cocrystals of carbamazepine 
and indomethacin in synthetic surfactants
7-11
.  These models consider cocrystal dissociation, 
cocrystal constituent ionization, and constituent solubilization by solubilizing agents. 
Physiologically relevant surfactants composed of bile salts and phospholipids have been shown 
to greatly influence the solubility and bioavailability of poorly soluble drugs
13-17
.  Administration 
of danazol with a lipid-rich meal results in a four-fold increase in absolute bioavailability due to 
increased solubilization and absorption in the presence of high concentrations of bile salts
18, 19
.  
The effect of physiologically relevant surfactants on the solubility of cocrystals of poorly soluble 
drugs remains to be established. While there are examples of cocrystal solubility and dissolution 
studies in biorelevant media containing physiologically relevant surfactants to simulate in vivo 
conditions
5, 20
, relationships between observed results and solution phase interactions of cocrystal 
constituents have not been published.   
The complexity of cocrystal interactions with solubilizing agents has been documented in 
the literature.  For the case of a sorbic acid cocrystal of the weakly basic drug AMG 517, the 
cocrystal was discovered when it precipitated in a suspending vehicle which contained a 
relatively high concentration (10% w/v) of Pluronic F108, a nonionic surfactant
5
.  However, a 
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dissolution study in fasted simulated intestinal fluid (FaSSIF) containing physiologically relevant 
mixed micelles of sodium taurocholate and lecithin showed that the cocrystal achieved 10-fold 
higher drug concentrations after 1 hour relative to the crystalline drug
5
.  The authors noted the 
contradictory nature of observing lower cocrystal solubility relative to the drug leading to its 
precipitation in the Pluronic F108 surfactant, but observing improved solubility and dissolution 
characteristics relative to the drug in FaSSIF.  An understanding of the specific interactions of 
cocrystals with physiologically relevant surfactants would allow for the prediction of cocrystal 
solubility in the presence of these surfactants and aid in-vitro evaluation and formulation.   
The aim of this work is to understand the mechanisms of cocrystal solubilization in 
biorelevant media and derive models to predict this behavior.  The solubilities of seven 
cocrystals comprised of hydrophobic drugs, several of which are reported to exhibit food 
effects
18, 19, 21
 were measured in fed state simulated intestinal fluid (FeSSIF) and pH 5 acetate 
buffer.  FeSSIF was chosen due to its relatively high concentration of sodium taurocholate 
(NaTC) and the phosopholipid lecithin which are known to form mixed micelles in solution and 
significantly solubilize poorly soluble drugs
17
. The cocrystals studied include: 1:1 
carbamazepine-saccharin (CBZ-SAC), 1:1 carbamazepine-salicylic acid (CBZ-SLC), 2:1 
carbamazepine 4-aminobenzoic acid hydrate, (CBZ-4ABA-HYD), 1:1 piroxicam-saccharin 
(PXC-SAC), 1:1 indomethacin-saccharin (IND-SAC), 1:1 danazol-hydroxybenzoic acid (DNZ-
HBA), and 1:1 danazol-vanillin (DNZ-VAN).  The work with the CBZ and IND cocrystals has 
been previously published
10
.  The selected cocrystals include both 1:1 and 2:1 cocrystal 
stoichiometries and cover a range of ionization behaviors for both drug and coformers.  PXC is a 
zwitterionic drug with pKa values of 1.86 and 5.46
22
, and IND is a monoprotic weakly acidic 
drug with a pKa of 4.2
23
.  SAC is a monoprotic weak acid with pKa values reported between 1.6-
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2.2
24, 25
, SLC is a monoprotic weak acid with a reported pKa value of 3.0
24
, 4ABA is amphoteric 
with pKa values 2.6 and 4.8
26
, HBA is a monoprotic weak acid with a reported pKa value of 
4.48
27
 and VAN is a monoprotic weak acid with a pKa of 7.4
28
.   
Theoretical 
Estimation of cocrystal solubilization ratio from drug solubilization ratio 
The relationship between cocrystal and drug solubilization ratios (SRcocrystal) and (SRdrug) 
has been previously described
7, 29
.  SRcocrystal in a drug solubilizing agent such as a surfactant, 
complexing agent, or lipid can be estimated once SRdrug is known under the same conditions 
(solubilizing agent concentration, pH, and temperature).  The general form of the equation for a 
cocrystal with stoichiometry AxBy, where A and B are the cocrystal constituents, drug and 
coformer respectively; and x and y are the stoichiometric coefficients or molar ratios, is
7
 
 
x
x+y
cocrystal drugSR = SR          (2.1) 
where 
T
aq
S
SR=
S
 
  
 
            (2.2)  
for either cocrystal or drug.  ST is defined as the sum of the concentrations of all species 
dissolved (ST = Saq + Ss).  Saq represents the cocrystal aqueous solubility at a particular pH in the 
absence of solubilizing agent (Saq = Snonionized,aq + Sionized,aq) and is the sum of the nonionized and 
ionized contributions to the aqueous solubility.  Ss represents the cocrystal solubilized by 
solubilizing agents (Ss = Snonionized,s + Sionized,s) and contributions from the ionized species as 
appropriate.   
Equation (2.1) allows for the facile estimation of SRcocrystal in a particular solubilizing 
agent at a specific pH for a cocrystal of a given drug.  From the general form of the relationship 
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between SRcocrystal and SRdrug in equation (2.1), the following equations can be derived for 
cocrystals of 1:1 and 2:1 stoichiometry (systems studied in this work): 
For a 1:1 cocrystal: 
cocrystal drugSR = SR           (2.3) 
For 2:1 cocrystal: 
2
3
cocrystal drugSR = SR           (2.4) 
These equations assume that coformer solubilization by solubilizing agents is negligible, 
and that drug solubilization is not affected by the presence of coformer.  The assumption that 
coformer solubilization is negligible is often justified as cocrystals are generally composed of 
poorly water-soluble, hydrophobic drugs and soluble, hydrophilic coformers. Coformers, 
therefore, interact to a far lesser extent with solubilizing agents than the drug constituents.  
The above relationships are derived from the full solubility equations for drug and 
cocrystal in solubilizing agents assuming that Ks
coformer
 = 0 and that the pH of the solubilizing 
agent and buffer for both cocrystal and drug are equal
12
. For the first case considered here, of a 
1:1 cocrystal of a nonionizable drug and an ionizable (monoprotic) acidic coformer, the cocrystal 
solubility in a solubilizing agent is  
  drug pH pKa,coformer coformercocrystal,T sp s sS K 1 K [M] 1 10 K [M]        (2.5) 
Ksp is the cocrystal solubility product, Ks stands for solubilization constants of cocrystal 
constituents, and [M] is solubilizing agent concentration.  For the case of a micellar surfactant, 
[M] is the total surfactant concentration minus the critical micellar concentration (CMC).  Ka 
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represents the dissociation constant of a monoprotic acidic coformer.   When the solubilizing 
agent enhances drug solubility and not coformer solubility, (Ks
coformer
 = 0), the cocrystal total 
solubility equation becomes 
  drug pH pKa,coformercocrystal,T sp sS K 1 K [M] 1 10          (2.6) 
The above equation can also be expressed in terms of cocrystal and drug aqueous solubilities, 
and drug total solubility, Sdrug,T by considering that  
 pH pKa,coformercocrystal,aq spS K 1 10           (2.7) 
and that  
 drugT s
aq drug
S
= 1+K [M]
S
 
  
 
         (2.8)  
to yield the relationship between cocrystal solubilization ratio and drug solubilization ratio 
presented in equation (2.3).  Equation (2.4) for 2:1 cocrystals is similarly derived
7
 from the 
equation that describes cocrystal total solubility. 
Cocrystal and drug solubilities have different dependence on solubilizing agent 
concentration:  (1:1) cocrystals have a square-root dependence whereas drugs have a linear 
dependence on solubilizing agent concentration. Cocrystal solubility measurements will not be 
the same in buffer alone and in the presence of drug solubilizing agents.   As indicated by the 
equations above, drug solubilizing agents will increase cocrystal solubility and solubilization 
ratio to a lesser extent than the drug.     
  43 
Figure 2.2 illustrates the influence of a drug solubilizing agent on the solubility and 
solubilization of a hypothetical drug and 3 different (1:1) cocrystals of the drug.  All cocrystals 
are shown to be more soluble than the drug in aqueous media (Scocrystal,aq are 2, 3, and 4-fold 
times higher than Sdrug,aq), but this is not the case in the presence of a drug solubilizing agent.  
The solubilizing agent increases the drug solubility by a factor of 9 (SRdrug = 9) and the cocrystal 
solubility by a factor of 3. According to equation (3), SRcocrystal = drugSR  thus SRcocrystal = 9  
= 3.  Under the assumptions to derive the simple square root relationship, the cocrystal 
solubilization ratio is only dependent on drug solubilization ratio.  
 
Figure 2.2.  Solubility values for a drug and three 1:1 cocrystals of that drug in aqueous buffer 
() and in the presence of a solubilizing agent ().  Cocrystal solubility enhancement over drug 
in aqueous buffer is not maintained in the presence of solubilizing agent.  All cocrystals are more 
soluble than the drug in buffer, but not in the solubilizing agent. 
Another important observation from Figure 2.2 is that not all cocrystals exhibit enhanced 
solubility over the drug in the presence of the drug solubilizing agent:   Scocrystal1,T < Sdrug,T, 
Scocrystal2,T = Sdrug,T, and Scocrystal3,T > Sdrug,T.    Preferential drug solubilization in the presence of a 
drug solubilizing agent can lead to a cocrystal transition point at which Scocrystal,T = Sdrug,T.  Above 
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the transition point in the presence of a solubilizing agent, a cocrystal that is more soluble than 
the drug in aqueous buffer becomes less soluble.   Thus, cocrystal 2 is at the transition point, 
whereas cocrystals 1 and 3 are above and below the transition point, respectively. We have 
investigated the nature of cocrystal transition points for a series of drugs and cocrystals in the 
presence of synthetic surfactants and lipids
7-12
.  Excellent correlations were observed between 
the drug solubilization provided by the solubilizing agents and the transition points.  Large 
decreases in both cocrystal solubility enhancement compared to drug solubility (Scocrystal 
compared to Sdrug) and SRcocrystal compared to SRdrug were associated with increased drug 
solubilization by the additives. 
SRdrug can reach values in the order of 100 to 1000 in physiologically relevant surfactants 
and one would expect cocrystals of these drugs to have solubilization ratios that are at least an 
order of magnitude lower than the drug ( 100  and 1000 ).  These predictions will be compared 
with experimental observations for several cocrystals in physiologically relevant surfactants in 
the results section. 
Cocrystal solubility in the presence of physiologically relevant surfactants 
In addition to estimating SRcocrystal from SRdrug, cocrystal total solubility in 
physiologically relevant surfactants can be derived from cocrystal constituent dissociation, 
ionization, and micellar solubilization 
7-11, 30-33
.  Cocrystal solubility in synthetic surfactants has 
been thoroughly described in the literature for cocrystals of nonionizing drugs
7-9
.  Here, we 
similarly derive expressions for cocrystal solubility in physiologically relevant surfactants for 
cocrystals of ionizable drugs and coformers.   
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For cocrystal RHA of nonionizable drug (R) and a monoprotic weakly acidic coformer 
(HA), the relevant solution equilibria are: 
RHA
solid
K
sp
R
aq
+HA
aq
         (2.9) 
HA
aq
K
a A
aq
- +H
aq
+                     (2.10) 
R
aq
+M
K
s
R
R
m
          (2.11) 
HA
aq
+M
K
s
HA
HA
m
         (2.12) 
A
aq
- +M
K
s
A-
A
m
-
          (2.13) 
and the associated equilibrium constants are given by 
sp aq aqK =[R] [HA]           (2.14) 
the cocrystal solubility product Ksp, 
- +
aq aq
a
aq
[A ] [H ]
K =
[HA]
          (2.15) 
the ionization constant Ka for the monoprotic weakly acidic coformer HA, 
R m
s
aq
[R]
K =
[R] [M]
          (2.16) 
the micellar solubilization constant Ks
R 
for nonionizable drug R, and the micellar solubilization 
constants Ks
HA
, and Ks
A 
for weakly acidic coformer HA 
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HA m
s
aq
[HA]
K =
[HA] [M]
          (2.17) 
-
-
A m
s -
aq
[A ]
K =
[A ] [M]
          (2.18) 
where the subscripts aq and m refer to aqueous and micellar pseudophases, respectively.  M is 
the micellar surfactant concentration, or the total surfactant minus the CMC. Activities are 
replaced by concentrations assuming dilute solution conditions. 
 The total stoichiometric solubility of RHA, SRHA,T, is equal to the total concentration of 
each cocrystal constituent in equilibrium with solution SRHA,T = [R]T = [A]T for this 1:1 cocrystal.  
An expression for SRHA,T in terms of experimentally accessible equilibrium constants and 
solution properties is derived by considering the mass balances of R and A: 
T aq m[R] =[R] +[R]           (2.19) 
- -
T aq m aq m[A] =[HA] +[HA] +[A ] +[A ]         (2.20) 
and by substituting the equilibrium constants above to yield 
  R pH pKa,coformer HA pH pKa,coformer ARHA,T sp s s sS K 1 K [M] 1 10 K [M] 10 K [M]
        (2.21) 
Biorelevant media containing physiologically relevant surfactants are often defined by a 
particular [M] and pH.  While the solubilization constant of the nonionized (Ks
HA
) and ionized 
(Ks
A-
) coformer can be determined experimentally at multiple pH values
34
, to quantify 
solubilization at a single pH, total solubilization constants (Ks
T
) can be calculated.  To simplify 
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equation (2.21), total solubilization constants in specified pH conditions (Ks
T
) can be substituted 
to yield   
  R,T pH-pKa,coformer HA,Tcocrystal sp s sS = K 1+K [M] 1+10 +K [M]      (2.22) 
For nonioinzable drug R, Ks
R,T
 is simply the solubilization constant for the nonionionized 
constituent (Ks
R
).  For ionizable constituents, the total solubilization constant takes into account 
the equilibrium solubilization constants in a given media for both the ionized and unionized 
species.  For example, for weakly acidic component HA, the total solubility in a surfactant as a 
function of intrinsic aqueous solubility Saq, ionization constant Ka, and micellar solubilization is 
given by: 
S
T
HA=S
aq
HA 1+10pH-pKa,acid+ K
s
HA+10pH-pKa,acidK
s
A
-
( )
K
s
A,T
[M]
æ
è
ç
ç
çç
ö
ø
÷
÷
÷÷
     (2.23) 
where the solubilization constants of the inionized and nonionized constituents are represented 
by the term Ks
A,T 
.  In this work, Ks
T
 values were calculated from solubility measurements in 
biorelevant media as explained in the Methods section. 
Materials and Methods 
Materials 
Cocrystal constituents 
Anhydrous carbamazepine form III (CBZ), anhydrous indomethacin form γ (IND) were 
purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  Anhydrous 
piroxicam form I was received as a gift from Pfizer (Groton, CT) and used as received.  
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Anhydrous danazol was received as a gift from Renovo Research (Atlanta, GA) and used as 
received.   
Anhydrous saccharin (SAC), 4- aminobenzoic acid (4ABA), and salicylic acid (SLC), 
were purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  
Anhydrous hydroxybenzoic acid was purchased from Acros Organics (Pittsburgh, PA) and used 
as received.  Anhydrous vanillin was purchased from Fisher Scientific (Fair Lawn, NJ) and used 
as received. Carbamazepine dihydrate (CBZ (H)), piroxicam monohydrate (PXC (H)), and 
hydroxybenzoic acid monohydrate (HBA (H)) were prepared by slurrying CBZ, PXC, and HBA 
in deionized water for at least 24 hours.  All crystalline drugs and coformers were characterized 
by X-ray power diffraction (XRPD) and differential scanning calorimetry (DSC) before carrying 
out experiments. 
Solvents and buffer components 
Ethyl acetate and ethanol were purchased from Acros Organics (Pittsburgh, PA) and used 
as received, and HPLC grade methanol and acetonitrile were purchased from Fisher Scientific 
(Pittsburgh, PA). Trifluoroacetic acid spectrophometric grade 99% was purchased from Aldrich 
Company (Milwaukee, WI) and phosphoric acid ACS reagent 85% was purchased from Sigma 
Chemical Company (St. Louis, MO).  Water used in this study was filtered through a double 
deionized purification system (Milli Q Plus Water System) from Millipore Co. (Bedford, MA). 
FeSSIF and acetate buffer were prepared using sodium taurocholate (NaTC) purchased 
from Sigma Chemical Company (St. Louis, MO), lecithin purchased from Fisher Scientific 
(Pittsburgh, PA), sodium hydroxide pellets (NaOH) purchased from J.T. Baker (Philipsburg, NJ), 
and acetic acid and potassium chloride (KCl) purchased from Acros Organics (Pittsburgh, PA).  
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Methods 
FeSSIF and acetate buffer preparation 
FeSSIF and acetate buffer were prepared according to the protocol of Galia and 
coworkers
35
.   Acetate buffer was prepared as a stock solution at room temperature by dissolving 
8.08 g NaOH (pellets), 17.3 g glacial acetic acid and 23.748 g NaCl in 2 L of purified water. The 
pH was adjusted to 5.00 with 1 N NaOH and 1N HCl.  FeSSIF was prepared by dissolving 0.41 g 
sodium taurocholate in 12.5 mL of pH 5.00 acetate buffer. 0.148 g lecithin was added with 
magnetic stirring at 37 °C until dissolved.  The volume was adjusted to exactly 50 mL with 
acetate buffer.  
Cocrystal synthesis 
Cocrystals were prepared by the reaction crystallization method
36
 at 25°C.  The 1:1 
indomethacin-saccharin cocrystal (IND-SAC) was synthesized by adding stoichiometric amounts 
of cocrystal constituents (IND and SAC) to nearly saturated SAC solution in ethyl acetate.  The 
1:1 carbamazepine saccharin cocrystal (CBZ-SAC) was prepared by adding stoichiometric 
amounts of cocrystal constituents (CBZ and SAC) to nearly saturated SAC solution in ethanol. 
The 1:1 carbamazepine-salicylic acid cocrystal (CBZ-SLC) was prepared by adding 
stoichiometric amounts of cocrystal constituents (CBZ and SLC) to nearly saturated SLC 
solution in acetonitrile. The 2:1 carbamazepine-4-aminobenzoic acid monohydrate cocrystal 
(CBZ-4ABA (H)) was prepared by suspending stoichiometric amounts of cocrystal constituents 
(CBZ and 4ABA) in a 0.01M 4ABA aqueous solution at pH 3.9.  The 1:1 piroxicam-saccharin 
cocrystal (PXC-SAC) was prepared by adding stoichiometric amounts of cocrystal constituents 
(PXC and SAC) to nearly saturated SAC in acetonitrile.  The 1:1 danazol-hydroxybenxoic acid 
cocrystal (DNZ-HBA) was prepared by adding stoichiometric amounts of cocrystal constituents 
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(DNZ and HBA) to nearly saturated HBA solution in ethyl acetate.  The 1:1 danazol-vanillin 
cocrystal (DNZ-VAN) was prepared by adding stoichiometric amounts of cocrystal constituents 
(DNZ and VAN) to nearly saturated VAN solution in ethyl acetate.  Prior to carrying out any 
solubility experiments, solid phases were characterized by XRPD and DSC and stoichiometry 
verified by HPLC.   Full conversion to cocrystal was observed in 24 hours. 
Solubility measurements of cocrystal constituents 
Cocrystal constituent solubilities were measured in FeSSIF and pH 5.00 acetate buffer 
(FeSSIF without NaTC and lecithin).  Solubilities of cocrystal constituents were determined by 
adding excess solid (drug or coformer) to 3 mL of media (FeSSIF or buffer). Solutions were 
magnetically stirred and maintained at 25 ±  0.1°C using a water bath for up to 96 h. At 24 hr 
intervals, 0.30 mL of samples were collected, pH of solutions measured, and filtered through a 
0.45 µm pore membrane.   After dilution with mobile phase, solution concentrations of drug or 
coformer were analyzed by HPLC. The equilibrium solid phases were characterized by XRPD 
and DSC. 
 Total solubilization constants, Ks
T
, were evaluated from solubility measurements of drug 
and coformer in FeSSIF and buffer.  For weakly acidic constituent HA, the total solubility in 
FeSSIF is given by   
 HA HA pH-pKa,acid A,TT aq sS =S 1+10 +K [M]          (2.24) 
Solving for Ks,
A,T
:  
HA
pH-pKa,acidT
HA
aqA,T
s
S
-1-10
S
K =
[M]            (2.25) 
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Derivations of equations to calculate Ks
T
 for other ionizable constituents are included in the 
Appendix.   For an amphoteric component like 4ABA, Ks
T 
was calculated from 
ABH
pH-pKa1,amphoteric pKa2,amphoteric-pHT
ABH
aqABH,T
s
S
-1-10 -10
S
K =
[M]
      (2.26) 
For a zwitterionic component like PXC, Ks
T 
was obtained from 
- +
- +
- +
ABH
pH-pKa1,zwitterionic pKa2,zwitterionic-pHT
ABH
aqABH ,T
s
S
-1-10 -10
S
K =
[M]      (2.27) 
Cocrystal solubility measurements  
Cocrystal equilibrium solubilities were measured in FeSSIF and pH 5.00 acetate buffer 
(FeSSIF without NaTC and lecithin) at the eutectic point, where drug and cocrystal solid phases 
are in equilibrium with solution
37, 38
. The eutectic point between cocrystal and drug was 
approached by cocrystal dissolution (suspending solid cocrystal (~100 mg) and drug (~50 mg) in 
3 mL of media (FeSSIF or buffer)) and by cocrystal precipitation (suspending solid cocrystal 
(~50 mg) and drug (~100 mg) in 3 mL of media (FeSSIF or buffer) nearly saturated with 
coformer).  Solutions were magnetically stirred and maintained at 25 ± 0.1°C using a water bath 
for up to 96 h. At 24 hr intervals, 0.30 mL aliquots of suspension were collected, pH was 
measured, before filtration through a 0.45 µm pore membrane.   Solid phases were also collected 
at 24 hr intervals to ensure the sample was at the eutectic point (confirmed by presence of both 
drug and cocrystal solid phases and constant [coformer] and [drug] solution concentrations).  
After dilution of filtered solutions with mobile phase, drug and coformer concentrations were 
analyzed by HPLC. The equilibrium solid phases were characterized by XRPD and DSC. 
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The cocrystal stoichiometric solubility was calculated from measured total eutectic 
concentrations of drug and coformer ([drug]T,eu and [coformer]T,eu) according to the following 
equations for 1:1 and 2:1 cocrystals
37
: 
1:1 cocrystal
T T,eu T,euS = [drug] [coformer]         (2.28) 
2
T,eu T,eu2:1 cocrystal 3
T
[drug] [coformer]
S =2
4
 
 
 
 
       (2.29)
This method of calculating the stoichiometric solubility of cocrystals from equilibrium solubility 
measurements in nonstoichiometric conditions is well established in the literature
7-10, 37-39
.   
X-ray powder diffraction 
X-ray powder diffraction diffractograms of solid phases were collected on a benchtop 
Rigaku Miniflex X-ray diffractometer (Rigaku, Danverse, MA) using Cu Kα radiation (λ= 
1.54Å), a tube voltage of 30 kV, and a tube current of 15 mA. Data were collected from 5 to 40° 
at a continuous scan rate of 2.5°/min.  
Thermal analysis 
Solid phases collected during solubility studies were dried at room temperature and 
analyzed by differential scanning calorimetry (DSC) using a TA instrument (Newark, DE) 
2910MDSC system equipped with a refrigerated cooling unit. DSC experiments were performed 
by heating the samples at a rate of 10 °C/min under a dry nitrogen atmosphere. A high purity 
indium standard was used for temperature and enthalpy calibration.  Standard aluminum sample 
pans were used for all measurements.  
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High performance liquid chromatography 
Solution concentrations were analyzed by a Waters HPLC (Milford, MA) equipped with 
an ultraviolet-visible spectrometer detector. For the IND-SAC and CBZ-SAC, CBZ-SLC, CBZ-
4ABA-HYD cocrystals and their components, a C18 Thermo Electron Corporation (Quebec, 
Canada) column (5µm, 250 x 4.6 mm) at ambient temperature was used. For the IND-SAC 
cocrystal, the injection volume was 20 µl and analysis conducted using an isocratic method with 
a mobile phase composed of 70% acetonitrile and 30% water with 0.1% trifluoroacetic acid and 
a flow rate of 1 ml/min. Absorbance of IND and SAC were monitored at 265 nm. For the CBZ 
cocrystals, the injection volume was 20 µl and analysis conducted using an isocratic method with 
a mobile phase composed of 55% methanol and 45% water with 0.1% trifluoroacetic acid and a 
flow rate of 1 mL/min. Absorbance was monitored as follows:  
CBZ and 4ABA at 284 nm, SAC at 265 nm, and SLC at 303 nm. For the PXC-SAC, 
DNZ-HBA, and DNZ-VAN cocrystals and their components, a C18 Waters Atlantis (Milford, 
MA) column (5 µM 250 x 6 mm) at ambient temperature was used.  For PXC-SAC, the injection 
volume was 20 µL and analysis was conducted using an isocratic method with a mobile phase 
composed of 70% methanol and 30% water with 0.3% phosphoric acid and a flow rate of 1 
mL/min.  Absorbance of PXC was monitored at 340 nm and SAC at 240 nm.  For the DNZ 
cocrystals, the injection volume was 20 µL in FeSSIF experiments, and 100 µL in buffer 
experiments due to the extremely low solubility of DNZ in aqueous solutions.  Analysis was 
conducted using an isocratic method composed of 80% methanol and 20% water with 0.1% 
trifluoroacetic acid and a flow rate of 1 mL/min.  Absorbance of DNZ was monitored at 285 nm, 
HBA at 242 nm, and VAN at 300 nm.  For all cocrystals, the Waters’ operation software 
Empower 2 was used to collect and process data. 
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Results 
Cocrystal solubilization in FeSSIF 
The influence of FeSSIF on drug and cocrystal solubilization is shown in Figure 2.3.  
Results indicate that cocrystals and drugs are solubilized to different extents in FeSSIF.  Drugs 
are solubilized to a greater extent than cocrystals, as indicated by SRdrug values that are higher 
than SRcocrystal as predicted by equations (2.3) and (2.4) .  Such behavior is due to preferential 
solubilization of drug over coformer.  DNZ was found to be 720 times more soluble in FeSSIF 
compared to aqueous buffer, whereas its cocrystals, DNZ-HBA and DNZ-VAN, were only 23 
and 24 times more soluble in FeSSIF than in buffer.  This highlights the order of magnitude 
reduction in cocrystal solubilization that is possible compared to their highly solubilized 
constituent drugs. DNZ showed the largest solubilization by FeSSIF and most extreme difference 
in constituent drug and cocrystal solubilization among the cocrystals studied.   IND-SAC also 
exhibited a large decrease in solubilization compared to IND.  IND was 16 times more soluble in 
FeSSIF compared to buffer while the 1:1 IND-SAC cocrystal was only solubilized 4.5 times.  
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Figure 2.3.  Solubilization ratios for cocrystals () and constituent drugs () in FeSSIF at 
experimental pH values indicated in Table 2.4 and Table 2.5 at 25°C.  Error bars represent 
standard errors of measurements. 
PXC and CBZ exhibit a less pronounced decrease in SRcocrystal compared to SRdrug since 
these drugs are solubilized to a lower extent in FeSSIF.  PXC (H) was moderately solubilized 
(2.0 times more soluble in FeSSIF compared to buffer), and the 1:1 PXC-SAC cocrystal was 
only 1.40 times more soluble. CBZ (H) was 1.8 times more soluble in FeSSIF than in buffer, and 
its cocrystals ranged from 1.03-1.33 times more soluble in FeSSIF for the 1:1 cocrystals CBZ-
SAC and CBZ-SLC and 1.49 times more soluble in FeSSIF for the 2:1 cocrystal CBZ-4ABA-
HYD.   
Cocrystal and drug solubilities measured in FeSSIF and buffer are presented in Figure 2.4 
and Figure 2.5 together with the cocrystal and drug solubilization ratios in FeSSIF.    
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Figure 2.4.  Drug and cocrystal solubility measured in FeSSIF () and buffer () at 25°C for 
IND, IND-SAC, DNZ, DNZ-VAN, and DNZ-HBA.  SR in FeSSIF calculated from solubility 
values is also shown ().  The initial pH was 5.00 in both buffer and FeSSIF.  The final pH of 
each solubility measurement in FeSSIF and buffer, respectively, are as follows: IND (4.98±0.06 
and 4.96±0.03), IND-SAC (3.65±0.05 and 3.66±0.02), DNZ (5.01±0.05 and 4.96±0.01), DNZ-
VAN (5.00±0.01 and 4.96±0.01), and DNZ-HBA (4.46±0.06 and 4.47±0.01). 
 
 
Figure 2.5.  Drug and cocrystal solubility measured in FeSSIF () and buffer () at 25°C for 
CBZ (H), CBZ-4ABA (H), CBZ-SLC, CBZ-SAC, PXC (H), and PXC-SAC.  SR in FeSSIF 
calculated from solubility values is also shown ().  The final pH of each solubility 
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measurement in FeSSIF and buffer, respectively, are as follows: CBZ (H) (4.86±0.05 and 
4.95±0.01), CBZ-4ABA (H) (4.94±0.02 and 4.84±0.03), CBZ-SLC (4.29±0.02 and 4.37±0.02), 
CBZ-SAC (3.11±0.02 and 3.08±0.03), PXC (H) (5.03±0.02 and 4.98±0.01), and PXC-SAC 
(3.79±0.02 and 3.64±0.02). 
Results for the more hydrophobic drugs IND and DNZ and their cocrystals (Figure 2.4) indicate 
that cocrystals are more soluble than drugs in buffer and that this cocrystal solubility 
enhancement is maintained in FeSSIF but to a lower extent than in buffer.   Similar behavior is 
observed for cocrystals of the less hydrophobic drugs CBZ and PXC (Figure 2.5). 
We have recently shown that cocrystal solubility at the transition point (S*) can be 
calculated from the aqueous cocrystal and drug solubilities according to S* = (Scocrystal,aq)
2
/Sdrug,aq 
for a 1:1 cocrystal
12
.  For the series of cocrystals studied in the present work, S* values are much 
higher than the measured cocrystal solubilities in FeSSIF, therefore all cocrystals are below their 
transition point under the conditions studied.  These findings are in agreement with the observed 
cocrystal solubility enhancement over drug in FeSSIF. 
The predicted and measured SRcocrystal values in FeSSIF are shown in Figure 2.6 and 
Table 2.1.  SRcocrystal was predicted from measured SRdrug values from the simple SR equations 
(2.3) and (2.4) .   
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Figure 2.6.  SRcocrystal dependence on drugSR  for 1:1 cocrystals in FeSSIF at 25°C.  Line 
represents the theoretical relationship according to equation (2.3).  Symbols represent 
experimentally determined SR values in equilibrium conditions for  IND-SAC (), CBZ-SAC 
(), CBZ-SLC (), , PXC-SAC (), DNZ-HBA (), and DNZ-VAN (). 
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Table 2.1.  Comparison of experimentally measured and predicted SRcocrystal values. 
a) Experimentally measured in absence of coformer. 
b) Predicted from experimental SRdrug values using equation (2.3) for 1:1 cocrystals and 
(2.4) for 2:1 cocrystals. 
c) Determined from Scocrystal measurement at eutectic points. 
Results demonstrate excellent agreement between the predicted and measured SRcocrystal values.   
As predicted by the models, SRcocrystal for a given drug did not significantly vary for the systems 
studied (DNZ cocrystals 23 and 24 and CBZ 1:1 cocrystals 1.03 and 1.3).  The simple 
relationships used in these calculations were derived from the more rigorous solubility equations 
for cocrystal and drug that consider cocrystal Ksp and the pKa and Ks
T
 values of cocrystal 
constituents under the assumption that coformer Ks
T
 is negligible.  Prediction of cocrystal 
solubility in FeSSIF using the more rigorous equations is presented in the next section. 
Cocrystal 
SRdrug, 
exp
a
 
pH 
FeSSIF 
pH 
buffer 
SRcocrystal, 
pred
b
 
SRcocrystal 
exp
c
 
pH 
FeSSIF 
pH 
buffer 
CBZ-SAC 
(1:1) 
1.8 ± 0.1 4.86±0.05 4.95±0.01 1.3 1.03±0.04 3.11±0.02 3.08±0.03 
CBZ-SLC 
(1:1) 
1.8 ± 0.1 4.86±0.05 4.95±0.01 1.3 1.33±0.05 4.29±0.02 4.37±0.02 
CBZ-4ABA (H) 
(2:1) 
1.8 ± 0.1 4.86±0.05 4.95±0.01 1.5 1.49±0.06 4.94±0.02 4.84±0.03 
PXC-SAC 
(1:1) 
2.0 ± 0.2 5.02±0.02 4.98±0.01 1.4 1.40±0.03 3.79±0.02 3.64±0.02 
IND-SAC 
(1:1) 
16 ± 1 4.98±0.06 4.96±0.03 4.0 4.5±0.3 3.65±0.05 3.66±0.02 
DNZ-HBA 
(1:1) 
720 ± 80 5.01±0.05 4.96±0.01 27 23±3 4.46±0.06 4.47±0.04 
DNZ-VAN 
(1:1) 
720 ± 80 5.01±0.05 4.96±0.01 27 24±4 5.00±0.01 4.96±0.01 
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Predicting cocrystal solubility in FeSSIF and buffer from relevant equilibrium constants 
Table 2.2 shows the cocrystal solubility equations in buffer and FeSSIF for the systems 
studied.  The derivation for equation (2.22) for a 1:1 cocrystal of a nonionizable drug R and a 
weakly acidic coformer HA is shown in the theoretical section.  Full derivations for cocrystals of 
other constituents can be found in the Appendix. 
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Table 2.2.  Cocrystal solubility equations in aqueous buffer and FeSSIF. 
Cocrystal Solubility in buffer Solubility in FeSSIF 
RHA 
(CBZ-SAC, 
CBZ-SLC, 
DNZ-HBA, 
DNZ-VAN) 
 RHA RHA pH-pKa,coformerT spS = K 1+10    
RHA RHA R,T pH-pKa,coformer HA,T
T sp s s
S = K 1+K [M] 1+10 +K [M]  
R2ABH 
(CBZ-4ABA-
HYD) 
 
2
2
R ABH
spR ABH pH-pKa1,coformer pKa2,coformer-pH3
T
K
S =2 1+10 +10
4
    
2
2
R ABH
2spR ABH R,T pH-pKa1,coformer pKa2,coformer-pH ABH,T3
T s s
K
S =2 1+K [M] 1+10 +10 +K [M]
4
 
HDHA 
(IND-SAC) 
  HDHA HDHA pH-pKa,drug pH-pKa,coformerT spS = K 1+10 1+10    
HDHA HDHA pH-pKa,drug HD,T pH-pKa,coformer HA,T
T sp s s
S = K 1+10 +K [M] 1+10 +K [M]  
-ABH+HA 
(PXC-SAC) 
  
- + - +
ABH HA ABH HA pH-pKa1,drug pKa2,drug-pH pH-pKa,coformer
T sp
S = K 1+10 +10 1+10
 
  
- + - + - +
ABH HA ABH HA pH-pKa1,drug pKa2,drug-pH ABH ,T pH-pKa,coformer HA,T
T sp s s
S = K 1+10 +10 +K [M] 1+10 +K [M]
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The parameter values used in cocrystal solubility predictions are summarized in Table 2.3 
and Table 2.5.  Ksp values used in solubility predictions (Table 2.3) were either obtained from the 
literature or experimentally determined in our laboratory.  The Ks
T
 values were determined from 
drug and solubility measurements in FeSSIF and buffer (Table 2.5).  pKa values (Table 2.5) were 
obtained from the literature. 
Table 2.3.  Ksp and pKsp values for the cocrystals studied. 
Cocrystal Ksp pKsp 
CBZ-SLC 1.13±0.05 mM
2 a
 5.95±0.02 
CBZ-SAC 1.00±0.05 mM
2 b
 6.00±0.02 
CBZ-4ABA (H) 1.2±0.2 mM
3 a
 8.92±0.07 
PXC-SAC (7.6±0.3) x 10
-2
 mM
2 c
 7.11±0.02 
IND-SAC (1.38±0.09) x 10
-3
 mM
2 b
 8.86±0.07 
DNZ-HBA (1.1 ± 0.4) x10
-2 
mM
2 c
 8.0±0.2 
DNZ-VAN (3.5 ± 0.5) x10
-3 
mM
2 c
 8.46±0.06 
a) From reference 40. 
b) From reference 25. 
c) Experimentally determined at 25°C. 
Results of cocrystal solubility measurements at the eutectic point and Ksp evaluation for PXC and 
the DNZ cocrystals can be found in the Appendix.  
The predicted and experimentally measured cocrystal solubilities in FeSSIF and buffer 
are presented in Table 2.4 and Figure 2.7. The predicted cocrystal solubilities are in good 
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agreement with the experimentally observed values in both FeSSIF and buffer, with all 
predictions falling within a factor of two of the measured values.  Cocrystal solubilities ranged 
from 10.1 mM for CBZ-SAC to 1.39 mM for DNZ-VAN in FeSSIF and from 9.8 mM for CBZ-
SAC to 0.057 mM for DNZ-VAN in buffer.  Some cocrystals, such as PXC-SAC in FeSSIF and 
CBZ-SAC in buffer, showed deviations between experimental and predicted values, which may 
be due to a number of factors such as reduced drug solubilization in the presence of coformer 
and interactions between constituents in solution that are assumed to be negligible by the models 
presented in this work.  The models, however, provide valuable insights into why and how 
biorelevant media influence cocrystal solubilization from knowledge of drug solubilization 
characteristics. 
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Table 2.4.  Comparison between predicted and experimentally measured cocrystal solubility 
values. 
 
(a) Predicted from equations in Table 2.2 and parameter values in Table 2.3 and Table 2.5. 
(b) Calculated from experimentally measured eutectic concentrations using equation (2.28) 
for 1:1 cocrystals and equation (2.29) for 2:1 cocrystals. 
 
Since many of the cocrystals contain acidic components, the pH at the eutectic point was 
often lower than 5.00 (the pH of FeSSIF and the aqueous buffer), especially for cocrystals of 
SAC.  The pH at the eutectic point ranged from 3.79-3.08 for PXC-SAC, IND-SAC, and CBZ-
SAC.  Cocrystal solubility has been shown to vary with pH
39
, making it imperative to consider 
its influence when comparing  predictions with measurements.  The cocrystal solubility in 
FeSSIF and buffer was predicted at the pH of the experimental conditions in Table 2.4. 
 
S
cocrystal 
FeSSIF(mM) 
 
S
cocrystal 
buffer (mM) 
 
Cocrystal Preda Expb pHc Preda Expb pHc 
CBZ-SAC 7.7 10.1±0.1 3.11 ± 0.02 5.6 9.8±0.3 3.08 ± 0.03 
CBZ-SLC 6.6 6.71±0.09 4.29 ± 0.02 5.2 5.1±0.1 4.37 ± 0.02 
PXC-SAC 4.2 2.60±0.03 3.79 ±0.02 2.8 1.85±0.03 3.64 ±0.02 
DNZ-HBA 4.2 2.8±0.1 4.46±0.06 0.15 0.12±0.01 4.47±0.04 
IND-SAC 4.4 3.6±0.2 3.65 ± 0.05 0.42 0.79±0.03 3.66 ± 0.02 
CBZ-4ABA (H) 2.7 2.57±0.05 4.94 ± 0.02 0.17 1.73±0.06 4.84 ± 0.03 
DNZ-VAN 1.7 1.39±0.03 5.00 ± 0.01 5.9 x 10
-2
 (5.7±0.2)x10
-2
 4.96 ± 0.01 
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Figure 2.7.  Comparison of predicted and observed cocrystal solubility in FeSSIF (filled 
symbols) and buffer (open symbols) at 25°C for IND-SAC (), CBZ-SAC (), CBZ-SLC (), 
CBZ-4ABA (H) (), PXC-SAC (), DNZ-HBA (), and DNZ-VAN ().  Line indicates the 
function y = x, where the predicted and observed solubilities are equivalent.  Errors fit within the 
size of each symbol.  Solubilities were predicted according to the equations in Table 2.2 
according to the equilibrium constants in Table 2.3 and Table 2.5. 
Cocrystal solubility can be predicted over orders of magnitude using the equations in 
Table 2.2.  These mathematical models allow for the prediction of cocrystal solubility in the 
presence of solubilizing agents from knowledge of Ksp, as well as the Ka and Ks
 
values of the 
drug and coformer.  Ksp can be obtained from a single solubility measurement in aqueous buffer, 
and these models are particularly useful to predict the influence of solubilizing agents on 
cocrystal solution behavior without doing experiments when limited quantities of cocrystal are 
available. 
Drug and coformer solubilization in FeSSIF 
Drug and coformer solubilities were measured in FeSSIF and in buffer.  Drugs were 
significantly solubilized by FeSSIF and SRdrug ranged from 1.8 to 720 as shown in Figure 2.8. 
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Figure 2.8.  Drug solubility measured in FeSSIF () and buffer () at 25°C.  SRdrug in FeSSIF 
calculated from solubility values is also shown ().  The final pH of each drug solubility 
measurement in FeSSIF and buffer, respectively, are as follows: DNZ (5.01±0.05 and 
4.96±0.01), IND (4.98±0.06 and 4.96±0.03), PXC (H) (5.03±0.02 and 4.98±0.01), and CBZ (H) 
(4.86±0.05 and 4.95±0.01).  PXC (H) represents the monohydrate form of PXC and CBZ (H) 
represents the dihydrate form of CBZ, which are the stable forms in aqueous solution.   
 Solubilization by physiologically relevant surfactants similar to those in FeSSIF has been shown 
to be directly proportional to the hydrophobicity of a compound as measured by the 
octanol/water partition coefficient (log P)
17, 41, 42
.  More hydrophobic drugs (DNZ, log P 4.53
43
 
and IND, log P 4.27
44
) were solubilized to a higher extent than less hydrophobic drugs (CBZ, log 
P 2.32
45
 and PXC, log P 1.80
46
).  The most hydrophobic drug studied, DNZ, was remarkably 720 
times more soluble in FeSSIF compared to aqueous buffer, showing extremely high 
solubilization by the bile salt/lecithin mixed micelles. 
One of the underlying assumptions of equations (2.3) and (2.4) is that the coformer 
solubilization by FeSSIF is negligible.  Figure 2.9 shows measured coformer solubilities in 
FeSSIF and buffer and solubilization ratios (SRcoformer).    
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Figure 2.9.  Coformer solubility measured in FeSSIF () and buffer () at 25°C.  SRcoformer in 
FeSSIF calculated from solubility values is also shown ().  The final pH of each coformer 
solubility measurement in FeSSIF and buffer, respectively, are as follows: 4ABA (4.72±0.02 and 
4.57±0.04), VAN (4.99±0.01 and 4.94±0.01), HBA (H) (4.45±0.02 and 4.41±0.02), SLC 
(3.78±0.03 and 3.58±0.06), and SAC (2.60±0.02 and 2.58±0.02).  HBA (H) represents the 
monohydrate form of HBA which is the stable form in aqueous solution.   
All coformers had slightly higher solubilities in FeSSIF compared to buffer with the exception of 
SAC.  Coformers showed negligible solubilization by FeSSIF, and SRcoformer ranged from 1.0-1.2.  
Log P values range from 0.77 for 4ABA to 2.26 for SLC
47, 48
 and the low observed SR values of 
the coformers are expected due to their hydrophilic nature.  Since the assumption that coformer 
solubilization is negligible is justified for this set of cocrystals in FeSSIF, equations (2.3) and 
(2.4) can be used to predict SRcocrystal from SRdrug. 
Values of total equilibrium solubilization constants (Ks,
T
) were calculated for cocrystal 
components at the pH of the solubility measurements from measured drug and coformer 
solubilities in FeSSIF and buffer, (Table 2.5) using equations (2.25) - (2.27). 
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Table 2.5.  Drug and coformer solubility measurements in FeSSIF and buffer and calculated Ks
T
. 
 
Component S
FeSSIF
(mM) pH
FeSSIF
 S
buffer
 (mM) pH
buffer
 pKa Ks
T
 (mM
-1
)f 
Drugs 
CBZ (H) (7.5±0.2)x10
-1
 4.86±0.05 (4.2±0.2)x10
-1
 4.95±0.01 --- 0.054±0.003 
PXC (H) (6.0±0.3)x10
-2
 5.03±0.02 (3.1±0.1)x10
-2
 4.98±0.01 1.86, 5.45
a
 0.080±0.005 
IND (3.7±0.2)x10
-1
 4.97±0.06 (2.3±0.1)x10
-2
 4.96±0.03 4.2
b
 8.2±0.6 
DNZ (1.11±0.09) x10
-1
 5.01±0.05 (1.6±0.2)x10
-4
 4.96±0.01 --- 49±5 
Coformers 
SAC 105.3±0.5 2.60±0.02 111±1 2.58±0.02 1.6
c
 0 
4-ABA 80.0±0.9 4.72±0.02 64.4±0.8 4.57±0.04 2.6, 4.8
d
 0.0021±0.0003 
VAN 64±2 4.99±0.01 54±1 4.94±0.01 7.4
e
 0.012±0.001 
HBA (H) 96.4±0.6 4.45±0.02 84±2 4.41±0.02 4.48
e
 0.018±0.001 
SLC 108.2±0.9 3.78±0.03 97±1 3.58±0.06 3.00
c
 0.043±0.003 
(a) from reference 22. 
(b) from reference 23. 
(c) from reference 24. 
(d) from reference 26. 
(e) from reference 28. 
(f) Calculated from equations (2.25)-(2.27) with pKa, and solubility values in Table 2.5. 
 
The Ks
T
 values in Table 2.5 indicate the same trend that was observed with SRdrug and SRcoformer 
values in Figure 2.8 and Figure 2.9.  Highly hydrophobic drugs IND and DNZ have much higher 
Ks
T
 values of 8.2 mM
-1
 and 49 mM
-1
 respectively, compared to less hydrophobic drugs PXC and 
CBZ which had Ks
T
 values of 0.080 mM
-1 
and 0.054 mM
-1
, respectively.  Coformers had much 
lower Ks
T
 values, ranging from 0 mM
-1 
for SAC to 0.043 mM
-1
 for SLC.  These solubilization 
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constants, along with pKa values reported in the literature, were used to predict cocrystal 
solubility in FeSSIF, as discussed in a previous section. 
Cocrystal solubility measurements at eutectic points 
 Cocrystals with a solubility much higher than the drug require high [coformer]eu to reach 
the eutectic point.  These coformer concentrations in solution are orders of magnitude above the 
stoichiometric ratio of the cocrystal.   CBZ-SAC, IND-SAC, and PXC-SAC had very high 
[SAC]eu concentrations in buffer and in FeSSIF (Appendix).  [coformer]eu values were as high as 
six orders of magnitude [drug]eu for the DNZ cocrystals in buffer.  In FeSSIF, however, the 
difference between [drug]eu and [coformer]eu  was lowered due to the preferential solubilization 
of the drug.  In FeSSIF, the [coformer]eu was only three orders of magnitude higher than [drug]eu 
for DNZ cocrystals due to this solubilization effect.    
 Very high coformer concentrations at the eutectic point can lead to nonideal solution 
conditions where the assumption that drug interactions with solubilizing agents are unaffected by 
coformer in solution is no longer justified.   These high concentrations in solution can alter drug 
solubility at the eutectic point and reduce drug solubilization in these conditions.  As in the case 
of CBZ-SAC, this reduced solubilization leads to smaller SRdrug and Ks values at the eutectic 
point compared to those measured and calculated in the absence of coformer.  However, for the 
systems studied, coformer concentrations at the eutectic points did not significantly influence 
SRcocrystal or cocrystal solubility evaluations.  Information regarding drug and cocrystal 
solubilities and solubilization in FeSSIF at the eutectic point can be found in the Appendix. 
Conclusions 
This work shows that the behavior of cocrystal solubilization in FeSSIF is different from 
that of the drug solubilization.   A theoretical framework that allows for the simple and 
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quantitative prediction of cocrystal solubilization ratio from drug solubilization ratio is 
developed.  For a 1:1 cocrystal, the cocrystal solubilization ratio can be obtained from the square 
root of the drug solubilization ratio.  SRcocrystal in solubilizing agents was observed to be orders 
of magnitude lower than SRdrug.  Cocrystals of drugs with a wide range of solubilization ratios in 
FeSSIF were studied.  SRdrug values range from 720 for DNZ, to 16 for indomethancin, to 2.0 for 
piroxicam, to 1.8 for CBZ (H).   SRcocrystal values in FeSSIF range from 23 and 24 for DNZ-HBA 
and DNZ-VAN, to 4 for IND-SAC, to 1.4 for PXC-SAC, and 1.03, 1.3, and 1.5 for CBZ-SAC, 
CBZ-SLC and CBZ-4ABA (H). The observed SRcocrystal values were all in excellent agreement 
with predictions from the simple equations.   
The decrease in SRcocrystal in FeSSIF compared to SRdrug ranges from 30 fold for the DNZ 
cocrystals to about 2 fold or less for the CBZ cocrystals.  Large decreases in SRcocrystal over 
SRdrug for cocrystals of the more hydrophobic drugs is a result of the higher drug solubilization 
provided by FeSSIF. This finding has important implications for poorly soluble, lipophilic drugs 
that show large food effect, like DNZ.  Cocrystals of drugs like DNZ are solubilized to a lesser 
extent than the constituent drugs, which can lead to smaller differences between fed and fasted 
state solubilities.  For these drugs, cocrystallization may be a promising approach to diminish 
food effects. The presented models can be used with drug solubilization descriptors that are 
measured independently or reported in the literature to predict SRcocrystal and cocrystal solubility.  
The hope is that these simple yet realistic models can support cocrystal development by 
predicting cocrystal characteristics that have not been measured and that influence cocrystal 
performance.   
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Appendix 
Cocrystal and drug solubility at the eutectic point 
Table 2.6 shows the measured cocrystal solubilities at the eutectic point in FeSSIF and 
buffer.   
Table 2.6.  Measured eutectic concentrations and calculated stoichiometric solubility in FeSSIF 
and buffer. 
Media Cocrystal [drug]eu (mM) 
[coformer]
eu
 
(mM) 
S
cocrystal
 (mM)
a
 
pH 
(eutectic) 
buffer 
DNZ-HBA (2.0±0.4)x10
-4
 79±4 (1.2±0.1)x10
-1
 4.47±0.04 
DNZ-VAN (2.1±0.1)x10
-4
 16±3 (5.7±0.2)x10
-2
 4.96±0.01 
IND-SAC (6.0±0.3)x10
-3
 104±20 (7.9±0.3)x10
-2
 3.66 ± 0.02 
PXC-SAC (3.64±0.01)x10
-2
 94±2 1.85±0.03 3.64 ±0.02 
CBZ-SAC (7.8±0.5)x10
-1
 124±3 9.8±0.3 3.08 ± 0.03 
CBZ-SLC (5.1±0.2)x10
-1
 49.8±0.9 5.1±0.1 4.37 ± 0.02 
CBZ-4ABA 
(H) 
(4.4±0.2)x10
-1
 13.1±0.4 1.73±0.06 4.84 ± 0.03 
FeSSIF 
PXC-SAC (6.80±0.06)x10
-2
 97±1 2.60±0.03 3.79 ±0.02 
DNZ-HBA (9.9±0.8)x10
-2
 78±1 2.8±0.1 4.46±0.06 
IND-SAC (1.50±0.2)x10
-1
 87±4 3.6±0.2 3.65 ± 0.05 
DNZ-VAN (1.0±0.2)x10
-1
 19.4±0.8 1.39±0.03 5.00±0.01 
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(a) Calculated using equation (2.28) for 1:1 cocrystals and equation (2.29) for 2:1 cocrystals 
from experimentally measured eutectic concentrations as described in the text. 
 
Highly soluble cocrystals require high [coformer]eu to reach the eutectic point.  CBZ-SAC, IND-
SAC, and PXC-SAC had very high [SAC]eu concentrations in buffer and in FeSSIF.  
[coformer]eu values were as much as six orders of magnitude higher than the [drug]eu as in the 
case of the DNZ cocrystals in buffer.  In FeSSIF, however, the difference in [drug]eu and 
[coformer]eu was muted due to the preferential solubilization of the drug.  In FeSSIF, the 
[coformer]eu was only three orders of magnitude higher than [drug]eu for DNZ cocrystals due to 
this solubilization effect.   Extremely high coformer concentrations at the eutectic point can 
create nonideal solution conditions where the assumption that drug interactions with solubilizing 
agents are unaffected by coformer in solution is no longer justified.  This will be discussed in a 
subsequent section.   
Cocrystals that have much higher solubilities than their constituent drugs require excess 
coformer to reach the equilibrium solubility.  Solubility of these highly soluble cocrystals is 
measured at the eutectic point, where two solid phases (cocrystal and drug) are in equilibrium 
with solution
37
.  At the eutectic point, cocrystal dissolution leads to high concentrations of 
coformer in solution.  The drug concentration at the eutectic point also serves as a measure of the 
equilibrium solubility of the drug in the presence of coformer in solution since the solution is 
saturated with drug as well as cocrystal phases.  Table 2.7 shows the comparison of drug 
CBZ-SAC 1.07±0.03 95.9±0.3 10.1±0.1 3.11 ± 0.02 
CBZ-SLC (9.1±0.2)x10
-1
 49.9±0.6 6.71±0.09 4.29 ± 0.02 
CBZ-4ABA 
(H) 
(7.4±0.3)x10
-1
 15.6±0.4 2.57±0.05 4.94 ± 0.02 
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solubility measured in the absence of coformer (independently measured) to the solubility 
measured at the eutectic point in the presence of coformer. To analyze the impact of coformer on 
drug solubilization, Ks
T
 values were calculated and compared from both the independently 
measured and eutectic point solubility values. 
Table 2.7 Comparison of drug solubilities in FeSSIF buffer measured in the absence of and in 
the presence of coformer and calculated Ks
T
 values. 
Component 
S
FeSSIF
 (mM) 
drug 
pH
FeSSIF
 
S
buffer
 (M) 
drug 
pH
buffer
 
K
s,T 
(M
-1
) 
drug
a 
CBZ (H) 0.75±0.02 4.86±0.05 0.42±0.02 4.95±0.01 0.054±0.003 
CBZ-SLC 0.91±0.02 4.29±0.02 0.51±0.02 4.37±0.02 0.052±0.004 
CBZ-4ABA 
(H) 
0.74±0.03 4.94±0.02 0.44±0.02 4.84±0.03 0.045±0.003 
CBZ-SAC 1.07±0.03 3.11±0.02 0.78±0.05 3.08±0.03 0.025±0.002 
PXC (H) (6.0±0.3)x10
-2
 5.03±0.02 (3.1±0.1)x10
-2
 4.98±0.01 0.080±0.005 
PXC-SAC (6.80±0.06)x10
-2
 3.79±0.02 (3.64±0.01)x10
-2
 3.64±0.02 0.057±0.004 
IND (3.7±0.2)x10
-1
 4.97±0.06 (2.3±0.1)x10
-3
 4.96±0.03 8.2±0.6 
IND-SAC (1.5±0.2)x10
-1
 3.65±0.05 (6.0±0.3)x10
-3
 3.66±0.02 1.6±0.2 
DNZ (1.11±0.09) x10
-1
 5.01±0.05 (1.6±0.2)x10
-4
 4.96±0.01 49±5 
DNZ-HBA (9.9±0.8) x10
-2
 4.46±0.06 (2.0 ±0.4)x10
-4
 4.47±0.04 34±4 
DNZ-VAN (1.0±0.2)x10
-1
 5.00±0.01 (2.1±0.1)x10
-4
 4.96±0.01 33±3 
(a) Calculated as described by equations (2.25)-(2.27). 
Solubility and Ks
T
 values for drugs can be influenced by both the coformer concentration 
at the eutectic point and the pH differences between the solubility measurements in the absence 
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and the presence of coformer.  The presence of excess coformer in solution at the eutectic 
pointcan alter the pH of the media when coformers are ionizable, which is the case for most of 
the systems studied in this work. The impact of these differences in Ks
T
 on cocrystal solubility 
prediction will be examined in the next section. 
Table 2.8 shows the experimentally determined and the predicted solubility values in 
FeSSIF using both independently measured and eutectic point measured Ks
T
 values and 
equations in Table 2.2.  The solubility predictions in buffer do not change between the two 
methods because there is no solubilization and therefore no Ks
T
. 
Table 2.8. Comparison of experimentally measured cocrystal solubility and predicted solubility 
from Ks
T
 determined independently and at the eutectic point. 
(a)  
(b) Predicted using equations in Table 2.2, Ksp values in Table 2.3, and pKa and Ks
T
 values in 
Table 2.5. 
 
S
cocrystal 
FeSSIF (mM) 
 
S
cocrystal 
buffer (mM) 
 
Cocrystal 
Pred, Ks
T
 
indep
a 
Pred, Ks
T
 
eu
b 
Exp
c 
Eutectic 
pH 
Pred
d 
Exp
c 
Eutectic 
pH 
CBZ-SAC 7.7 6.7 10.1±0.1 3.11 ± 0.02 5.6 9.8±0.3 3.08 ± 0.03 
CBZ-SLC 6.6 6.5 6.71±0.09 4.29 ± 0.02 5.2 5.1±0.1 4.37 ± 0.02 
PXC-SAC 4.2 4.5 2.60±0.03 3.79 ±0.02 2.8 1.85±0.03 3.64 ±0.02 
DNZ-HBA 4.2 3.5 2.8±0.1 4.46±0.06 0.15 0.12±0.01 4.47±0.04 
IND-SAC 4.4 1.9 3.6±0.2 3.65 ± 0.05 0.42 0.79±0.03 3.66 ± 0.02 
CBZ-4ABA (H) 2.7 2.5 2.57±0.05 4.94 ± 0.02 0.17 1.73±0.06 4.84 ± 0.03 
DNZ-VAN 1.7 1.5 1.39±0.03 5.00 ± 0.01 5.9 x 10
-2
 (5.7±0.2)x10
-2
 4.96 ± 0.01 
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(c) Predicted using equations in Table 2.2, Ksp values in Table 2.3, pKa values in Table 2.5, 
and Ks
T
 values measured at the eutectic point in Table 2.7. 
(d) Calculated using equation (2.28) for 1:1 cocrystals and equation (2.29) for 2:1 cocrystals 
from experimentally measured eutectic concentrations. 
(e) Predicted using equations in Table 2.2, Ksp values in Table 2.3, and pKa values in Table 
2.5. 
For all cocrystals, predicted solubility values in FeSSIF are within a factor of two of the 
experimentally measured value regardless of which Ks
T
 value is used.  Since Ks
T
 values 
measured in the absence of coformer do an equally good job of predicting cocrystal solubility 
compared to Ks
T
 values measuered at the eutectic point, it is clear that cocrystal solubility can be 
quantitatively predicted without performing the cocrystal eutectic measurements in FeSSIF for 
these systems.   
Derivation of Ks
T 
equations 
Explanation of terms: 
Subscript aq – aqueous  
Subscript m – micellar  
Subscript T – total (aqueous + micellar) 
ABH – amphoteric coformer (nonionized) 
-ABH+ - zwitterionic drug (neutral) 
M – micellar surfactant (total surfactant concentration – critical micellar concentration) 
Ka – acid dissociation constant 
Ks – micellar solubilization constant 
S – solubility 
 
For a monoprotic weakly acidic constituent: 
 
-
A,T
s
HA HA pH-pKa,acid HA pH-pKa,acid A
T aq s s
K
S =S 1+10 + K +10 K [M]
 
 
 
 
 
      (2.30) 
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or 
 HA HA pH-pKa,acid A,TT aq sS =S 1+10 +K [M]          (2.31) 
Solving for Ks,
A,T
:  
HA
pH-pKa,acidT
HA
aqA,T
s
S
-1-10
S
K =
[M]           (2.32) 
 
For an amphoteric constituent: 
 
- +
ABH,T
s
ABH ABH pH-pKa1,amphoteric pKa2,amphoteric-pH ABH pH-pKa1,amphoteric AB pKa2,amphoteric-pH HABH
T aq s s s
K
S =S 1+10 +10 K +10 K +10 K [M]
 
 
 
 
 
 (2.33) 
or: 
 ABH ABH pH-pKa1,amphoteric pKa2,amphoteric-pH ABH,TT aq sS =S 1+10 +10 +K [M]       (2.34) 
solving for Ks
T
: 
ABH
pH-pKa1,amphoteric pKa2,amphoteric-pHT
ABH
aqABH,T
s
S
-1-10 -10
S
K =
[M]
      (2.35) 
For a zwitterionic constituent: 
 
- + - + = + - +
= +
ABH ,T
s
ABH ABH pH-pKa1,zwitterionic pKa2,zwitterionic-pH ABH pH-pKa1,zwitterionic AB pKa2,zwitterionic-pH HABH
T aq s s s
K
S =S 1+10 +10 K +10 K +10 K [M]
 
 
 
 
 
 (2.36) 
Or: 
 
- + - + - +ABH ABH pH-pKa1,zwitterionic pKa2,zwitterionic-pH ABH ,T
T aq sS =S 1+10 +10 +K [M]     (2.37) 
Solving for Ks
T
: 
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- +
- +
- +
ABH
pH-pKa1,zwitterionic pKa2,zwitterionic-pHT
ABH
aqABH ,T
s
S
-1-10 -10
S
K =
[M]
     (2.38) 
 
Solubility derivations 
Explanation of terms: 
Subscript aq – aqueous  
Subscript m – micellar  
Subscript T – total (aqueous + micellar) 
R – nonionizable drug 
HA – monoprotic weakly acidic coformer (nonionized) 
ABH – amphoteric coformer (nonionized) 
-ABH+ - zwitterionic drug (neutral) 
M – micellar surfactant (total surfactant concentration – critical micellar concentration) 
Ksp – cocrystal solubility product 
Ka – acid dissociation constant 
Ks – micellar solubilization constant 
S – solubility 
RHA (1:1 nonionizable drug R, monoprotic weakly acidic coformer HA) 
Relevant equilibria: 
sp
solid aq aq
K
RHA R HA  (2.39) 
a
aq aq aq
K
HA A H   (2.40) 
R
s
aq m
K
R M R  (2.41) 
HA
s
aq m
K
HA M HA  (2.42) 
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A
s
aq m
K
A M A

   (2.43) 
Associated equilibrium constants are given by: 
sp aq aqK [R] [HA]  (2.44) 
aq aq
a
aq
[A ] [H ]
K
[HA]
 
  (2.45) 
mR
s
aq
[R]
K
[R] [M]
  (2.46) 
mHA
s
aq
[HA]
K
[HA] [M]
  (2.47) 
mA
s
aq
[A ]
K
[A ] [M]



  (2.48) 
Cocrystal RHA total solubility in solubilizing agents 
Mass balance on R is given by: 
T aq m[R] [R] [R]   (2.49) 
Substituting equilibrium constants gives: 
 sp RT s
aq
K
[R] 1 K [M]
[HA]
   (2.50) 
Mass balance on A is given by: 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (2.51) 
Substituting equilibrium constants into (2.51) gives 
 pH pKa,coformer HA pH pKa,coformer AT aq s s[A] [HA] 1 10 K [M] 10 K [M]
      (2.52) 
Combining (2.50) and (2.52) gives: 
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  sp R pH pKa,coformer HA pH pKa,coformer AT s s s
T
K
[R] 1 K [M] 1 10 K [M] 10 K [M]
[A]
       (2.53) 
Cocrystal solubility in stoichiometric conditions: 
RHA,T T TS [R] [A]   (2.54) 
Substituting (2.54) into (2.53), 
  R pH pKa,coformer HA pH pKa,coformer ARHA,T sp s s sS K 1 K [M] 1 10 K [M] 10 K [M]
       (2.55) 
Substituting the total solubilization constant Ks
T
: 
  R pH-pKa,coformer HA,TRHA,T sp s sS = K 1+K [M] 1+10 +K [M]  (2.56) 
HDHA (1:1 monoprotic weakly acidic drug HD, monoprotic weakly acidic coformer HA) 
Relevant equilibria are given by: 
sp
solid aq aq
K
HDHA HD HA  (2.57) 
HD
a
aq aq aq
K
HD D H   (2.58) 
HA
a
aq aq aq
K
HA A H   (2.59) 
HD
s
aq m
K
HD M HD  (2.60) 
HA
s
aq m
K
HA M HA  (2.61) 
D
s
aq aq
K
D M D

   (2.62) 
A
s
aq m
K
A M A

   (2.63) 
Associated equilibrium constants are given by: 
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sp aq aqK [HD] [HA]  (2.64) 
aq aqHD
a
aq
[D ] [H ]
K
[HD]
 
  (2.65) 
aq aqHA
a
aq
[A ] [H ]
K
[HA]
 
  (2.66) 
mHD
s
aq
[HD]
K
[HD] [M]
  (2.67) 
mHA
s
aq
[HA]
K
[HA] [M]
  (2.68) 
mD
s
aq
[D ]
K
[D ] [M]



  (2.69) 
mA
s
aq
[A ]
K
[A ] [M]



  (2.70) 
Cocrystal HDHA total solubility in solubilizing agents 
Mass balance on D is given by: 
T aq aq m m[D] [HD] [D ] [HD] [D ]
      (2.71) 
Substituting (2.64), (2.65), (2.67), and (2.69) into (2.71) gives: 
 sp pH pKa,drug HD pH pKa,drug DT s s
aq
K
[D] 1 10 K [M] 10 K [M]
[HA]
      (2.72) 
Mass balance on A is given by: 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (2.73) 
Substituting (2.66), (2.68), and (2.70) into (2.73) gives: 
 pH pKa,coformer HA pH pKa,coformer AT aq s s[A] [HA] 1 10 K [M] 10 K [M]
      (2.74) 
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Combining (2.72) and (2.74) gives: 
 
 
sp pH pKa,drug pH pKa,drugDX D
s sT
T
pH pKa,coformer pH pKa,coformerHA A
s s
K
[D] 1 10 K [M] 10 K [M]
[A]
1 10 K [M] 10 K [M]


 
 
   
  
 (2.75) 
Cocrystal solubility in stoichiometric solutions is given by: 
HDHA,T T TS [D] [A]   (2.76) 
Substituting (2.75) into (2.76), 
  pH pKa,drug HD pH pKa,drug D pH pKa,coformer HA pH pKa,coformer AHDHA,T sp s s s sS K 1 10 K [M] 10 K [M] 1 10 K [M] 10 K [M]
          
(2.77) 
Substituting Ks
T
 values for HD and HA: 
  HDHA HDHA pH-pKa,drug HD,T pH-pKa,coformer HA,Tsp s sTS = K 1+10 +K [M] 1+10 +K [M]  (2.78) 
R2HAB (2:1 monoprotic weakly basic drug R, amphoteric coformer ABH) 
Relevant equilibria are given by: 
sp
2 solid aq aq
K
R ABH 2R ABH  (2.79) 
2ABH
a
2aq aq aq
K
ABH ABH H

   (2.80) 
ABH
a
aq aq aq
K
ABH AB H   (2.81) 
R
s
aq m
K
R M R  (2.82) 
2ABH
s
2aq 2 m
K
ABH M ABH

   (2.83) 
ABH
s
aq m
K
ABH M ABH  (2.84) 
AB
s
aq m
K
AB M AB

   (2.85) 
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Associated equilibrium constants are given by: 
2
sp aq aqK [R] [ABH]  (2.86) 
2
aq aqABH
a
2 aq
[ABH] [H ]
K
[ABH ]



  (2.87) 
aq aqABH
a
aq
[AB ] [H ]
K
[ABH]
 
  (2.88) 
mR
s
aq
[R]
K
[R] [M]
  (2.89) 
2
2 mABH
s
2 aq
[ABH ]
K
[ABH ] [M]



  (2.90) 
mABH
s
aq
[ABH]
K
[ABH] [M]
  (2.91) 
mAB
s
aq
[AB ]
K
[AB ] [M]



  (2.92) 
Cocrystal R2HAB total solubility in solubilizing agents 
Mass balance on R is given by: 
T aq m[R] [R] [R]   (2.93) 
Substituting (2.86) and (2.89) into (2.93) gives: 
 
2sp2 R
T s
aq
K
[R] 1 K [M]
[ABH]
   (2.94) 
Mass balance on AB is given by: 
T aq 2 aq aq m 2 m m[AB] [ABH] [ABH ] [AB ] [ABH] [ABH ] [AB ]
          (2.95) 
Substituting (2.87), (2.88), and (2.90)-(2.92) into (2.95) gives: 
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2ABHpH pKa1,amphoteric pKa2,amphoteric pH ABH pKa2,amphoteric pH
s s
aqT
pH pKa1,amphoteric AB
s
1 10 10 K [M] 10 K [M]
[AB] [ABH]
10 K [M]


  

 
 
 
 
   


(2.96) 
Combining (2.94) and (2.96) gives 
 
2ABHpH pKa1,amphoteric pKa2,amphoteric pH pKa2,amphoteric pHABH2sp s s2 R
sT pH pKa1,amphoteric AB
T s
K 1 10 10 K [M] 10 K [M]
[R] 1 K [M]
[AB] 10 K [M]


  

 
 
 
 
   
 

(2.97) 
Cocrystal solubility in stoichiometric solutions of cocrystal constituents is given by: 
2R ABH,T T T
1
S [R] [A]
2
   (2.98) 
Substituting equilibrium constants in terms of molar concentrations of drug: 
 
2 2
pH pKa1,amphoteric pKa2,amphoteric pH ABH
2 ssp R
3 sR ABH,T ABHpKa2,amphoteric pH pH pKa1,amphoteric AB
s s
1 10 10 K [M]K
S 2 1 K [M]
4 10 K [M] 10 K [M]
 
 
 
 
 
 
 
  
 
 
 (2.99) 
In terms of total solubilization constant Ks
T
: 
   
2
2
R ABH
2spR ABH R,T pH-pKa1,amphoteric pKa2,amphoteric-pH ABH,T3
T s s
K
S =2 1+K [M] 1+10 +10 +K [M]
4
 (2.100) 
-
ABH
+
HA (1:1 zwitterionic drug 
–
ABH
+
, monoprotic weakly acidic coformer HA) 
Relevant equilibria are given by: 
sp
solid aq aq
K
ABH HA ABH HA      (2.101) 
2ABH
a
2aq aq aq
K
ABH ABH H

     (2.102) 
AB
a
aq aq aq
K
AB AB H

    (2.103) 
HA
a
aq aq aq
K
HA A H   
2ABH
s
2aq 2 m
K
ABH M ABH

   (2.104) 
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ABH
s
aq m
K
ABH M ABH
 
     (2.105) 
AB
s
aq m
K
AB M AB

   (2.106) 
mHA
s
aq
[HA]
K
[HA] [M]
  (2.107) 
mA
s
aq
[A ]
K
[A ] [M]



  (2.108) 
Mass balance on 
–
ABH
+
 is given by: 
T aq 2 aq aq m 2 m m[ ABH ] [ ABH ] [ABH ] [ AB] [ ABH ] [ABH ] [ AB]
                (2.109) 
Substituting (2.87), (2.88), and (2.90)-(2.92) into (2.95) gives: 
2ABHpH pKa1,zwitterionic pKa2,zwitterionic pH ABH pKa2,zwitterionic pH
s s
aqT
pH pKa1,zwitterionic AB
s
1 10 10 K [M] 10 K [M]
[ ABH ] [ ABH ]
10 K [M]
 

  
   

 
 
 
 
   


(2.110) 
Mass balance on A is given by: 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (2.111) 
Substituting (2.66), (2.68), and (2.70) into (2.73) gives: 
 pH pKa,acid HA pH pKa,acid AT aq s s[A] [HA] 1 10 K [M] 10 K [M]
       (2.112) 
Combining equations: 

 
2ABHpH pKa1,zwitterionic pKa2,zwitterionic pH ABH pKa2,zwitterionic pH
s s
pH pKa1,zwitterionic AB
s
pH pKa,acid HA pH pKa,acid A
s s
sp
T
T
1 10 10 K [M] 10 K [M]
10 K [M] 1 10 K [M] 10 K [M]
K
[ ABH ]
[A]
 
 
  
  
 
    
 
 
 
 
   
  (2.113) 
Cocrystal solubility in stoichiometric solutions of constituents is given by: 
T TABH HA,T
S [ ABH ] [A] 
           (2.114) 
Substituting X into X and substituting KsT values gives: 
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  
- + - + - +ABH HA ABH HA pH-pKa1,zwitterionic pKa2,zwitterionic-pH ABH ,T pH-pKa,acid HA,T
T sp s sS = K 1+10 +10 +K [M] 1+10 +K [M]
(2.115) 
Ksp Measurements 
DNZ-HBA 
DNZ-HBA Ksp was determined by linear regression analysis of cocrystal eutectic point 
concentrations measured in pH 2 (10 mM phosphate) buffer, pH 5 (12 mM acetate) buffer, and 
unbuffered aqueous solution (water) according to the following equation: 
 sp pH-pKa,HBAeu
eu
K
[HBA] = 1+10
[DNZ]
        (2.116) 
 
 
Regression parameters:  
  Coefficients Standard Error t Stat P-value 
Intercept 5.307E-04 4.915E-03 0.108 9.167E-01 
X Variable 1 3.806E-02 3.259E-03 11.678 2.637E-06 
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Regression Statistics 
Multiple R 0.972 
R Square 0.945 
Adjusted R Square 0.938 
Standard Error 5.182E-03 
Observations 10 
 
 Table 2.9 shows the comparison between Ksp obtained by linear regression of all data points and 
those calculated at each specific pH measurement according to: 
sp eu 0,euK =[DNZ] [HBA]          (2.117) 
Where  
T,eu
0,eu pH-pKa,HBA
[HBA]
[HBA] =
1+10
         (2.118) 
 
Table 2.9.  Comparison of Ksp values obtained by linear regression and single point calculations 
for DNZ-HBA. 
pH Ksp (mM
2
) 
4.47±0.04 8.56 x 10
-3
 
3.07±0.04 1.50 x 10
-2
 
2.12±0.03 1.43 x 10
-2
 
Regression (all points) (1.1±0.4) x 10
-2
 
 
DNZ-VAN 
DNZ-VAN Ksp was determined by eutectic point measurements in pH 2 (10 mM phosphate) 
buffer, and pH 5 (12 mM acetate) buffer.  The Ksp value reported is the average of the Ksp values 
determined by the two sets of eutectic point measurements: 
 
Table 2.10. Eutectic concentrations of DNZ and VAN used to calculate Ksp of DNZ-VAN. 
pH 
[DNZ]eu 
(mM) 
error 
[VAN]T,eu 
(mM) 
error 
[VAN]0,eu 
(mM) 
Ksp (mM
2
) 
 
4.96 1.95 x10
-4
 3.66x10
-6
 16.1 2.66x10
-2
 16.0 3.13Ex10
-3
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4.96 2.03x10
-4
 3.90x10
-5
 18.5 0.226 18.5 3.75x10
-3
  
4.95 2.16x10
-4
 3.04x10
-5
 16.3 0.137 16.2 3.51x10
-3
  
2.15 1.96x10
-4
 1.46x10
-5
 21.0 2.77x10
-2
 21.0 4.11x10
-3
  
2.18 2.19x10
-4
 8.73x10
-5
 20.0 5.97x10
-2
 20.0 4.39x10
-3
  
     
AVERAGE 3.5x10
-3
  
     
STDEV 5.0x10
-4
  
 
 
PXC-SAC 
PXC-SAC Ksp was determined by a single point eutectic measurement in pH 5 acetate buffer 
 
Table 2.11. Eutectic concentrations of PXC and SAC used to calculate the Ksp of PXC-SAC. 
 
pH 
[PXC]T,eu 
(mM) 
[PXC]eu0 
(mM) 
[SAC]T,eu 
(mM) 
[SAC]eu0 
(mM) 
Ksp 
(mM
2
) 
 
3.64 3.55x10
-2
 3.45x10
-2
 93.1 2.09 7.18x10
-2
 
 
3.63 3.68x10
-2
 3.57x10
-2
 93.4 2.14 7.63x10
-2
 
 
3.64 3.61x10
-2
 3.49x10
-2
 97.3 2.18 7.61x10
-2
 
 
3.63 3.89x10
-2
 3.77x10
-2
 92.6 2.12 8.00x10
-2
 
 
3.63 3.56x10
-2
 3.45x10
-2
 94.1 2.16 7.45x10
-2
 
 
3.62 3.68x10
-2
 3.57x10
-2
 95.4 2.23 7.97x10
-2
 
 
3.64 3.53x10
-2
 3.42x10
-2
 94.0 2.11 7.21x10
-2
 
AVERAGE 3.632857 3.64x10
-2
 3.53x10
-2
 94.3 2.15 7.58x10
-2
 
STDEV 0.007559 1.24x10
-3
 1.20x10
-3
 1.59 5.01E-02 3.27x10
-3
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CHAPTER 3  
COCRYSTAL SUPERSATURATION DURING DISSOLUTION IN 
PHYSIOLOGICALLY RELEVANT SURFACTANTS 
 
Introduction  
Cocrystallization with hydrophilic coformers has been reported to improve the solubility, 
dissolution, and ultimately oral absorption and bioavailability of poorly soluble hydrophobic 
drugs
1-6
.  Cocrystals that are more soluble than the drug are prone to solution-mediated phase 
transformation to the less soluble drug during dissolution in aqueous environments, negating any 
solubility enhancement benefit.  Recently, synthetic formulation surfactants have been shown to 
impart thermodynamic stability to cocrystals of carbamazepine and indomethacin that were 
otherwise unstable in aqueous solution
7-9
.  Cocrystal solubility increases with the concentration 
of solubilizing agent in solution, while the cocrystal solubility advantage over drug 
(Scocrystal/Sdrug) decreases
7-9
.  This behavior is explained by the preferential solubilization of the 
constituent drug by the solubilizing agent compared to the coformer.  When drug is preferentially 
solubilized by solubilizing agents, Scocrystal/Sdrug decreases, and solubilizing agent concentration 
can be selected to target a particular level of supersaturation
7-11
.   
Mathematical models have been derived to predict cocrystal solubility, and Scocrystal/Sdrug 
based on the solution equilibria for cocrystal dissociation, and constituent ionization and micellar 
solubilization and the models confirmed by experimental data for several cocrystals in the 
presence of solubilizing agents.  Preliminary powder dissolution studies of the indomethacin-
 92 
 
saccharin cocrystal in the presence of Tween 80 have explored the connection between 
Scocrystal/Sdrug and kinetic cocrystal dissolution behavior.  When Scocrystal/Sdrug was reduced from 26 
in aqueous solution to 6 by addition of 0.01% Tween 80, the cocrystal exhibited slowed 
conversion kinetics and maintained supersaturated indomethacin concentrations longer than in 
aqueous buffer
10
.  There are no other reported studies to our knowledge that explore the impact 
of Scocrystal/Sdrug reduction due to preferential solubilization on kinetic dissolution behavior of 
cocrystals to our knowledge.  Furthermore, cocrystal dissolution is routinely evaluated in 
biorelevant media containing physiologically relevant solubilizing agents without any knowledge 
of the drug concentrations and supersaturations to anticipate.   
The aim of this work was to evaluate the relationship between Scocrystal/Sdrug and cocrystal 
powder dissolution behavior.  In particular, the impact of Scocrystal/Sdrug reduction due to 
preferential solubilization on cocrystal dissolution was explored in the physiologically relevant 
surfactant fed-state simulated intestinal fluid (FeSSIF).  FeSSIF is routinely used in dissolution 
testing and it contains relatively high concentrations of sodium taurocholate and lecithin which 
are known to form mixed micelles in aqueous solution and solubilize hydrophobic drugs.  It is 
hypothesized that the preferential solubilization of constituent drugs by FeSSIF will result in 
lower peak supersaturations, sustained supersaturated drug concentrations, and slowed or 
prevented transformation to drug during powder dissolution.  The cocrystals studied include: 1:1 
carbamazepine-saccharin (CBZ-SAC), 1:1 carbamazepine-salicylic acid (CBZ-SLC), 2:1 
carbamazepine 4-aminobenzoic acid hydrate, (CBZ-4ABA-HYD), 1:1 piroxicam-saccharin 
(PXC-SAC), 1:1 indomethacin-saccharin (IND-SAC), 1:1 danazol-hydroxybenzoic acid (DNZ-
HBA), and 1:1 danazol-vanillin (DNZ-VAN).  The selected cocrystals include both 1:1 and 2:1 
cocrystal stoichiometries and cover a range of ionization behaviors for both drug and coformers.  
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PXC is a zwitterionic drug with pKa values of 1.86 and 5.46
12
, and IND is a monoprotic weakly 
acidic drug with a pKa of 4.2
13
.  SAC is a monoprotic weak acid with pKa values reported 
between 1.6-2.2
14
, SLC is a monoprotic weak acid with a reported pKa value of 3.0
14
, 4ABA is 
amphoteric with pKa values 2.6 and 4.8
15
, HBA is a monoprotic weak acid with a reported pKa 
value of 4.48
16
 and VAN is a monoprotic weak acid with a pKa of 7.4
16
. 
Theoretical 
Calculation of cocrystal solubility and thermodynamic stability from eutectic point 
measurements 
The stoichiometric solubility of the cocrystals (cocrystal at equilibrium with solution 
concentrations of constituents equal to their molar ratio) is calculated total eutectic 
concentrations by the following equations for 1:1 and 2:1 cocrystals
17
: 
1:1 cocrystal
T T,eu T,euS = [drug] [coformer]         (3.1) 
2
T,eu T,eu2:1 cocrystal 3
T
[drug] [coformer]
S =2
4
 
 
 
 
       (3.2) 
[constituent]T,eu is defined as the sum of the concentrations of all species dissolved at the eutectic 
point ([constituent]T,eu = [constituent]aq,eu + [constituent]m,eu) in the presence of a solubilizing 
agent.  [constituent]aq,eu represents the total aqueous concentration at a particular pH in the 
absence of solubilizing agent ([constituent]aq,eu = [constituent]nonionized,aq,eu + 
[constituent]ionized,aq,eu) and is the sum of the nonionized and ionized contributions to the eutectic 
concentration.  [constituent]m,eu represents the cocrystal solubilized by solubilizing agents 
([constituent]m,eu = [constituent]nonionized,m,eu +  [constituent]ionized,s,eu) and contributions from the 
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ionized species as appropriate.  These methods of accessing cocrystal equilibrium solubility in 
nonstoichiometric conditions are well established in the literature
7-9, 17, 18
. 
The cocrystal thermodynamic stability can be calculated from the drug and coformer 
eutectic concentrations by calculating the eutectic constant, Keu.  Keu is a directly measurable 
parameter calculated according to
19
: 
T,eu
eu
T,eu
[coformer]
K =
[drug]
            (3.3) 
The eutectic constant is related to the cocrystal thermodynamic stability, also called the cocrystal 
solubility advantage (Scocrystal/Sdrug).  For cocrystal AxBy, where A and B are the cocrystal 
constituents, drug and coformer respectively; and x and y are the stoichiometric coefficients or 
molar ratios, Keu is a function of Scocrystal/Sdrug as follows
17, 19
: 
 x+y
x y
cocrystalT,eu y
eu
T,eu drug
S[coformer]
K = =xy
[drug] S
 
  
 
       (3.4) 
This relationship is valid in both aqueous and solubilizing agent solutions as it relies on the total 
measured eutectic concentrations of drug and coformer in the conditions of interest.   
  Scocrystal/Sdrug in the presence of a solubilizing agent can be predicted using the full 
cocrystal and drug solubility equations
10
.  For a 1:1 cocrystal of a nonionizable drug R with a 
monoprotic weakly acidic coformer HA: 
 
 
HA
RHA R HAa
RHA sp s,T s,T+
cocrystal
R R
drug aq s,T
K
K 1+K [M] 1+ +K [M]
[H ]S
=
S S 1+K [M]
 
 
   
  
 
      (3.5) 
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For a 1:1 cocrystal of a monoprotic weakly acidic drug HD with a monoprotic weakly acidic 
coformer HA: 
HD HA
HDHA HD HAa a
HDHA sp s,T s,T+ +
cocrystal
HD
HD HDdrug a
aq s,T+
K K
K 1+ +K [M] 1+ +K [M]
[H ] [H ]S
=
S K
S 1+ +K [M]
[H ]
  
  
    
     
 
 
    (3.6) 
For a 1:1 cocrystal of a zwitterionic drug 
–
ABH
+
 with a monoprotic weakly acidic coformer HA: 
- +
- + - +
- +
- +
- +
- + - +
- +
ABH HA+
ABH HA ABH ,T HA,Ta1 a
ABH HA sp s s+ +ABH
a2cocrystal
ABH +
drug ABH ABH ,Ta1
aq s+ ABH
a2
K K[H ]
K 1+ + +K [M] 1+ +K [M]
[H ] [H ]KS
=
S K [H ]
S 1+ + +K [M]
[H ] K
  
       
     
  
 
 (3.7) 
For a 2:1 cocrystal of a nonionizable drug with an amphoteric coformer: 
 
 
2
2
R ABH ABH +
2sp R,T ABH,Ta1
3R ABH s s+ ABH
a2cocrystal
R R
drug aq s,T
K K [H ]
2 1+K [M] 1+ + +K [M]
4 [H ] KS
=
S S 1+K [M]
 
 
   
  
 
   (3.8) 
Equations (3.5)-(3.8) take into account the total solubilization of ionizable components, as 
indicated by total solubilization constants at a defined pH, or Ks,
T
.  Ks
T 
definitions and 
derivations can be found in the Appendix of Chapter 2. 
Scocrystal/Sdrug in FeSSIF and in buffer can be experimentally determined by two methods.  
Method 1:  Scocrystal/Sdrug can be calculated from the experimentally determined Keu as described 
by equation (3.4) from measured eutectic point drug and coformer concentration measurements.  
Method 2: Scocrystal/Sdrug can be calculated from Scocrystal measured at the eutectic point as 
described by equations (3.1) and (3.2) and from Sdrug measured in the absence of coformer (drug 
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solid phase only), but corrected for pH to be at the pH of the cocrystal solubility measurement 
(pHeu).  This ensures that the Scocrystal and Sdrug pH conditions to be equivalent.  The main 
difference between these two methods is that in Method 1, the drug solubility is measured in the 
presence of coformer at the eutectic point.  At the eutectic point, drug solid phase and cocrystal 
solid phase are in equilibrium with the solution, so high coformer concentrations in solution are 
possible. In Method 2, the drug solubility is measured in equilibrium with solid phase only, and 
in the absence of coformer in solution.  If the presence of coformer affects the drug solubility, 
the Scocrystal/Sdrug values obtained by these two methods will vary.  Under stoichiometric 
conditions, the concentration of coformer in solution will be less than the coformer concentration 
present at the eutectic point (Method 1), but higher than no coformer at all (Method 2).  
Comparison of the Scocrystal/Sdrug obtained by these two methods will show of the range of 
Scocrystal/Sdrug values that can be anticipated for the cocrystals studied and reveal the possible 
sources of error in their calculation. 
Scocrystal/Sdrug in FeSSIF and in buffer can also be predicted from the reported or 
experimentally determined equilibrium constants (Ksp, pKa, Ks
T
, Saq
drug
) as well as the solution 
conditions of interest (pH, [M]) as described by equations (3.6)-(3.8).  These models are useful 
to predict Scocrystal/Sdrug in conditions that the cocrystal and/or drug solubility have not yet been 
measured. 
Materials and Methods 
Materials 
Cocrystal constituents 
Anhydrous carbamazepine form III (CBZ), anhydrous indomethacin form γ (IND) were 
purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  Anhydrous 
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piroxicam form I was received as a gift from Pfizer (Groton, CT) and used as received.  
Anhydrous danazol was received as a gift from Renovo Research (Atlanta, GA) and used as 
received.   
Anhydrous saccharin (SAC), 4- aminobenzoic acid (4ABA), and salicylic acid (SLC), 
were purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  
Anhydrous hydroxybenzoic acid was purchased from Acros Organics (Pittsburgh, PA) and used 
as received.  Anhydrous vanillin was purchased from Fisher Scientific (Fair Lawn, NJ) and used 
as received. Carbamazepine dihydrate (CBZ (H)), piroxicam monohydrate (PXC (H)), and 
hydroxybenzoic acid monohydrate (HBA (H)) were prepared by slurrying CBZ, PXC, and HBA 
in deionized water for at least 24 hours.  All crystalline drugs and coformers were characterized 
by X-ray power diffraction (XRPD) and differential scanning calorimetry (DSC) before carrying 
out experiments. 
Solvents and buffer components 
Ethyl acetate and ethanol were purchased from Acros Organics (Pittsburgh, PA) and used 
as received, and HPLC grade methanol and acetonitrile were purchased from Fisher Scientific 
(Pittsburgh, PA). Trifluoroacetic acid spectrophometric grade 99% was purchased from Aldrich 
Company (Milwaukee, WI) and phosphoric acid ACS reagent 85% was purchased from Sigma 
Chemical Company (St. Louis, MO).  Water used in this study was filtered through a double 
deionized purification system (Milli Q Plus Water System) from Millipore Co. (Bedford, MA). 
FeSSIF and acetate buffer were prepared using sodium taurocholate (NaTC) purchased 
from Sigma Chemical Company (St. Louis, MO), lecithin purchased from Fisher Scientific 
(Pittsburgh, PA), sodium hydroxide pellets (NaOH) purchased from J.T. Baker (Philipsburg, NJ), 
and acetic acid and potassium chloride (KCl) purchased from Acros Organics (Pittsburgh, PA).  
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Methods 
FeSSIF and acetate buffer preparation 
FeSSIF and acetate buffer were prepared according to the protocol of Galia and 
coworkers
20
.  Acetate buffer was prepared as a stock solution at room temperature by dissolving 
8.08 g NaOH (pellets), 17.3 g glacial acetic acid and 23.748 g NaCl in 2 L of purified water. The 
pH was adjusted to 5.00 with 1 N NaOH and 1N HCl.  FeSSIF was prepared by dissolving 0.41 g 
sodium taurocholate in 12.5 mL of pH 5 acetate buffer. 0.148 g lecithin was added with magnetic 
stirring at 37 °C until dissolved.  The volume was adjusted to exactly 50 mL with acetate buffer.  
Cocrystal synthesis 
Cocrystals were prepared by the reaction crystallization method
21
 at 25°C. The 1:1 
indomethacin-saccharin cocrystal (IND-SAC) was synthesized by adding stoichiometric amounts 
of cocrystal components (IND and SAC) to nearly saturated SAC solution in ethyl acetate.  The 
1:1 carbamazepine saccharin cocrystal (CBZ-SAC) was prepared by adding stoichiometric 
amounts of cocrystal components (CBZ and SAC) to nearly saturated SAC solution in ethanol. 
The 1:1 carbamazepine-salicylic acid cocrystal (CBZ-SLC) was prepared by adding 
stoichiometric amounts of cocrystal components (CBZ and SLC) to nearly saturated SLC 
solution in acetonitrile. The 2:1 carbamazepine-4-aminobenzoic acid monohydrate cocrystal 
(CBZ-4ABA (H)) was prepared by suspending stoichiometric amounts of cocrystal components 
(CBZ and 4ABA) in a 0.01M 4ABA aqueous solution at pH 3.9.  The 1:1 piroxicam-saccharin 
cocrystal (PXC-SAC) was prepared by adding stoichiometric amounts of cocrystal components 
(PXC and SAC) to nearly saturated SAC in acetonitrile.  The 1:1 danazol-hydroxybenxoic acid 
cocrystal (DNZ-HBA) was prepared by adding stoichiometric amounts of cocrystal components 
(DNZ and HBA) to nearly saturated HBA solution in ethyl acetate.  The 1:1 danazol-vanillin 
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cocrystal (DNZ-VAN) was prepared by adding stoichiometric amounts of cocrystal components 
(DNZ and VAN) to nearly saturated VAN solution in ethyl acetate.  Prior to carrying out any 
solubility experiments, solid phases were characterized by XRPD and DSC and stoichiometry 
verified by HPLC.   Full conversion to cocrystal was observed in 24 hours. 
Solubility measurements of cocrystal constituents 
Cocrystal constituent solubilities were measured in FeSSIF and pH 5.00 acetate buffer 
(FeSSIF without NaTC and lecithin).  Solubilities of cocrystal constituents were determined by 
adding excess solid (drug or coformer) to 3 mL of media (FeSSIF or buffer). Solutions were 
magnetically stirred and maintained at 25 ±  0.1°C using a water bath for up to 96 h. At 24 hr 
intervals, 0.30 mL of samples were collected, pH of solutions measured, and filtered through a 
0.45 µm pore membrane.   After dilution with mobile phase, solution concentrations of drug or 
coformer were analyzed by HPLC. The equilibrium solid phases were characterized by XRPD 
and DSC. 
Cocrystal solubility measurements 
Cocrystal equilibrium solubilities were measured in FeSSIF and pH 5.00 acetate buffer 
(FeSSIF without NaTC and lecithin) at the eutectic point, where drug and cocrystal solid phases 
are in equilibrium with solution. The eutectic point between cocrystal and drug was approached 
by cocrystal dissolution (suspending solid cocrystal (~100 mg) and drug (~50 mg) in 3 mL of 
media (FeSSIF or buffer)) and by cocrystal precipitation (suspending solid cocrystal (~50 mg) 
and drug (~100 mg) in 3 mL of media (FeSSIF or buffer) nearly saturated with coformer).  
Solutions were magnetically stirred and maintained at 25 ± 0.1°C using a water bath for up to 96 
h. At 24 hr intervals, 0.30 mL aliquots of suspension were collected, pH was measured, before 
filtration through a 0.45 µm pore membrane.   Solid phases were also collected at 24 hr intervals 
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to ensure the sample was at the eutectic point (confirmed by presence of both drug and cocrystal 
solid phases and constant [coformer] and [drug] solution concentrations).  After dilution of 
filtered solutions with mobile phase, drug and coformer concentrations were analyzed by HPLC. 
The equilibrium solid phases were characterized by XRPD and DSC. 
Calculation of Scocrystal/Sdrug 
Scocrystal/Sdrug in FeSSIF and in buffer was experimentally determined by two methods.  
Method 1:  Scocrystal/Sdrug was calculated from the experimentally determined Keu as described by 
equation (3.4) from measured eutectic point drug and coformer concentration measurements.  
This is described in more detail in the theoretical section. Method 2: Scocrystal/Sdrug was calculated 
from Scocrystal measured at the eutectic point as described by equations (3.1) and (3.2) and from 
Sdrug measured in the absence of coformer (drug solid phase only), but corrected for pH to be at 
the pH of the cocrystal solubility measurement (pHeu). 
Scocrystal/Sdrug in FeSSIF and in buffer was also predicted from the reported or 
experimentally determined equilibrium constants (Ksp, pKa, Ks
T
, Saq
drug
) as well as the solution 
conditions of interest (pH, [M]) as described by equations (3.6)-(3.8) in the theoretical section.  
Cocrystal dissolution studies 
250 mg of sieved cocrystal (45-106 µm) was suspended in 30 mL of FeSSIF or acetate 
buffer at 25 ± 0.1°C. The resulting slurry was stirred at 150 rpm using an overhead impeller 
stirrer. Aliquots were withdrawn at predetermined time points and filtered through a 0.45 µm 
PVDF syringe filter. Solution concentrations were analyzed by HPLC. Final solid phases after 4 
hours were characterized by XRPD and DSC.  
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X-ray powder diffraction 
X-ray powder diffraction diffractograms of solid phases were collected on a benchtop 
Rigaku Miniflex X-ray diffractometer (Rigaku, Danverse, MA) using Cu Kα radiation (λ= 
1.54Å), a tube voltage of 30 kV, and a tube current of 15 mA. Data were collected from 5 to 40° 
at a continuous scan rate of 2.5°/min.  
Thermal analysis 
Solid phases collected from the slurry studies were dried at room temperature and 
analyzed by differential scanning calorimetry (DSC) using a TA instrument (Newark, DE) 
2910MDSC system equipped with a refrigerated cooling unit. DSC experiments were performed 
by heating the samples at a rate of 10 °C/min under a dry nitrogen atmosphere. A high purity 
indium standard was used for temperature and enthalpy calibration.  Standard aluminum sample 
pans were used for all measurements.  
High performance liquid chromatography 
Solution concentrations were analyzed by a Waters HPLC (Milford, MA) equipped with 
an ultraviolet-visible spectrometer detector. For the IND-SAC and CBZ-SAC, CBZ-SLC, CBZ-
4ABA-HYD cocrystals and their components, a C18 Thermo Electron Corporation (Quebec, 
Canada) column (5µm, 250 x 4.6 mm) at ambient temperature was used. For the IND-SAC 
cocrystal, the injection volume was 20 µl and analysis conducted using an isocratic method with 
a mobile phase composed of 70% acetonitrile and 30% water with 0.1% trifluoroacetic acid and 
a flow rate of 1 ml/min. Absorbance of IND and SAC were monitored at 265 nm. For the CBZ 
cocrystals, the injection volume was 20 µl and analysis conducted using an isocratic method with 
a mobile phase composed of 55% methanol and 45% water with 0.1% trifluoroacetic acid and a 
flow rate of 1 mL/min. Absorbance was monitored as follows:  
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CBZ and 4ABA at 284 nm, SAC at 265 nm, and SLC at 303 nm. For the PXC-SAC, 
DNZ-HBA, and DNZ-VAN cocrystals and their components, a C18 Waters Atlantis (Milford, 
MA) column (5 µM 250 x 6 mm) at ambient temperature was used.  For PXC-SAC, the injection 
volume was 20 µL and analysis was conducted using an isocratic method with a mobile phase 
composed of 70% methanol and 30% water with 0.3% phosphoric acid and a flow rate of 1 
mL/min.  Absorbance of PXC was monitored at 340 nm and SAC at 240 nm.  For the DNZ 
cocrystals, the injection volume was 20 µL in FeSSIF experiments, and 100 µL in buffer 
experiments due to the extremely low solubility of DNZ in aqueous solutions.  Analysis was 
conducted using an isocratic method composed of 80% methanol and 20% water with 0.1% 
trifluoroacetic acid and a flow rate of 1 mL/min.  Absorbance of DNZ was monitored at 285 nm, 
HBA at 242 nm, and VAN at 300 nm.  For all cocrystals, the Waters’ operation software 
Empower 2 was used to collect and process data. 
Results 
Drug solubility 
Comparison of drug solubility measured at the eutectic point and drug solubility 
measured in the absence of coformer, or in equilibrium with drug solid phase only is presented in 
the Appendix of Chapter 2.  For the purpose of comparing deviations in Scocrystal/Sdrug values 
obtained from Methods 1 and 2, drug solubility values measured in the presence of coformer at 
the eutectic point (for Method 1), measured in the absence of coformer, and in the absence of 
coformer at the pH of the eutectic point measurement (Method 2) are presented in Table 3.1. 
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Table 3.1.  Comparison of drug solubility values measured at the eutectic point (in the presence 
of coformer in solution) and in the absence of coformer. 
Media Cocrystal Sdrug,eu
a 
pHeu Sdrug
b 
pH Sdrug at pHeu
c 
buffer 
CBZ-SAC 0.78±0.05 3.08±0.03 0.42±0.02 4.95±0.01 0.42±0.02 
CBZ-SLC 0.51±0.02 4.37±0.02 0.42±0.02 4.95±0.01 0.42±0.02 
CBZ-4ABA-
HYD 
0.44±0.02 4.84±0.03 0.42±0.02 4.95±0.01 0.42±0.02 
PXC-SAC (3.64±0.01)x10
-2
 3.64±0.02 (3.1±0.1)x10
-2
 4.98±0.01 (2.4±0.1)x10
-2
 
IND-SAC (6.0±0.3)x10
-3
 3.66±0.02 (2.3±0.1)x10
-3
 4.96±0.03 (4.3±0.2)x10
-3
 
DNZ-HBA (2.0 ±0.4)x10
-4
 4.47±0.04 (1.6±0.2)x10
-4
 4.96±0.01 (1.6±0.2)x10
-4
 
DNZ-VAN (2.1±0.1)x10
-4
 4.96±0.01 (1.6±0.2)x10
-4
 4.96±0.01 (1.6±0.2)x10
-4
 
FeSSIF 
CBZ-SAC 1.07±0.03 3.11±0.02 0.75±0.02 4.86±0.05 0.75±0.02 
CBZ-SLC 0.91±0.02 4.29±0.02 0.75±0.02 4.86±0.05 0.75±0.02 
CBZ-4ABA-
HYD 
0.74±0.03 4.94±0.02 0.75±0.02 4.86±0.05 0.75±0.02 
PXC-SAC (6.80±0.06)x10
-2
 3.79±0.02 (6.0±0.3)x10
-2
 5.03±0.02 (5.0±0.3)x10
-2
 
IND-SAC (1.5±0.2)x10
-1
 3.65±0.05 (3.7±0.2)x10
-1
 4.97±0.06 (7.3 ±0.2)x10
-2
 
DNZ-HBA (9.9±0.8) x10
-2
 4.46±0.06 (1.11±0.09) x10
-1
 5.01±0.05 1.11±0.09) x10
-1
 
DNZ-VAN (1.0±0.2)x10
-1
 5.00±0.01 (1.11±0.09) x10
-1
 5.01±0.05 1.11±0.09) x10
-1
 
(a) Measured at the eutectic point in the presence of cocrystal and drug solid phases and 
in equilibrium with solution. 
(b) Measured independently in the presence of only drug solid phase in equilibrium with 
solution. 
(c) Calculated from the drug solubility values measured independently to be at the pHeu. 
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Drug solubility can be influenced by both the coformer concentration at the eutectic point 
and the pH differences between the solubility measurements in the absence and the presence of 
coformer.  The presence of excess coformer in solution at the eutectic point can alter the pH of 
the media when coformers are ionizable, which is the case for most of the systems studied in this 
work. 
CBZ solubility is unaffected by pH differences (as it is nonionizable) and is not affected 
significantly by the presence of coformer except for the case of SAC.  The extremely high SAC 
concentration at the eutectic point Table 3.1 actually increases the solubility of CBZ in aqueous 
buffer.  The CBZ solubility at the eutectic point was 0.78 mM in presence of SAC, which is 
nearly double the CBZ solubility measured independently in pH 5 aqueous buffer (0.42 mM).  
This was confirmed by an independent solubility experiment where CBZ solubility (0.75 mM) 
was measured in a high SAC concentration without the presence of cocrystal.   
For IND, the difference between the independently measured and eutectic point solubility 
is partially due to a pH difference between the two experimental conditions.  IND is a weak acid 
with a pKa of 4.2.  The eutectic pH values are around 3.65 while the pH of the independent 
solubility measurement is around 5.00.  Therefore, IND concentrations in FeSSIF at pH<pKa are 
two fold lower than at pH>pKa (0.15 mM at pH 3.65 vs. 0.37 mM at pH 4.97).  In buffer, 
however, this pH effect is overshadowed by supersaturated IND concentrations.  In buffer, IND-
SAC is 132 times more soluble than IND, and it is likely that the eutectic point measurement had 
supersaturated IND concentrations due to this large solubility advantage.  The growth of a higher 
energy (and solubility) form of IND from supersaturated solutions has been shown to increase 
IND solubility by as much as 3 fold from highly supersaturated solutions
49
.   
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PXC and DNZ do not have large differences in the drug solubility in the absence or in the 
presence of coformer.  The drug solubility values measured independently and at the eutectic 
point are in good agreement. For DNZ, there is not a large solubility difference between the 
values measured at the eutectic point versus those measured in the absence of coformer as shown 
in Table 3.1; however, DNZ has a very low solubility in aqueous buffer (on the order of 10
-4
 
mM), and even small changes in Sbuffer lead to moderate differences in Scocrystal/Sdrug.  The impact 
of these differences in Scocrystal/Sdrug will be examined in a subsequent section. 
Cocrystal solubility 
 A comprehensive discussion of cocrystal solubility and solubility prediction in the 
presence of physiologically relevant surfactants has been presented in Chapter 2 of this 
dissertation.  The solubility of a cocrystal is the highest theoretical concentration that can be 
attained during cocrystal dissolution assuming the dose of the cocrystal is sufficient to reach the 
solubility.  The solubility may not be reached during dissolution if the dose is too low, if 
cocrystal undergoes solution-mediated transformation to a more stable and less soluble solid 
form, and if the time-frame of the dissolution study is too short to reach equilibrium.  
Nevertheless, knowledge of cocrystal solubility under dissolution conditions is useful to 
anticipate the concentrations that may be achieved during cocrystal dissolution in stoichiometric 
conditions. From eutectic measurements in FeSSIF and buffer, the stoichiometric cocrystal 
solubility can be calculated from the experimentally drug and coformer eutectic concentrations 
using equation (3.1) and (3.2).  All the coformers studied in this work have ionizable acidic 
groups, and excess coformer in solution at the eutectic point leads to a reduction in pH compared 
to the pH under stoichiometric conditions and/or the starting pH.  During dissolution in 
stoichiometric conditions, the bulk solution pH will likely remain close to the initial starting pH 
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of the dissolution media, so the cocrystal solubility at pH 5.00 was predicted and compared to the 
measured solubility at the eutectic point in Table 3.2. 
Table 3.2.  Cocrystal constituent eutectic concentrations and stoichiometric solubility at the 
eutectic point compared to solubility at pH 5.00.   
(a) Calculated from measured constituent eutectic concentrations using equation (3.1) for 1:1 
cocrystals and (3.2) for 2:1 cocrystals. 
(b) Calculated using the equations in Table 2.2, Ksp values in Table 2.3, and pKa and Ks
T
 
values in Table 2.5. 
 
Media Cocrystal [drug]
eu
 (mM) 
[coformer]
eu
 
(mM) 
S
cocrystal
 (mM)
a
 pHeu 
Scocrystal at pH 
5.00
b 
(mM) 
buffer 
DNZ-VAN (2.1±0.1)x10
-4
 16±3 (5.7±0.2)x10
-2
 4.96±0.01 5.9x10
-2
 
DNZ-HBA (2.0±0.4)x10
-4
 79±4 (1.2±0.1)x10
-1
 4.47±0.04 0.22 
CBZ-4ABA (H) (4.4±0.2)x10
-1
 13.1±0.4 1.73±0.06 4.84 ± 0.03 1.8 
IND-SAC (6.0±0.3)x10
-2
 104±20 (7.9±0.3)x10
-2
 3.66 ± 0.02 5.0 
CBZ-SLC (5.1±0.2)x10
-1
 49.8±0.9 5.1±0.1 4.37 ± 0.02 11 
PXC-SAC (3.64±0.01)x10
-2
 94±2 1.85±0.03 3.64 ±0.02 16 
CBZ-SAC (7.8±0.5)x10
-1
 124±3 9.8±0.3 3.08 ± 0.03 50 
FeSSIF 
DNZ-VAN (1.0±0.2)x10
-1
 19.4±0.8 1.39±0.03 5.00±0.01 1.7 
DNZ-HBA (9.9±0.8)x10
-2
 78±1 2.8±0.1 4.46±0.06 6.0 
CBZ-4ABA (H) (7.4±0.3)x10
-1
 15.6±0.4 2.57±0.05 4.94 ± 0.02 2.9 
IND-SAC (1.50±0.2)x10
-1
 87±4 3.6±0.2 3.65 ± 0.05 21 
CBZ-SLC (9.1±0.2)x10
-1
 49.9±0.6 6.71±0.09 4.29 ± 0.02 14 
PXC-SAC (6.80±0.06)x10
-2
 97±1 2.60±0.03 3.79 ±0.02 22 
CBZ-SAC 1.07±0.03 95.9±0.3 10.1±0.1 3.11 0.02 67 
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All measured cocrystal solubilities (Table 3.2) are higher in FeSSIF compared to buffer due 
to micellar solubilization except for CBZ-SAC, which was not solubilized.  Cocrystal solubility 
increased by as much as 24 fold as for the case of DNZ-VAN, where the solubility increased 
from 0.057 mM to 1.39 mM in FeSSIF.  At pH 5.00, cocrystal solubilities are predicted to 
exhibit similar increases due to micellar solubilization compared to those observed at the eutectic 
point, so higher concentrations of drug are anticipated during cocrystal dissolution in FeSSIF 
compared to aqueous buffer.  If solubilities measured at the eutectic point are compared to those 
predicted at pH 5.00, it is clear that solubility increases as pH increases for all the cocrystals 
studied due to the ionization of acidic components.  SAC cocrystals, in particular, exhibited large 
solubility increases due to the ionization of SAC.  PXC-SAC solubility is predicted to increase 
by an order of magnitude between the eutectic pH values of 3.64-3.79 and 5.00.  This large 
increase in cocrystal solubility at pH 5.00 compared to the eutectic point indicates that the 
cocrystal solubility advantage (Scocrystal/Sdrug) may be higher in dissolution conditions than those 
measured at the eutectic point.  This increase in solubility advantage due to ionization can lead to 
the cocrystal being more unstable in dissolution conditions due to a larger thermodynamic 
driving force for conversion to the constituent drug.  Scocrystal/Sdrug and implications for 
dissolution of cocrystals will be discussed in a subsequent section.  
Cocrystal thermodynamic stability 
As described in the theoretical section, the Keu is related to Scocrystal/Sdrug and is a directly 
measurable parameter that can inform cocrystal dissolution studies.  Scocrystal/Sdrug is the 
maximum theoretical supersaturation achievable during cocrystal dissolution so knowledge of 
Keu (and thus Scocrystal/Sdrug) is useful to predict this supersaturation.   Figure 3.1 shows the Keu for 
1:1 cocrystals calculated from directly measured eutectic concentrations (Method 1) plotted 
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against Scocrystal/Sdrug predicted using the full equations (3.5)-(3.8) under the eutectic conditions 
(pH, [M]) and measured or reported equilibrium constants. 
 
Figure 3.1.  Keu dependence on cocrystal solubility advantage (Scocrystal/Sdrug) in FeSSIF (filled 
symbols) and buffer (open symbols) at 25°C for 1:1 cocrystals IND-SAC (), CBZ-SAC (), 
CBZ-SLC (), PXC-SAC (), DNZ-HBA (), and DNZ-VAN ().  Experimental errors fit 
within the size of each symbol.  The line represents Keu = (Scocrystal/Sdrug)
2
.  Keu values are 
experimentally determined at the eutectic point according to equation (3.3) (Method 1) and 
Scocrystal/Sdrug values are predicted using equations (3.5)-(3.7).   
 
Since Keu and Scocrystal/Sdrug values span several orders of magnitude for this set of cocrystals, 
results are presented in a log-log plot.  The line in Figure 3.1 represents the theoretical 
relationship between Keu and Scocrystal/Sdrug:  
2
cocrystal
eu
drug
S
K =
S
 
  
 
          (3.9) 
Figure 3.1 shows that the experimentally measured Keu values correlate with the 
Scocrystal/Sdrug as predicted by equations (3.5)-(3.7).  The relationship between Keu and 
Scocrystal/Sdrug for these 1:1 cocrystals is predicted by equation (3.9) which is represented by the 
line in the plot.  There are slight deviations for some cocrystals, particularly where the 
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Scocrystal/Sdrug is larger than that predicted by the Keu, which will be addressed in the subsequent 
section.  Overall, Scocrystal/Sdrug can be reasonably estimated by calculating the Keu from measured 
constituent eutectic concentrations.  
 For a 2:1 cocrystal, the relationship between Keu and Scocrystal/Sdrug is given by
19
: 
3
cocrystal
eu
drug
S
K =4
S
 
  
 
           (3.10) 
Where the cocrystal solubility is in terms of molarity (moles of drug/L of solvent) which means 
the solubility of a 2:1 cocrystal is in terms of drug concentration.  Table 3.3 shows the 
comparison between the calculated Scocrystal/Sdrug calculated from the measured Keu (Method 1), 
the calculated Scocrystal/Sdrug from cocrystal solubility measured at the eutectic point and drug 
solubility measured in the absence of coformer (Method 2), and those predicted from the full 
equations (3.5)-(3.8) at the pH of the eutectic point from reported or measured equilibrium 
constants. 
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Table 3.3.  Experimentally determined Keu and Scocrystal/Sdrug calculated from Methods 1 and 2 
compared to predicted Scocrystal/Sdrug using equations (3.5)-(3.8) at the eutectic point pH. 
Cocrystal Media Keu
a
 
Scocrystal/Sdrug exp
b
 
Method 1 
Scocrystal/Sdrug exp
c
 
Method 2 
Scocrystal/Sdrug 
pred
d
 
pH 
DNZ-HBA 
Buffer 440000±70000 660±50 770±90 770 4.47±0.04 
FeSSIF 790±60 28±1 25±3 25 4.46±0.06 
DNZ-VAN 
Buffer 80000±4000 280±20 370±70 360 4.96±0.01 
FeSSIF 200±10 14±1 13±1 13 5.00±0.01 
IND-SAC 
Buffer 17000±900 132±4 181±3 180 3.66±0.02 
FeSSIF 600±50 24±1 49±1 38 3.65±0.05 
PXC-SAC 
Buffer 2600±100 51±1 78±3 60 3.64±0.04 
FeSSIF 1400±100 37±1 52±2 43 3.79±0.02 
CBZ-SAC 
Buffer 160±10 12.6±0.4 23±2 13.8 3.08±0.03 
FeSSIF 90±2 9.5±0.1 13.5±0.5 13.5 3.11±0.02 
CBZ-SLC 
Buffer 97±3 9.9±0.2 12±1 12 4.37±0.02 
FeSSIF 54±1 7.4±0.1 9.0±0.3 8.9 4.29±0.02 
CBZ-4ABA-
HYD 
Buffer 30±2 3.9±0.07 4.1±0.3 4.1 4.84±0.03 
FeSSIF 21±1 3.5±0.1 3.4±0.1 3.4 4.94±0.02 
(a) Calculated from experimentally measured constituent eutectic concentrations in Table 3.2 
according to equation (3.3). 
(b) Calculated using Method 1 from Keu according to equation (3.9) for 1:1 cocrystals and 
(3.10) for 2:1 cocrystals. 
(c) Calculated using Method 2 from Scocrystal measured at the eutectic point according to 
equation (3.1) for 1:1 cocrystals and equation (3.2) for 2:1 cocrystals and Sdrug calculated 
at pHeu from Table 3.1. 
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(d) Calculated using Ksp values from Table 2.3, pKa values and Ks
T
 values from Table 2.5 
according to equations (3.5)-(3.8). 
 
Results in Table 3.3 show the utility of Keu for determining the Scocrystal/Sdrug of cocrystals 
measured at the eutectic point.  The measured Scocrystal/Sdrug values calculated using Methods 1 
and 2 under eutectic conditions are in reasonable agreement.  Significant deviations do occur for 
DNZ-HBA, DNZ-VAN, IND-SAC, PXC-SAC, and CBZ-SAC due to the differences in drug 
solubility measured at the eutectic point to that measured independently at pHeu as shown in 
Table 3.1.  CBZ-4ABA-HYD and CBZ-SLC are well predicted as CBZ solubility did not vary 
significantly in the presence and absence of coformer in solution.  The cocrystals studied range 
from 660 times more soluble than drug for DNZ-HBA to 3.9 times more soluble in aqueous 
buffer, and 37 times more soluble than drug for PXC-SAC to 3.5 times more soluble in FeSSIF 
as determined using Method 1.   
Significant differences between measured Scocrystal/Sdrug calculated by Method 1 and the 
values predicted from equilibrium constants using equations (3.5)-(3.8) do exist for some 
cocrystals, particularly CBZ-SAC, IND-SAC, DNZ-HBA, and DNZ-VAN.  The presence of 
SAC at the eutectic point has been observed to decrease CBZ solubilization (described in detail 
in Chapter 2) which explains the discrepancy in Scocrystal/Sdrug in Table 3.3 for CBZ-SAC in 
FeSSIF.  For IND-SAC, the disagreement in Scocrystal/Sdrug is likely due to the difference in Sdrug 
at the eutectic point compared to that predicted by equation (3.6).  As described in Chapter 2, 
IND solubility at the eutectic point is much higher than IND solubility in a single saturated 
solution in the absence of coformer. This is due to supersaturation with respect to IND (IND 
dissolving from cocrystal rather than from solid drug), which results in a higher Sdrug and a lower 
Scocrystal/Sdrug compared to that predicted by equation (3.6).  DNZ-VAN deviations likely occur 
due to this difference in DNZ solubility at the eutectic point versus solubility in the absence of 
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coformer.  As described, in Chapter 2, DNZ solubility measured at the eutectic point is nearly 
twice that measured independently, and this difference likely caused large discrepancy in 
Scocrystal/Sdrug calculated using Method 1 and predicted using  equations (3.5)-(3.8) in Table 3.3.   
Equations (3.5)-(3.8) require Sdrug
aq
 values that are measured in the absence of coformer 
in solution as an input.  The Scocrystal/Sdrug values calculated by Method 2 and the predicted values 
using equations (3.5)-(3.8) are in good agreement for this reason.   
Values in Table 3.3 reveal that Scocrystal/Sdrug decreases in FeSSIF compared to aqueous 
buffer for many of the cocrystals studied.  Figure 3.2 shows the measured (Scocrystal/Sdrug)aq and 
(Scocrystal/Sdrug)FeSSIF  calculated by Method 1 for the cocrystals studied.  
 
Figure 3.2.  Scocrystal/Sdrug values measured at pHeu at 25°C in FeSSIF () and buffer ().  Values 
were calculated by Method 1 as described in the Theoretical and Methods sections using 
equation (3.9) for 1:1 cocrystals and equation (3.10) for 2:1 cocrystals. pH values for each 
measurement are in Table 3.2. 
All cocrystals retain a solubility advantage over drug in both FeSSIF and buffer (Scocrystal/Sdrug 
>1).  For cocrystals of highly solubilized drugs such as DNZ and IND, the Scocrystal/Sdrug is 
reduced dramatically in FeSSIF compared to buffer due to preferential solubilization of the drug 
over coformer, whereas for less solubilized drugs such as PXC and CBZ, this large reduction is 
not observed. 
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Table 3.4 shows the log P, Ks
drug
 values and Scocrystal/Sdrug in buffer relative to 
Scocrystal/Sdrug in FeSSIF calculated using Method 1.   
Table 3.4.  Log P, Ks
drug
 and Scocrystal/Sdrug decrease in FeSSIF compared to buffer calculated 
using Method 1. 
Cocrystal Log P drug Ks
drug
 (mM
-1
)
e 
(Scocrystal/Sdrug)buffer/ 
(Scocrystal/Sdrug)FeSSIF
 f
 
 
DNZ-HBA 4.53
a 
49±5 23 
DNZ-VAN 4.53
a 
49±5 20 
IND-SAC 4.27
b 
8.2±0.6 5.5 
PXC-SAC 1.8
c 
0.080±0.005 1.4 
CBZ-SAC 2.32
d 
0.054±0.003 1.3 
CBZ-SLC 2.32
d 
0.054±0.003 1.3 
CBZ-4ABA-HYD 2.32
d 
54±3 1.1 
(a) From reference 22. 
(b) From reference 23. 
(c) From reference 24. 
(d) From reference 25. 
(e) Calculated from measured drug solubilities in FeSSIF and buffer in Table 2.5 using 
equations (2.25)-(2.27). 
(f) Calculated using Method 1 from measured Keu values according to equation (3.9) for 1:1 
cocrystals and (3.10) for 2:1 cocrystals.  
 
DNZ, a very hydrophobic (log P = 4.53) and highly solubilized drug (Ks = 4.9 mM
-1
) 
exhibits the largest reduction in Scocrystal/Sdrug in FeSSIF compared to buffer.  DNZ-HBA’s 
solubility advantage over DNZ was 23 fold lower in FeSSIF compared to buffer, while DNZ-
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VAN’s advantage was reduced by a factor of 20.  IND, another hydrophobic (log P= 4.27) and 
highly solubilized (Ks = 8.2 mM
-1
) drug had a large reduction in Scocrystal/Sdrug in FeSSIF 
compared to buffer of 5.5 as well.  Less hydrophobic, less solubilized drugs CBZ and PXC had 
lower reductions in Scocrystal/Sdrug in FeSSIF for the cocrystal systems studied.  Scocrystal/Sdrug is the 
thermodynamic limit of the cocrystal solubility advantage and is a measure of the maximum 
supersaturation possible during cocrystal dissolution.  Scocrystal/Sdrug values also indicate the 
thermodynamic driving force for conversion from a metastable highly soluble cocrystal back to 
the poorly soluble, stable drug form.  The large reduction in Scocrystal/Sdrug in FeSSIF compared to 
buffer for DNZ and IND cocrystals, therefore indicate a lower driving force for conversion 
during dissolution in FeSSIF compared to buffer may slow or prevent transformation in these 
media. 
As described earlier, there can be large pH differences between the eutectic point 
conditions and the initial pH of 5.00 of FeSSIF and blank aqueous buffer.  Knowledge of 
Scocrystal/Sdrug at pH 5.00 is essential to anticipate supersaturation values during dissolution studies 
in these media where the bulk pH is unlikely to vary much from initial pH.  Table 3.5 shows the 
measured Scocrystal/Sdrug in buffer and FeSSIF at the eutectic point and the calculated Scocrystal/Sdrug 
at pH 5.00 using equations (3.5)-(3.8).  
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Table 3.5.  Scocrystal/Sdrug calculated using Method 1 at the eutectic pH compared to Scocrystal/Sdrug 
predicted at pH 5.00. 
 Scocrystal/Sdrug pH eu
a 
  Scocrystal/Sdrug pH 5.00
b 
 
Cocrystal Buffer FeSSIF pH exp 
(Scocrystal/Sdrug)
buffer
/ 
(Scocrystal/Sdrug)
FeSSIF
 
Buffer FeSSIF 
(Scocrystal/Sdrug)
buffer
/ 
(Scocrystal/Sdrug)
FeSSIF
 
DNZ-HBA 660±50 28±1 4.46±0.06 23 1400±100 54±2 26 
DNZ-VAN 280±6 14±1 5.00±0.01 20 380±40 16±2 25 
IND-SAC 132 ± 4 24 ± 1 3.65±0.05 5.5 220±40 57±7 7 
PXC-SAC 52± 1 37 ±1 3.79±0.02 1.4 520±60 370±40 1.5 
CBZ-SAC 12.6 ± 0.4 9.5 ± 0.1 3.11±0.02 1.3 120±10 89±2 1.3 
CBZ-SLC 9.9 ± 0.2 7.4 ± 0.1 4.29±0.02 1.3 25±1 19±1 1.3 
CBZ-4ABA 
HYD 
3.9 ± 0.1 3.5 ± 0.1 4.94±0.04 1.1 4.4±0.1 3.8±0.1 1.2 
(a) Calculated using Method 1 from measured eutectic drug and coformer concentrations 
using equations (3.9)for 1:1 cocrystals and (3.10) for 2:1 cocrystals 
(b) Predicted using equations (3.5)-(3.8), Ksp values from Table 2.3 and pKa and Ks
T
 values 
from Table 2.5. 
 
 
Table 3.5 shows that the solubility advantage of these cocrystals increases as pH 
increases due to the ionization of acidic cocrystal components.  Scocrystal/Sdrug for all cocrystals 
studied were higher at pH 5.00 compared to the experimental pH at the eutectic point.  Though 
the Scocrystal/Sdrug changed by as much as an order of magnitude between the eutectic pH and pH 
5.00, as in the case of PXC-SAC, the decrease of Scocrystal/Sdrug in FeSSIF compared to buffer was 
similar at pH 5.00 compared to the eutectic point for the cocrystals studied.  Similar to 
Scocrystal/Sdrug values at the eutectic pH, highly solubilized, hydrophobic drugs like DNZ and IND 
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exhibited larger decreases in solubility advantage at pH 5.00 compared to PXC and CBZ.   IND-
SAC and PXC-SAC were selected for powder dissolution testing in FeSSIF and buffer to assess 
the impact that a reduced Scocrystal/Sdrug in FeSSIF compared to buffer has on the dissolution 
profile and transformation kinetics.   
Cocrystal dissolution and supersaturation 
IND-SAC and PXC-SAC were selected for powder dissolution testing to examine the 
impact of Scocrystal/Sdrug reduction due to preferential micellar solubilization on the powder 
dissolution profile, supersaturation generated during dissolution, and transformation kinetics.  
Since IND-SAC exhibited a relatively large decrease in Scocrystal/Sdrug in FeSSIF compared to 
buffer (5.5 fold lower at eutectic and 7 fold lower at pH 5.00), it is predicted that the driving 
force for transformation will be reduced in FeSSIF compared to buffer, leading to a slower 
transformation to parent drug.  On the other hand, PXC-SAC, which had a relatively small 
decrease in Scocrystal/Sdrug in FeSSIF compared to buffer (1.4 fold lower at eutectic, 1.5 fold at pH 
5.00), is not predicted to have a large difference in dissolution profile in FeSSIF compared to 
aqueous buffer because the driving force for transformation is relatively unchanged. 
Figure 3.3a shows the powder dissolution profile of IND-SAC in FeSSIF and buffer.  
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 (a)       (b) 
 
Figure 3.3.  IND-SAC dissolution in FeSSIF () and buffer () at 25°C.  (a) [IND]T vs time 
profile for dissolution and (b) supersaturation generated by IND-SAC during dissolution 
([IND]T/ST
IND
. 
 
As predicted by solubility values in Table 3.2, IND-SAC obtains and maintains a higher drug 
solution concentration in FeSSIF compared to buffer (Figure 3.3a).  IND-SAC achieves a 
maximum concentration of 4.1 mM in FeSSIF which remains relatively constant for the duration 
of the experiment.  This is less than the predicted solubility of 21 mM in Table 3.2, but it is 
unlikely that the cocrystal reached equilibrium during the four hour experiment.  The solid phase 
at the end of the experiment was observed to be pure IND-SAC, indicating no solution-mediated 
transformation occurred.  Additionally, the pH of FeSSIF was monitored and remained relatively 
constant between 5.00-4.95 for the duration of the experiment as shown in Figure 3.4a.   
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   (a)      (b) 
 
Figure 3.4.  pH during cocrystal dissolution for (a) IND-SAC and (b) PXC-SAC in () FeSSIF 
and () buffer at 25°C. 
If conversion to IND were to occur, a large decrease in pH would be expected as the SAC 
concentration in solution increased.  Additionally, no excess SAC was measured in solution, as 
shown in Figure 3.5b, further evidence that the cocrystal did not transform in FeSSIF during the 
time course of the experiment. 
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   (a)      (b)   
 
Figure 3.5. Concentration-time profile for [IND]T () and [SAC]T () during dissolution of 
IND-SAC in (a) buffer and (b) FeSSIF.  
Figure 3.5b shows that only at later time points (210 and 240 minutes), do the SAC 
concentrations start to increase while IND decrease, indicating that solution-mediated 
transformation may be beginning to occur.  If the time course of the experiment was extended, it 
is likely that the transformation would have been detected by solid phase analysis and 
accompanied by a solution pH decrease.   
In buffer, the cocrystal achieves a peak concentration of 0.36 mM at around 10 minutes, 
but this rapidly decreases by orders of magnitude, and by the end of the experiment, the 
concentration of IND is 0.034 mM which is very close to the solubility of IND in the aqueous 
buffer (0.023 mM).   This is much less than the IND-SAC predicted solubility in buffer of 5.00 
mM in Table 3.2, indicated solution-mediated transformation occurred.  The solid phase at the 
end of the experiment was observed to be a mixture of IND-SAC and IND, the pH of the 
solution was 4.71 as shown in Figure 3.4a, and a 600 fold excess of SAC was measured in 
solution (Figure 3.5a), verifying that transformation to drug had occurred. 
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The supersaturation values in Figure 3.3b indicate that as hypothesized, the 5.5 fold 
decrease in Scocrystal/Sdrug in FeSSIF compared to buffer led to a reduced but sustained 
supersaturation and slower transformation to drug.  In buffer, IND-SAC reached a peak 
supersaturation of 15.5 which rapidly decreased to 1.5 as it converted to IND.  In FeSSIF, a 
supersaturation of 11 was achieved and maintained for the duration of the experiment.  The 5.5 
fold reduction in Scocrystal/Sdrug in FeSSIF led to a lower but sustained supersaturation as well as 
higher IND concentrations due to the solubilization of IND by FeSSIF. 
Figure 3.6a shows the powder dissolution profile of PXC-SAC in FeSSIF and buffer.   
(a)       (b) 
 
Figure 3.6.  PXC-SAC dissolution in FeSSIF () and buffer () at 25°C.  (a) [PXC]T vs time 
profile for dissolution from neat cocrystal and (b) supersaturation generated by PXC-SAC during 
dissolution ([PXC]T/SPXC,T. 
 
PXC-SAC obtains and maintains a higher drug solution concentration in FeSSIF compared to 
buffer (Figure 3.6a).  PXC-SAC achieves a maximum concentration of 0.86 mM in FeSSIF 
which remains relatively constant for the duration of the experiment.  The solid phase at the end 
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of the experiment was observed to be pure PXC-SAC, indicating no solution-mediated 
transformation occurred.  Additionally, the pH of FeSSIF was monitored and remained constant 
around 5.00 for the duration of the experiment as shown in Figure 3.4b, and no excess SAC was 
measured in solution as shown in Figure 3.7b, further evidence that the cocrystal did not 
transform.   
   (a)      (b) 
 
Figure 3.7.  Concentration-time profile for [PXC]T () and [SAC]T () during dissolution of 
PXC-SAC in (a) buffer and (b) FeSSIF. 
In buffer, the cocrystal achieves a peak concentration of 0.088 mM at the first time point 
at 1 minute, and this decreases until the end of the experiment where the concentration of PXC is 
0.025 mM which is approximately the solubility of PXC (H) in the aqueous buffer (0.03 mM).   
This is much less than the PXC-SAC predicted solubility in buffer of 16 mM in Table 3.2, 
indicated solution-mediated transformation occurred.  The solid phase at the end of the 
experiment was observed to be pure PXC (H), the pH of the solution was 4.73 as shown in 
Figure 3.4b, and a 500 fold excess of SAC (Figure 3.7a) was measured in solution and a 
verifying that transformation to drug had occurred. 
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Since the PXC-SAC reduction in Scocrystal/Sdrug in FeSSIF compared to buffer was only 
1.4, it was not hypothesized that a slower transformation to drug would occur since the driving 
force for conversion is relatively unchanged.  However, PXC-SAC did not undergo solution-
mediated transformation to drug in FeSSIF, while it did in aqueous buffer.   As seen in Figure 
3.6b, the peak supersaturation of 3 of PXC is observed at 1 minute in buffer, but this rapidly 
decreases as the cocrystal converts to drug.  In FeSSIF, however, a supersaturation of 14 is 
observed and maintained for the duration of the experiment. PXC-SAC achieved a higher drug 
concentration, sustained supersaturation, and no conversion to drug in FeSSIF compared to 
buffer even though the driving force for conversion was still high in this media.  This could 
possibly be due to kinetic phenomena where components in the FeSSIF media inhibit the 
nucleation or growth of PXC crystals, resulting in a huge difference in dissolution profile in 
FeSSIF compared to buffer. 
Conclusions 
In this work, reported mathematical models describing cocrystal solubility advantage 
(Scocrystal/Sdrug) were used to analyze cocrystals in FeSSIF and buffer.  All cocrystals exhibited 
lower solubility advantages in FeSSIF compared to aqueous buffer due to preferential 
solubilization of the drug constituent, with cocrystals of more hydrophobic and highly 
solubilized drugs exhibiting the largest decreases in Scocrystal/Sdrug. The reported models were in 
good agreement with the experimentally measured Scocrsytal/Sdrug values.  Up to a 23 fold decrease 
in Scocrystal/Sdrug was observed for the DNZ-HBA cocrystal of the highly solubilized drug DNZ 
(log P = 4.53).   
The effect of Scocrystal/Sdrug reduction due to preferential solubilization by FeSSIF on 
cocrystal powder dissolution profile was examined for IND-SAC and PXC-SAC.  IND-SAC and 
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PXC-SAC achieved higher concentrations during dissolution in FeSSIF compared to buffer due 
to the solubilization of IND and PXC.  The Scocrystal/Sdrug values measured at the eutectic point in 
FeSSIF and buffer were good indicators of the dissolution behavior for these systems.  The 
decreased Scocrystal/Sdrug resulted in sustained supersaturated drug concentrations and slower 
transformation to drug in FeSSIF compared to aqueous buffer.  During the course of the four 
hour dissolution experiment, both IND-SAC and PXC-SAC readily converted to drug in aqueous 
buffer but this transformation did not occur in FeSSIF due to the reduced driving force for 
transformation.  Scocrystal/Sdrug can be predicted from mechanism-based models presented here, 
and these values can be used to anticipate cocrystal disslotuion and transformation behavior in a 
variety of surfactant solutions as long as the drug solubility and the cocrystal Ksp, and drug and 
coformer Ka and Ks
T
 values are known. 
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CHAPTER 4  
UNDERSTANDING THE RELATIONSHIP BETWEEN COCRYSTAL 
SOLUBILIZATION RATIO AND DRUG HYDROPHOBICITY 
 
Introduction 
 The solubilization of drugs by solubilizing agents such as physiologically relevant 
surfactants has been shown to be correlated to their hydrophobicity
1-3
.  Specifically, the increase 
in solubility as a function of solubilizing agent can be predicted from the drug octanol-water 
partition coefficient (log P) and aqueous solubility of the drug.  Drugs with higher log P values 
are solubilized to a greater extent than less hydrophobic (lower log P) drugs.  Numerous studies 
have confirmed this relationship between the solubilization ratio (SR) of nonionizable drugs in 
the presence of physiologically relevant bile salts and the log P of the drug
3, 4
. 
 In ionizing conditions, log P is not a good predictor of drug solubilization
2
.  Ionized 
drugs interact differently than nonionized drugs and the log D (octanol-water distribution 
coefficient) at the pH of interest is a key parameter correlated with solubilization.  Log D takes 
into account the extent of ionization in media of interest and is calculated by many commonly 
used software packages based on drug structure.  In a study of ten drugs of varying ionization 
properties, log of the solubilization ratio (log SR) in fasted state intestinal fluid (FaSSIF), which 
has a pH of 6.50 and fed state intestinal fluid (FeSSIF), which has a pH of 5.00 was correlated 
with measured log P and calculated log D.  The R squared value of the linear regression of the 
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correlation improved from 0.32 to 0.74 when log D was used instead of log P, indicating that log 
D is a better predictor of log SR in ionizing conditions
2
.   
We have previously reported a simple mechanism-based approach to predict SRcocrystal 
from SRdrug when coformer solubilization is negligible
5
.  This relationship has been confirmed 
for cocrystals of varying ionization properties in the presence of FeSSIF, in which drugs are 
highly solubilized and coformers are not.  In this work, we develop correlations between the log 
D (as several of the drugs are ionizable) of the drug and the log SRcocrystal in FeSSIF.  
Additionally, since the relationship between SRdrug and SRcocrystal is known for these systems, 
differences between the log SRdrug- log D and log SRcocrystal-log D correlations are predicted and 
rationalized. The cocrystals studied include: 1:1 carbamazepine-saccharin (CBZ-SAC), 1:1 
carbamazepine-salicylic acid (CBZ-SLC), 2:1 carbamazepine 4-aminobenzoic acid hydrate, 
(CBZ-4ABA-HYD), 1:1 piroxicam-saccharin (PXC-SAC), 1:1 indomethacin-saccharin (IND-
SAC), 1:1 danazol-hydroxybenzoic acid (DNZ-HBA), and 1:1 danazol-vanillin (DNZ-VAN).  
The selected cocrystals include both 1:1 and 2:1 cocrystal stoichiometries and cover a range of 
ionization behaviors for both drug and coformers.  PXC is a zwitterionic drug with pKa values of 
1.86 and 5.46
6
, and IND is a monoprotic weakly acidic drug with a pKa of 4.2
7
.  SAC is a 
monoprotic weak acid with pKa values reported between 1.6-2.2
8, 9
, SLC is a monoprotic weak 
acid with a reported pKa value of 3.0
8
, 4ABA is amphoteric with pKa values 2.6 and 4.8
10
, HBA 
is a monoprotic weak acid with a reported pKa value of 4.48
11
 and VAN is a monoprotic weak 
acid with a pKa of 7.4
11
. 
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Theoretical 
Estimation of cocrystal solubilization ratio from drug solubilization ratio 
The relationship between cocrystal solubilization ratio (SRcocrystal) in drug solubilizing 
agents and drug solubilization ratio (SRdrug) assuming negligible coformer solubilization has 
been derived and described in detail in Chapter 2 of this dissertation.  To summarize, the general 
form of the equation for a cocrystal with stoichiometry AxBy, where A and B are the cocrystal 
constituents, drug and coformer respectively; and x and y are the stoichiometric coefficients or 
molar ratios, is
5
: 
 
x
x+y
cocrystal drugSR = SR          (4.1) 
where 
T
aq
S
SR=
S
 
  
 
            (4.2) 
for either cocrystal or drug.  ST is defined as the sum of the concentrations of all species 
dissolved (ST = Saq + Ss).  Saq represents the cocrystal aqueous solubility at a particular pH in the 
absence of solubilizing agent (Saq = Snonionized,aq + Sionized,aq) and is the sum of the nonionized and 
ionized contributions to the aqueous solubility.  Ss represents the cocrystal solubilized by 
solubilizing agents (Ss = Snonionized,s + Sionized,s) and contributions from the ionized species as 
appropriate. 
From the general form of the relationship between SRcocrystal and SRdrug in equation (4.1) 
above, the following equations can be derived for cocrystals of 1:1 and 2:1 stoichiometry 
(systems studied in this work): 
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For a 1:1 cocrystal: 
cocrystal drugSR = SR           (4.3) 
For 2:1 cocrystal: 
2
3
cocrystal drugSR = SR           (4.4) 
The above relationships are derived from the full solubility equations for drug and 
cocrystal in solubilizing agents assuming that Ks
coformer
 = 0 and that the pH of the solubilizing 
agent and buffer for both cocrystal and drug are equal.  
Building log SR-log D relationships 
It is well established in the literature that the solubilization of drugs by solubilizing 
agents correlates to their hydrophobicity as described by their log P and/or log D
1-3
.  SRdrug 
increases as log P and/or log D increases and linear regression analysis can be used to correlate 
log SRdrug with log P in nonionizing conditions and log D in ionizing conditions.  The purpose of 
this work is to examine the relationships between SRcocrystal in FeSSIF and the hydrophobicity of 
the drug.  In order to build log-log relationships between the octanol-water partition coefficient 
(log P) or distribution constant (log D), log SRcocrystal must be considered. When a compound 
contains ionizable components, the log D, which takes ionization into account, is a better 
predictor of solubilization by solubilizing agents.  The octanol-water log D is defined as: 
octanol
aq,ionized aq,unionized
[drug]
log D=log
[drug] +[drug]
 
  
 
        (4.5) 
Since several of the drugs studied in this work are ionizable in the conditions of FeSSIF, 
all further derivations will use log D instead of log P to improve the correlation fit.  In order to 
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derive a log-log relationship between log D and SRcocrystal or SRdrug, we must consider how they 
are related in terms of logs.  In terms of logs, equation (4.3) becomes: 
FeSSIF FeSSIF
buffer buffercocrystal drug
S S1
log = log
S 2 S
   
   
   
       (4.6) 
For a 2:1 cocrystal, the SRcocrystal-SRdrug relationship is: 
2
3
FeSSIF FeSSIF
buffer buffercocrystal drug
S S
=
S S
   
   
   
          (4.7) 
And in terms of logs, equation (4.7) becomes: 
FeSSIF FeSSIF
buffer buffercocrystal drug
S S2
log = log
S 3 S
   
   
   
        (4.8) 
These relationships are useful for applying log SRdrug-log D correlations to cocrystals of 
these drugs.  That is, by correlating measured log SRdrug and log D in a solubilizing agent, one 
can anticipate what log SRcocrystal would be for a cocrystal of a drug with a particular log D.  For 
example, if the linear regression relationship between experimentally determined SRdrug values 
and log D is determined, an equation of the following form is obtained: 
FeSSIF
drug drug drug
buffer drug
S
log = m logD +b
S
 
 
 
         (4.9) 
By relating the log SRdrug to log SRcocrystal using equations (4.6) and (4.8), one can 
determine how SRcocrystal will relate to drug log D.  For the case of 1:1 cocrystals, logSRcocrystal = 
(1/2)log SRdrug as shown by equation (4.3).  Therefore, a log SRcocrystal-logD linear regression for 
1:1 cocrystals such as: 
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FeSSIF
cocrystal drug cocrystal
buffer cocrystal
S
log = m logD +b
S
 
 
 
       (4.10) 
can be predicted from simply knowing how the slope (m) and intercept (b) of a cocrystal linear 
regression equation are theoretically related to the experimentally determined drug linear 
regression equation.  For a 1:1 cocrystal, 
drug
cocrystal
m
m =
2
           (4.11) 
and 
drug
cocrystal
b
b =
2
            (4.12) 
By substituting, the linear regression equation for 1:1 cocrystals in terms of the experimentally 
determined drug regression equation is: 
drug drugFeSSIF
drug
buffer cocrystal
m bS
log = logD +
S 2 2
     
     
    
       (4.13) 
Similarly, for a 2:1 cocrystal using equation (4.8) to substitute: 
   FeSSIF drug drug drug
buffer cocrystal
S 2 2
log = m logD + b
S 3 3
 
 
 
      (4.14) 
These equations are useful for estimating log SRcocrystal where the drug log P/log D is 
known without experimentally measuring the SRcocrystal value.  SRdrug and log P and/or log D 
values in solubilizing agents are often available in the literature, and using equations (4.13) and 
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(4.14) the prediction of SRcocrystal in these conditions is possible from sole knowledge of drug 
hydrophobicity. 
Materials and Methods 
Materials 
Cocrystal constituents 
Anhydrous carbamazepine form III (CBZ), anhydrous indomethacin form γ (IND) were 
purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  Anhydrous 
piroxicam form I was received as a gift from Pfizer (Groton, CT) and used as received.  
Anhydrous danazol was received as a gift from Renovo Research (Atlanta, GA) and used as 
received.   
Anhydrous saccharin (SAC), 4- aminobenzoic acid (4ABA), and salicylic acid (SLC), 
were purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  
Anhydrous hydroxybenzoic acid was purchased from Acros Organics (Pittsburgh, PA) and used 
as received.  Anhydrous vanillin was purchased from Fisher Scientific (Fair Lawn, NJ) and used 
as received. Carbamazepine dihydrate (CBZ (H)), piroxicam monohydrate (PXC (H)), and 
hydroxybenzoic acid monohydrate (HBA (H)) were prepared by slurrying CBZ, PXC, and HBA 
in deionized water for at least 24 hours.  All crystalline drugs and coformers were characterized 
by X-ray power diffraction (XRPD) and differential scanning calorimetry (DSC) before carrying 
out experiments. 
Solvents and buffer components 
Ethyl acetate and ethanol were purchased from Acros Organics (Pittsburgh, PA) and used 
as received, and HPLC grade methanol and acetonitrile were purchased from Fisher Scientific 
(Pittsburgh, PA). Trifluoroacetic acid spectrophometric grade 99% was purchased from Aldrich 
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Company (Milwaukee, WI) and phosphoric acid ACS reagent 85% was purchased from Sigma 
Chemical Company (St. Louis, MO).  Water used in this study was filtered through a double 
deionized purification system (Milli Q Plus Water System) from Millipore Co. (Bedford, MA). 
FeSSIF and acetate buffer were prepared using sodium taurocholate (NaTC) purchased 
from Sigma Chemical Company (St. Louis, MO), lecithin purchased from Fisher Scientific 
(Pittsburgh, PA), sodium hydroxide pellets (NaOH) purchased from J.T. Baker (Philipsburg, NJ), 
and acetic acid and potassium chloride (KCl) purchased from Acros Organics (Pittsburgh, PA).  
Methods 
FeSSIF and acetate buffer preparation 
FeSSIF and acetate buffer were prepared according to the protocol of Galia and 
coworkers
12
.   Acetate buffer was prepared as a stock solution at room temperature by dissolving 
8.08 g NaOH (pellets), 17.3 g glacial acetic acid and 23.748 g NaCl in 2 L of purified water. The 
pH was adjusted to 5.00 with 1 N NaOH and 1N HCl.  FeSSIF was prepared by dissolving 0.41 g 
sodium taurocholate in 12.5 mL of pH 5.00 acetate buffer. 0.148 g lecithin was added with 
magnetic stirring at 37 °C until dissolved.  The volume was adjusted to exactly 50 mL with 
acetate buffer.  
Cocrystal synthesis 
Cocrystals were prepared by the reaction crystallization method
13
 at 25°C.  The 1:1 
indomethacin-saccharin cocrystal (IND-SAC) was synthesized by adding stoichiometric amounts 
of cocrystal constituents (IND and SAC) to nearly saturated SAC solution in ethyl acetate.  The 
1:1 carbamazepine saccharin cocrystal (CBZ-SAC) was prepared by adding stoichiometric 
amounts of cocrystal constituents (CBZ and SAC) to nearly saturated SAC solution in ethanol. 
The 1:1 carbamazepine-salicylic acid cocrystal (CBZ-SLC) was prepared by adding 
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stoichiometric amounts of cocrystal constituents (CBZ and SLC) to nearly saturated SLC 
solution in acetonitrile. The 2:1 carbamazepine-4-aminobenzoic acid monohydrate cocrystal 
(CBZ-4ABA (H)) was prepared by suspending stoichiometric amounts of cocrystal constituents 
(CBZ and 4ABA) in a 0.01M 4ABA aqueous solution at pH 3.9.  The 1:1 piroxicam-saccharin 
cocrystal (PXC-SAC) was prepared by adding stoichiometric amounts of cocrystal constituents 
(PXC and SAC) to nearly saturated SAC in acetonitrile.  The 1:1 danazol-hydroxybenxoic acid 
cocrystal (DNZ-HBA) was prepared by adding stoichiometric amounts of cocrystal constituents 
(DNZ and HBA) to nearly saturated HBA solution in ethyl acetate.  The 1:1 danazol-vanillin 
cocrystal (DNZ-VAN) was prepared by adding stoichiometric amounts of cocrystal constituents 
(DNZ and VAN) to nearly saturated VAN solution in ethyl acetate.  Prior to carrying out any 
solubility experiments, solid phases were characterized by XRPD and DSC and stoichiometry 
verified by HPLC.   Full conversion to cocrystal was observed in 24 hours. 
Solubility measurements of cocrystal constituents 
Cocrystal constituent solubilities were measured in FeSSIF and pH 5.00 acetate buffer 
(FeSSIF without NaTC and lecithin).  Solubilities of cocrystal constituents were determined by 
adding excess solid (drug or coformer) to 3 mL of media (FeSSIF or buffer). Solutions were 
magnetically stirred and maintained at 25 ± 0.1°C using a water bath for up to 96 h. At 24 hr 
intervals, 0.30 mL of samples were collected, pH of solutions measured, and filtered through a 
0.45 µm pore membrane.   After dilution with mobile phase, solution concentrations of drug or 
coformer were analyzed by HPLC. The equilibrium solid phases were characterized by XRPD 
and DSC. 
 
 134 
 
Cocrystal solubility measurements  
Cocrystal equilibrium solubilities were measured in FeSSIF and pH 5.00 acetate buffer 
(FeSSIF without NaTC and lecithin) at the eutectic point, where drug and cocrystal solid phases 
are in equilibrium with solution
37, 38
. The eutectic point between cocrystal and drug was 
approached by cocrystal dissolution (suspending solid cocrystal (~100 mg) and drug (~50 mg) in 
3 mL of media (FeSSIF or buffer)) and by cocrystal precipitation (suspending solid cocrystal 
(~50 mg) and drug (~100 mg) in 3 mL of media (FeSSIF or buffer) nearly saturated with 
coformer).  Solutions were magnetically stirred and maintained at 25 ± 0.1°C using a water bath 
for up to 96 h. At 24 hr intervals, 0.30 mL aliquots of suspension were collected, pH was 
measured, before filtration through a 0.45 µm pore membrane.   Solid phases were also collected 
at 24 hr intervals to ensure the sample was at the eutectic point (confirmed by presence of both 
drug and cocrystal solid phases and constant [coformer] and [drug] solution concentrations).  
After dilution of filtered solutions with mobile phase, drug and coformer concentrations were 
analyzed by HPLC. The equilibrium solid phases were characterized by XRPD and DSC. 
The cocrystal stoichiometric solubility was calculated from measured total eutectic 
concentrations of drug and coformer ([drug]T,eu and [coformer]T,eu) according to the following 
equations for 1:1 and 2:1 cocrystals
37
: 
1:1 cocrystal
T T,eu T,euS = [drug] [coformer]         (4.15) 
2
T,eu T,eu2:1 cocrystal 3
T
[drug] [coformer]
S =2
4
 
 
 
 
       (4.16)
This method of calculating the stoichiometric solubility of cocrystals from equilibrium solubility 
measurements in nonstoichiometric conditions is well established in the literature
7-10, 37-39
.   
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X-ray powder diffraction 
X-ray powder diffraction diffractograms of solid phases were collected on a benchtop 
Rigaku Miniflex X-ray diffractometer (Rigaku, Danverse, MA) using Cu Kα radiation (λ= 
1.54Å), a tube voltage of 30 kV, and a tube current of 15 mA. Data were collected from 5 to 40° 
at a continuous scan rate of 2.5°/min.  
Thermal analysis 
Solid phases collected from the slurry studies were dried at room temperature and 
analyzed by differential scanning calorimetry (DSC) using a TA instrument (Newark, DE) 
2910MDSC system equipped with a refrigerated cooling unit. DSC experiments were performed 
by heating the samples at a rate of 10 °C/min under a dry nitrogen atmosphere. A high purity 
indium standard was used for temperature and enthalpy calibration.  Standard aluminum sample 
pans were used for all measurements.  
High performance liquid chromatography 
Solution concentrations were analyzed by a Waters HPLC (Milford, MA) equipped with 
an ultraviolet-visible spectrometer detector. For the IND-SAC and CBZ-SAC, CBZ-SLC, CBZ-
4ABA-HYD cocrystals and their components, a C18 Thermo Electron Corporation (Quebec, 
Canada) column (5µm, 250 x 4.6 mm) at ambient temperature was used. For the IND-SAC 
cocrystal, the injection volume was 20 µl and analysis conducted using an isocratic method with 
a mobile phase composed of 70% acetonitrile and 30% water with 0.1% trifluoroacetic acid and 
a flow rate of 1 ml/min. Absorbance of IND and SAC were monitored at 265 nm. For the CBZ 
cocrystals, the injection volume was 20 µl and analysis conducted using an isocratic method with 
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a mobile phase composed of 55% methanol and 45% water with 0.1% trifluoroacetic acid and a 
flow rate of 1 mL/min. Absorbance was monitored as follows:  
CBZ and 4ABA at 284 nm, SAC at 265 nm, and SLC at 303 nm. For the PXC-SAC, 
DNZ-HBA, and DNZ-VAN cocrystals and their components, a C18 Waters Atlantis (Milford, 
MA) column (5 µM 250 x 6 mm) at ambient temperature was used.  For PXC-SAC, the injection 
volume was 20 µL and analysis was conducted using an isocratic method with a mobile phase 
composed of 70% methanol and 30% water with 0.3% phosphoric acid and a flow rate of 1 
mL/min.  Absorbance of PXC was monitored at 340 nm and SAC at 240 nm.  For the DNZ 
cocrystals, the injection volume was 20 µL in FeSSIF experiments, and 100 µL in buffer 
experiments due to the extremely low solubility of DNZ in aqueous solutions.  Analysis was 
conducted using an isocratic method composed of 80% methanol and 20% water with 0.1% 
trifluoroacetic acid and a flow rate of 1 mL/min.  Absorbance of DNZ was monitored at 285 nm, 
HBA at 242 nm, and VAN at 300 nm.  For all cocrystals, the Waters’ operation software 
Empower 2 was used to collect and process data. 
Results 
Log D is a better predictor of SR than log P for ionizable drugs 
Figure 4.1 shows the correlation of logSRdrug with log P and log D.  log D is a better 
predictor of log SRdrug compared to log P due to the ionization of IND, an acid (pKa = 4.2
7
), and 
PXC, a zwitterion (pKas = 1.86 and 5.46
6
). 
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(a)       (b) 
 
Figure 4.1.  Log SRdrug correlation with (a) log P and (b) log D.  Symbols ()  represent 
experimentally measured data and the lines are a result of linear regression of the data (a) y = 
(0.76±0.08)x – 1.3±0.3 and (b) y = (1.02±0.09)x – 1.9±0.3 where errors on regression parameters 
represent the 95% confidence interval.  Log P values are from the literature and log D values 
calculated at experimentally measured pH values in Table 4.1 using the ADMET Predictor 
Module in Gastro-Plus. For nonionizable drugs DNZ and CBZ (H), the measured log P was used 
in lieu of a calculated log D since the log D is not predicted to change with pH. 
 
The linear regression fit improves from an R
2
 value of 0.74 to 0.94 when log D is 
substituted for log P.    Table 4.1 shows the experimentally measured SR values (from Chapter 2) 
as well as the log P and log D values used for the fitted log SRdrug-log P and log SRdrug-log D 
correlations.  The pH of the solubility measurements in FeSSIF and in buffer used to calculate 
SR were very close to 5.00, the initial pH of FeSSIF and blank aqueous buffer.  The log D values 
were calculated at the pH of the solubility measurements indicated in Table 4.1. 
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Table 4.1.  Log P, log D, and SR values used to correlate log SRdrug with drug hydrophobicity. 
Drug log P
a
 log D
b
 pH
sol
 pHsol SRdrug log (SRdrug) 
DNZ 4.53 4.53 4.98±0.03 720 ± 80 2.86±0.05 
IND 4.27 2.92 4.97±0.01 16 ± 1 1.20±0.03 
CBZ (H) 2.32 2.32 4.90±0.07 1.8 ± 0.1 0.25±0.02 
PXC (H) 1.80 1.77 5.00±0.03 2.0 ± 0.2  0.29±0.04 
(a) Values from references 14-17. 
(b) Calculated using the ADMET predictor module in Gastro-Plus for IND and PXC (H). For 
nonionizable drugs DNZ and CBZ (H), the measured log P was used in lieu of a 
calculated log D since the log D is not predicted to change with pH. 
 
 
Though the sample set is small (4 drugs), it is clear that log SRdrug correlates with the log 
D of these drugs.  This is in good agreement with previously reported log SRdrug – log P and log 
D correlations for several of the drugs studied in this work in FeSSIF and other physiologically 
relevant surfactants containing sodium taurocholate (NaTC)
2, 3
.  In those studies, R
2 
values 
ranged from 0.74-0.99, though the particular regression parameters (slope and intercept) were 
different from those reported here.  These differences in fitted regression relationships are mainly 
due to the slight variation in solubilizing agent concentration between the literature and this 
work.   
Next, the log SRcocrystal correlation with the log P and log D of the drug is considered.  
From measured coformer solubilities in FeSSIF and buffer reported in Chapter 2, it was 
determined that the SRcoformer values for the cocrystal systems studied were negligible.  
Therefore, SRcocrystal should correlate with the hydrophobicity of the drug, since the assumption 
that coformers are not solubilized is justified for the systems studied.  As predicted by equations 
(4.13) and (4.14), the SRcocrystal-log P and/or log D relationship depend on the stoichiometry of 
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the cocrystal.  Only one 2:1 cocrystal (CBZ-4ABA-HYD) was studied in this work, so linear 
regression analysis was not performed on SRcocrystal-log D data for 2:1 cocrystals.  Figure 4.2 
shows the correlation of log SRcocrystal for 1:1 cocrystals with log P and log D of the constituent 
drug. 
  a)       (b) 
 
Figure 4.2.  Log SRcocrystal correlation with (a) log P and (b) log D.  Symbols () represent 
experimentally measured data and the lines are a result of linear regression of the data (a) y = 
(0.45±0.07)x – 0.9±0.3 and (b) y = (0.50±0.05)x – 1.0±0.2) where errors on regression 
parameters represent the 95% confidence interval.  Log P values are from literature and log D 
values calculated using the ADMET Predictor Module in Gastro-Plus. For nonionizable drugs 
DNZ and CBZ (H), the measured log P was used in lieu of a calculated log D since the log D is 
not predicted to change with pH. 
 
Log D is a better predictor of log SRcocrystal than log P due to the ionization of IND and 
PXC as was observed in the log SRdrug- log D correlation.  The R
2
 value increases from 0.84 to 
0.92 for the linear regression fits of the experimentally measured SR data when log D is used 
instead of log P.  SRcocrystal values are calculated from measured cocrystal solubilities in FeSSIF 
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and buffer at the eutectic point.  Since many of the cocrystals studied have weakly acidic 
components, the eutectic point pH values were lower than the initial pH of 5.00 of FeSSIF and 
blank aqueous buffer.  For the ionizable drugs IND and PXC, it is necessary to calculate the log 
D at the pH of the experimental conditions of the solubility measurements.  The log D values 
calculated for the correlation in Figure 4.3b were calculated at the eutectic point pHs shown in 
Table 4.2 since these are the conditions under which SR values were measured. 
 Table 4.2 shows the measured SRcocrystal at the eutectic point and the log P and log D 
values used in the log SRcocrystal- log P and log SRcocrystal- log D correlations for 1:1 cocrystals.   
Table 4.2.  Log P, log D, and SR values used to correlate log SRcocrystal of 1:1 cocrystals with 
drug hydrophobicity. 
Cocrystal log P
a
 drug log D
b
 drug pH
eu
 pHeu SRcocrystal logSRcocrystal 
DNZ-VAN 4.53 4.53 4.98±0.03 24±4 1.39±0.07 
DNZ-HBA 4.53 4.53 4.46±0.06 23±3 1.36±0.06 
IND-SAC 4.27 3.71 3.65 ± 0.05 4.5±0.3 0.66±0.05 
CBZ-SLC 2.32 2.32 4.29 ± 0.02 1.33±0.05 0.12±0.02 
CBZ-SAC 2.32 2.32 3.11 ± 0.02  1.03±0.04 0.023±0.007 
PXC-SAC 1.80 1.79 3.79 ±0.02 1.40±0.03 0.15±0.01 
(a) From references 14-17. 
(b) Calculated using the ADMET predictor module in Gastro-Plus for IND and PXC (H). For 
nonionizable drugs DNZ and CBZ (H), the measured log P was used in lieu of a 
calculated log D since the log D is not predicted to change with pH. 
 
 
The log SRcocrystal values correlate well with drug log D.  The pH of the eutectic point is 
significantly lower than pH 5.00 due to the presence of excess coformer in solution, especially in 
the case of the SAC cocrystals.  CBZ-SAC, IND-SAC, and PXC-SAC had pH values ranging 
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from 3.11-3.79.  The SRcocrystal values are different at pH 5.00 compared to the eutectic pH values 
since all cocrystals have ionizable drugs and/or coformers.  However, solubility measurements 
with a final pH equal to the initial pH of 5.00 of FeSSIF and blank aqueous buffer was 
impossible because all the cocrystals studied were unstable in aqueous solution and the only 
method of accessing the equilibrium solubility was at the eutectic point, with in the presence of 
excess coformer.  Since log SR-log D correlations were better fits for both SRdrug and SRcocrystal, 
only log D correlations will be considered for the remaining analysis in this work.  However, for 
systems without ionizable components, log P would be a good descriptor of drug hydrophobicity 
to correlate with drug and cocrystal solubilization. 
 Predicting log SRcocrystal from log SRdrug-log D correlations 
The fitted linear regression data in Figure 4.1 and Figure 4.2 indicate that log SRcocrystal 
for 1:1 cocrystals has a weaker dependence on log D compared to log SRdrug.  Figure 4.3 
compares the experimentally determined log SR-log D correlations for drug and 1:1 cocrystals. 
 
Figure 4.3.  Log SRcocrystal-log D for 1:1 cocrystals and log SRdrug-log D correlations. Symbols 
for drugs () and cocrystals () represent experimentally measured data and the lines are a 
result of linear regression of the data (y = (1.02±0.09)x – 1.9±0.3) for drugs and (y = 
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(0.50±0.05)x – 1.0±0.2) for cocrystals.  Errors on regression parameters indicate the 95% 
confidence interval.  log D values calculated using the ADMET Predictor Module in Gastro-
Plus. For nonionizable drugs DNZ and CBZ (H), the measured log P was used in lieu of a 
calculated log D since the log D is not predicted to change with pH. 
The slope and intercept of the 1:1 cocrystal log SR-log D correlation are significantly 
smaller than that of the drug.  Equations (4.6) and (4.8), indicate how log SRcocrystal is expected to 
relate to log SRdrug of the constituent drug as long as SRcoformer is negligible.  As described in the 
theoretical section, the slope (m) and intercept (b) of cocrystal linear regression equations are 
expected to be smaller than that of the drug.  For a 1:1 cocrystal, 
drug
cocrystal
m
m =
2
           (4.17) 
and 
drug
cocrystal
b
b =
2
            (4.18) 
It is possible to use these relationships to predict log SRcocrystal simply from knowledge of 
drug log D based on an experimentally determined log SRdrug-log D correlation.  After a log 
SRdrug-log D linear regression equation has been obtained from fitted data, equations (4.17) and 
(4.18) indicate how the slope and intercept of a1:1 cocrystal linear regression equation should 
relate to the experimentally determined slope and intercept of the drug linear regression equation. 
Table 4.3 compares the fitted linear regression equation of experimentally measured log 
SRcocrystal-log D (Figure 4.2b) for 1:1 cocrystals  to the predicted linear equation.  The predicted 
linear equation is calculated from equations (4.13) and the linear regression equation of the fitted 
experimentally measured log SRdrug-log D (y= (1.02±0.09)x -1.9±0.3) in Figure 4.2b.     
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Table 4.3.  Comparison of fitted and predicted linear relationships between log SRcocrystal of 1:1 
cocrystals and log D of the constituent drug. 
 Equation Slope (m)
a 
Intercept (b)
a 
Fitted y= (0.50±0.05)log D - 1.0±0.2 0.50±0.05 -1.0±0.2 
Predicted y = 0.51(log D) - 1.03 0.51 1.03 
(a) Errors on regression parameters represent the 95% confidence interval. 
There is excellent agreement between the equations for the linear regression of the 
experimentally determined log SRcocrystal- log D and the line predicted by equation (4.13).  
Theoretically, the slope and intercept of the cocrystal linear regression equation should be half 
that of the constituent drugs as predicted by equation (4.13).  The measured regression slope of 
0.50 for cocrystals is half that of the drug regression slope of 1.02 (mcocrystal/mdrug = 1/2) and the 
measured regression intercept of -1.0 is half that of the drug regression intercept of -1.9 
(bcocrystal/bdrug = 1/2).   
 Even though the SRcocrystal was only measured for one 2:1 cocrystal (and therefore no 
linear regression equation fitted to the data), the log SRcocrystal-log D relationship can be predicted 
from the linear regression equation for the log SRdrug- log D (y= (1.02±0.09)x -1.9±0.3) similar 
to the case for the 1:1 cocrystals.  As indicated by equation (4.14), the slope and intercept should 
be 2/3 those of the drug equation.  Table 4.4 shows the predicted linear regression equations for 
1:1 and 2:1 cocrystals based on the experimentally determined log SRdrug-log D equation. 
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Table 4.4.  Predicted logSRcocrystal-log D linear regression equations for 1:1 and 2:1 cocrystals. 
Stoichiometry Predicted Linear Regression Equation
a 
1:1 cocrystals y = 0.51(log D) – 1.03 
2:1 cocrystals y = 0.68(log D) – 1.38 
(a) Predicted from equations (4.13) and (4.14) based on the experimentally determined drug 
linear regression equation of y= (1.02±0.09)x -1.9±0.3. 
 
The equations in Table 4.4 are plotted against the experimentally determined log SRcocrystal and 
calculated log D values in Figure 4.4. 
 
Figure 4.4.  Log SRcocrystal correlation with log D.  Symbols represent experimentally measured 
values for 1:1 cocrystals () and 2:1 () cocrystals.  The lines represent predicted linear 
regression equations in Table X, y = 0.51(log D) – 1.03 for 1:1 cocrystals and y = 0.68(log D) – 
1.38 for 2:1 cocrystals.  Log D values are calculated using the ADMET Predictor Module in 
Gastro-Plus. For nonionizable drugs DNZ and CBZ (H), the measured log P was used in lieu of a 
calculated log D since the log D is not predicted to change with pH. 
 
The predicted linear regression equations are in good agreement with the experimentally 
measured SRcocrystal values.  Table 4.5 shows the predicted and measured SRcocrystal values. 
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Table 4.5.  Comparison of predicted and measured logSRcocrystal for 1:1 and 2:1 cocrystals. 
Cocrystal log D drug
a
  pHeu log SRcocrystal exp log SRcocrystal pred
b
 
DNZ-VAN (1:1) 4.53 4.46±0.06 1.39±0.07 1.28 
DNZ-HBA(1:1) 4.53 4.46±0.06 1.36±0.06 1.28 
IND-SAC (1:1) 3.71 3.65 ± 0.05 0.66±0.05 0.86 
CBZ-4ABA-HYD (2:1) 2.32 4.94 ± 0.02 0.17±0.02 0.20 
CBZ-SLC (1:1) 2.32 4.29 ± 0.02 0.12±0.02 0.15 
CBZ-SAC (1:1) 2.32 3.11 ±0.02 0.023±0.007 0.15 
PXC-SAC (1:1) 1.79 3.79 ± 0.02 0.15±0.01 0.03 
(a) Log D values are calculated at pHeu using the ADMET Predictor Module in Gastro-Plus. 
(b) Predicted using y = 0.51(log D) – 1.03 for 1:1 cocrystals and y = 0.68(log D) – 1.38 for 
2:1 cocrystals. 
 
The predicted logSRcocrystal values are in reasonable agreement with the experimentally 
measured values using the linear regression equations.  There are some deviations for cocrystals 
of less solubilized drugs, particularly for the CBZ-SAC and PXC-SAC cocrystals.  For CBZ-
SAC, the predicted log SR is much higher than the experimentally measured value.  High SAC 
concentrations at the eutectic point were observed to lower CBZ solubilization as described in 
Chapter 2, which causes the low measured SRcocrystal value for CBZ-SAC.  The deviation for 
PXC-SAC is likely due to the log D value used for prediction.  Log D values for PXC calculated 
15, 18-20
 using different software packages can differ by as much as 2 fold depending on the pH 
conditions of interest.  For the best prediction, a measured log D in the experimental conditions 
of interest would be optimal.     
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Considering that the predicted values are calculated from a log SRdrug-log D correlation 
of only 4 drugs, the fit for the majority of the cocrystals is reasonable.  A more robust log SRdrug-
log D correlation of more drugs of varying log D would lead to better log SRcocrystal predictions, 
and this work provides the theoretical framework to make these predictions. 
Conclusions 
In this work we develop mathematical models that describe the relationship between log 
SRcocrystal and logSRdrug for the purpose of comparing the correlation between log SR and drug 
hydrophobicity (as described by log P or log D) for drugs and cocrystals.  Ionizable drugs are 
considered and log D was determined to be a better drug hydrophobicity descriptor than log P for 
these drugs and cocrystals.  The log SRcocrystal exhibits a weaker dependence on drug log D for 
compared to log SRdrug, which is predicted from mathematical models presented here.  The 
presented models can be used to predict log SRcocrystal simply from knowledge of drug log D if a 
robust log SRdrug-log D linear regression correlation is calculated from experimentally measured 
SRdrug values.  These models are valuable since SRdrug and log P and/or log D are commonly 
measured and reported drug properties.   From the proposed models, SRcocrystal of a cocrystal of a 
given drug can be predicted before a cocrystal has even been synthesized.  These predictions can 
guide solid form selection decisions since the solubilization of a cocrystal of a given drug can be 
anticipated as long as the stoichiometry of that cocrystal is known.     
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CHAPTER 5  
COCRYSTAL SOLUBILIZATION IN THE PRESENCE OF MULTIPLE 
SOLUBILIZING AGENTS 
 
Introduction 
Cocrystal solubility is profoundly affected by the presence of solubilizing agents in 
solution
1-5
.  Differential solubilization of cocrystal constituents can lead to a reduction in the 
solubility advantage of the cocrystal over the drug (Scocrystal/Sdrug) when the drug constituent is 
solubilized and the coformer is not
1-5
.  Mathematical models that consider relevant solution 
equilibria have been derived to describe and predict the influence of single solubilizing agents on 
cocrystal solubility and thermodynamic stability.  The solubility values predicted by these 
models have been shown to be in good agreement with experimentally measured solubilities for 
cocrystals of carbamazepine and indomethacin in the presence of several synthetic surfactants
1-5
.  
In the presence of these additives, cocrystal solubility relative to the drug solubility was 
switched, and this behavior predicted using the reported models. 
It is likely that the solubility of a formulated cocrystal drug product would be affected by 
several additives simultaneously.  The cocrystal would encounter synthetic solubilizing agents in 
the formulation as well as endogenous surfactants in vivo.  A mechanistic understanding of the 
combined effect of several solubilizing agents on cocrystal solution behavior is yet to be 
established.  It has been reported that the in vitro dissolution profile of the danazol-vanillin 
cocrystal was improved drastically when formulated with a vitamin E-TPGS solubilizing agent 
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and hydroxypropylcellulose precipitation inhibitor in the presence of fasted state simulated 
intestinal fluid (FaSSIF)
6
.  The combined effect of the additives resulted in a 10 fold increase in 
area under the curve (AUC) of the plasma drug concentration- time profile in an in vivo study in 
rats compared to a 1.7 fold increase for the unformulated cocrystal
6
.  Could this behavior have 
been predicted from knowledge of the solubilization mechanisms of cocrystals in the presence of 
these solubilizing agents? Does solubilization by multiple solubilizing agents have an additive 
effect on cocrystal solubility and stability?  How does the decrease in Scocrystal/Sdrug observed in a 
single solubilizing agent compared to the decrease in multiple solubilizing agents?   
The aim of this work is to develop models to predict cocrystal solubility and Scocrystal/Sdrug 
in the presence of multiple solubilizing agents.  As a first approximation, solubility in the 
presence of two ideally mixing solubilizing agents will be considered.  This treatment of the 
solubilizing agents assumes that solublization by each solubilizing agent is unaffected by the 
presence of the other solubilizing agent.  Two 1:1 cocrystals of the poorly solubility drug danazol 
(DNZ) were chosen for study:  the danazol-hydroxybenzoic acid cocrystal (DNZ-HBA) and 
danazol-vanillin (DNZ-VAN).  DNZ is a nonionizable, hydrophobic drug (log P = 4.53
7
) that has 
been shown to be highly solubilized by solubilizing agents
6, 8-11
.  Hydroxybenzoic acid (HBA) is 
a weakly acidic (pKa = 4.48
12
) hydrophilic (log P = 1.60
13, 14
) coformer, and  vanillin is a weakly 
acidic (pKa = 7.4
12
), hydrophilic (log P = 1.26
13, 14
) coformer.  These cocrystals were chosen 
based on literature reports that their solubility is highly affected by multiple solubilizing agents
6
 
and their high aqueous solubility and Scocrystal/Sdrug.  Solubilizing agents were selected to mimic a 
cocrystal in the presence of one synthetic formulation additive (Tween 80) and one 
physiologically relevant surfactant (fed state simulated intestinal fluid (FeSSIF)).  Solubilizing 
agents were selected based on their high solubilizing capacity of DNZ.  
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Theoretical 
Cocrystal solubility in multiple surfactants  
Cocrystal solubility and thermodynamic stability in the presence of multiple solubilizing 
agents is determined by the equilibria between the cocrystal and drug solid phases and the drug 
and coformer constituents in the solution phase.  The effect of micellar solubilization of cocrystal 
constituents by multiple solubilizing agents can be mathematically modeled by examining the 
relevant solution equilibria and expanding upon previously reported models that consider a 
single solubilizing agents.  In this analysis, two micellar sufactants will be considered.  
 The relevant equilibria for a 1:1 cocrystal RHA, where R represents a nonionizable drug, 
HA represents a monoprotic weakly acidic coformer, MA represents micellar surfactant A, and 
MB represents micellar surfactant B, are: 
spK
solid aq aqRHA R +HA           (5.1) 
aK - +
aq aq aqHA A +H           (5.2) 
R
s,AK
aq A mAR +M R           (5.3) 
R
s,BK
aq B mBR +M R           (5.4) 
HA
s,AK
aq A mAHA +M HA          (5.5) 
HA
s,BK
aq B mBHA +M HA          (5.6) 
-A
s,AK- -
aq A mAA +M A          (5.7) 
 152 
 
-A
s,BK- -
aq B mBA +M A           (5.8) 
And the associated equilibrium constants are: 
The cocrystal solubility product Ksp: 
sp aq aqK =[R] [HA]            (5.9) 
The ionization constant Ka for the monoprotic weakly acidic coformer HA: 
- +
aq aq
a
aq
[A ] [H ]
K =
[HA]
          (5.10) 
The micellar solubilization constants Ks,A
R 
and Ks,B
R
 for drug R in surfactants A and B: 
R mA
s,A
aq A
[R]
K =
[R] [M]
           (5.11) 
R mB
s,B
aq B
[R]
K =
[R] [M]
          (5.12) 
The micellar solubilization constants Ks,A
HA 
and Ks,B
HA
 for unionized coformer HA in surfactants 
A and B: 
HA mA
s,A
aq A
[HA]
K =
[HA] [M]
          (5.13) 
HA mB
s,B
aq B
[HA]
K =
[HA] [M]
          (5.14) 
The micellar solubilization constants Ks,A
A- 
and Ks,B
A-
 for ionized coformer A
-
 in surfactants A 
and B: 
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-
-
A mA
s,A -
aq A
[A ]
K =
[A ] [M]
          (5.15) 
-
-
A mB
s,B -
aq B
[A ]
K =
[A ] [M]
          (5.16) 
The subscript aq refers to the aqueous phase while m refers to the micellar phase.  This 
way of defining the micellar solubilization constants utilizes the mass action model of 
solubilization and assumes that surfactants A and B mix ideally.  That is, that solubilization by 
either A or B is independent of solubilization by the other surfactant.  Assuming ideally mixing 
surfactants allows the solubilization contributions of each surfactant to the total cocrystal 
solubility to be treated additively.  Activities are replaced by concentrations assuming dilute 
solution conditions. 
 The total solubility of RHA, SRHA,T, is derived by considering the mass balances on R and 
HA: 
T aq mA mB[R] =[R] +[R] +[R]           (5.17) 
and 
- - -
T aq mA mB aq mA mB[A] =[HA] +[HA] +[HA] +[A ] +[A ] +[A ]       (5.18) 
and substituting the above equilibrium constants to give 
  
- -
R R pH-pKa HA HA A pH-pKa A pH-pKa
RHA,T sp s,A A s,B B s,A A s,B B s,A A s,B B
S = K 1+K [M ]+K [M ] 1+10 +K [M ]+K [M ]+K [M ]10 +K [M ]10  (5.19) 
in terms of the stoichiometric cocrystal solubility, which are equimolar drug and coformer in the 
case of this 1:1 cocrystal.   
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To simplify equation (5.19), total solubilization constants in specified pH conditions 
(Ks
T
) can be substituted. For nonioinzable drug R, Ks
R,T
 is simply the solubilization constant for 
the nonionionized component (Ks
R
) and the calculation of a total solubilization constant is not 
necessary.  For ionizable components, the total solubilization constant takes into account the 
equilibrium solubilization constants in a given media for both the ionized and unionized species.  
For example, for weakly acidic component HA, the total solubility in a surfactant as a function of 
intrinsic aqueous solubility Saq, ionization constant Ka, and micellar solubilization is given by: 
 
-
A,T
s
HA HA pH-pKa,acid HA pH-pKa,acid A
T aq s s
K
S =S 1+10 + K +10 K [M]
 
 
 
 
 
      (5.20) 
In order to take into account the solubilization of both unionized and ionized components, the 
solubilization constants can be grouped into Ks
HA,T 
which indicates the total solubilization of HA 
at a given pH in a particular surfactant. 
 HA HA pH-pKa,acid HA,TT aq sS =S 1+10 +K [M]          (5.21) 
The simplified equation for the solubility of 1:1 cocrystal RHA in two surfactants then 
becomes: 
  R R pH-pKa HA HARHA,T sp A,T A B,T B A,T A B,T BS = K 1+Ks [M ]+Ks [M ] 1+10 +Ks [M ]+Ks [M ]    (5.22) 
The micellar surfactant concentrations [MA] and [MB] are the total surfactant concentrations 
minus the critical micellar concentration (CMC) of each surfactant.  This assumes the CMC of 
each surfactant is unaffected by the presence of the other surfactant and is constant in the range 
of concentrations and solubilizations considered here. 
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 This equation can serve as an approximation of cocrystal solubility in in vivo conditions 
where the cocrystal may be in the presence of a formulation surfactant as well as endogenous 
surfactants.  Ks
T
 and Ka values of cocrystal components are often available in the literature and 
the prediction only requires a measure of cocrystal Ksp and knowledge of the solution conditions 
(pH, [M]) of interest.  This can be useful knowledge to design appropriate dissolution 
experiments and choose formulations that target a specific cocrystal solubility in vivo. 
 The stoichiometric solubility of the cocrystals (cocrystal at equilibrium with solution 
concentrations of constituents equal to their molar ratio) is calculated from experimentally 
measured total eutectic concentrations in the presence of surfactants by the following equation 
for 1:1 cocrystals
15, 16
: 
1:1 cocrystal
T T,eu T,euS = [drug] [coformer]         (5.23) 
This method of accessing cocrystal equilibrium solubility in nonstoichiometric conditions is well 
established in the literature
4, 5, 15-18
. 
Cocrystal solution stability in multiple surfactants 
Scocrystal/Sdrug, the ratio of the cocrystal solubility to the drug solubility, is a measure of the 
cocrystal thermodynamic stability in solution.  It has been previously reported in this dissertation 
and elsewhere that Scocrystal/Sdrug of a 1:1 cocrystal RHA of nonionizable drug R and monoprotic 
weakly acidic coformer HA in the presence of a surfactant is
4
: 
  
 
RHA RHA R pH-pKa HA
sp s,T s,Tcocrystal
0 R
drug R,aq s,T
K 1+K [M] 1+10 +K [M]S
=
S S 1+K [M]
 
  
 
      (5.24) 
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In the presence of two ideally mixing surfactants A and B, the solubilization by each surfactant is 
additive, and equation (5.24) becomes 
  
 
RHA R R pH-pKa HA HA
sp A,T A B,T B A,T A B,T Bcocrystal
R R
drug s,A A s,B B
0
R,aq
K 1+Ks [M ]+Ks [M ] 1+10 +Ks [M ]+Ks [M ]S
=
S S 1+K [M ]+K [M ]
 
 
 
   (5.25) 
The above equation allows for the prediction of Scocrystal/Sdrug in two surfactants from knowledge 
of cocrystal Ksp, drug and coformer Ks
T
 values in each surfactant, and drug intrinsic aqueous 
solubility (Sdrug,aq
0
).  This is helpful to predict if a cocrystal will be stabilized (Scocrystal/Sdrug = 1) 
in a given formulation or to target a theoretical supersaturation.   
Figure 5.1 shows the theoretical Scocrystal/Sdrug for two 1:1 cocrystals RHA (of the same 
drug R) in the presence of one or two surfactants.  The cocrystals are modeled as formulated 
cocrystals with one surfactant representing a physiologically relevant (endogenous) surfactant at 
the concentration of FeSSIF, and the other a synthetic formulation surfactant at varying 
concentrations.  The impact of different aqueous solubility advantages (Scocrystal/Sdrug)aq on the 
ability of these cocrystals to be stabilized by the formulation surfactant is examined.  Coformer 
solubilization was assumed to be negligible and the cocrystals to be in nonionizing conditions.  
Ks
drug,T
 values were selected from common range for hydrophobic drug solubilization in 
physiologically relevant and synthetic formulation surfactants. 
 157 
 
 
Figure 5.1. Scocrystal/Sdrug for two 1:1 cocrystals predicted from equation (5.24) for 1 surfactant 
(formulation only) and (5.25) for 2 surfactants (formulation + physiologically relevant) in 
increasing concentrations of a formulation surfactant.   Dotted lines represent cocrystal A with 
(Scocrystal/Sdrug)aq = 500 and solid lines represent cocrystal B with (Scocrystal/Sdrug)aq = 100.  
Conditions with only one solubilizing agent (formulation) are shown in orange and those with 
two solubilizing agents (formulation + physiologically relevant) are shown in green.  Values 
used for predictions are: Ksp = 2.5 mM
2
 for cocrystal A and 62.5 mM
2 
for cocrystal B, Sdrug,aq
0
 = 
0.5 mM, Ks,
formulation surfactant
 = 150 mM
-1
, Ks,
physiologically relevant
 = 50 mM
-1
, [M] of the 
physiologically relevant surfactant = 147 mM (that of FeSSIF).  
 
When (Scocrystal/Sdrug)aq = 100, cocrystal RHA is stabilized ((Scocrystal/Sdrug)T = 1) in both the 
formulation surfactant alone and in a physiologically relevant surfactant in addition to a 
formulation surfactant. The presence of two surfactants allows the cocrystal to be stabilized at a 
lower concentration of formulation surfactant.  In the presence of the physiologically relevant 
surfactant, only 18 mM of formulation surfactant is needed to stabilize the cocrystal, while in the 
absence, around 70 mM is necessary.  This highlights the large reduction in Scocrystal/Sdrug that is 
possible in the presence of multiple surfactants. 
(Scocrystal/Sdrug)aq has a large impact on the ability of a cocrystal to be stabilized in a 
formulation.  When (Scocrystal/Sdrug)aq = 500, the cocrystal cannot be stabilized in a reasonable 
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concentration of the formulation surfactant even when a physiologically relevant surfactant is 
present.  The lowest Scocrystal/Sdrug achievable is 5 at 150 mM of formulation surfactant in the 
presence physiologically relevant surfactant.  Even though very highly soluble cocrystals may 
not be able to be stabilized in multiple surfactants, it is clear that the Scocrystal/Sdrug can be 
decreased by orders of magnitude by selection of solubilizing agents with appropriate Ks
drug,T
 
values.  When more than one surfactant is present, the Scocrystal/Sdrug can be reduced effectively 
with a lower concentration of one of the surfactants since the stabilizing power of the surfactants 
is additive.  Selection of formulation surfactants to dial-in a target Scocrystal/Sdrug can optimize 
cocrystal dissolution profile to achieve higher drug concentrations and sustained 
supersaturations. 
Experimentally, Scocrystal/Sdrug is assessed from the drug and coformer eutectic 
concentrations by calculating the eutectic constant, Keu
15, 16
.  Keu is a directly measurable 
parameter calculated according to: 
eu
eu
eu
[coformer]
K =
[drug]
            (5.26) 
The eutectic constant is related to the cocrystal thermodynamic stability, also called the cocrystal 
solubility advantage Scocrystal/Sdrug.  For cocrystal AxBy, where A and B are the cocrystal 
constituents, drug and coformer respectively; and x and y are the stoichiometric coefficients or 
molar ratios,  Scocrystal/Sdrug is a function of Keu as follows
15, 16
: 
 x+y
x y
cocrystalT,eu y
eu
T,eu drug
S[coformer]
K = =xy
[drug] S
 
  
 
       (5.27) 
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This relationship is valid in both aqueous and solubilizing agent solutions as it relies on the total 
measured eutectic concentrations of drug and coformer in the conditions of interest.  For a 1:1 
cocrystal, equation (5.27) becomes 
2
cocrystaleu
eu
eu drug
S[coformer]
K = =
[drug] S
 
  
 
        (5.28) 
And 
cocrystal eu
drug eu
S [coformer]
=
S [drug]
 
  
 
          (5.29) 
Materials and Methods 
Materials 
Cocrystal constituents 
Anhydrous danazol was received as a gift from Renovo Research (Atlanta, GA) and used 
as received.  Anhydrous hydroxybenzoic acid was purchased from Acros Organics (Pittsburgh, 
PA) and used as received.  Anhydrous vanillin was purchased from Fisher Scientific (Fair Lawn, 
NJ) and used as received. Hydroxybenzoic acid monohydrate (HBA (H)) was prepared by 
slurrying HBA in deionized water for at least 24 hours.  All crystalline drugs and coformers were 
characterized by X-ray power diffraction (XRPD) and differential scanning calorimetry (DSC) 
before carrying out experiments. 
Solvents and buffer components 
Ethyl acetate was purchased from Acros Organics (Pittsburgh, PA) and used as received, 
and HPLC grade methanol was purchased from Fisher Scientific (Pittsburgh, PA). 
Trifluoroacetic acid spectrophometric grade 99% was purchased from Aldrich Company 
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(Milwaukee, WI).   Water used in this study was filtered through a double deionized purification 
system (Milli Q Plus Water System) from Millipore Co. (Bedford, MA). 
Tween 80 solutions, FeSSIF, and acetate buffer were prepared using Tween 80 purchased 
from Sigma Chemical Company (St. Louis, MO), sodium taurocholate (NaTC) purchased from 
Sigma Chemical Company (St. Louis, MO), lecithin purchased from Fisher Scientific 
(Pittsburgh, PA), sodium hydroxide pellets (NaOH) purchased from J.T. Baker (Philipsburg, NJ), 
and acetic acid and potassium chloride (KCl) purchased from Acros Organics (Pittsburgh, PA).  
Methods 
FeSSIF, acetate buffer, and Tween 80 solution preparation  
FeSSIF and acetate buffer were prepared according to the protocol of Galia and 
coworkers
19
.   Acetate buffer was prepared as a stock solution at room temperature by dissolving 
8.08 g NaOH (pellets), 17.3 g glacial acetic acid and 23.748 g NaCl in 2 L of purified water. The 
pH was adjusted to 5.00 with 1 N NaOH and 1N HCl.  FeSSIF was prepared by dissolving 0.41 g 
sodium taurocholate in 12.5 mL of pH 5.00 acetate buffer. 0.148 g lecithin was added with 
magnetic stirring at 37 °C until dissolved.  The volume was adjusted to exactly 50 mL with 
acetate buffer.  Tween 80 solutions were prepared by dissolving an appropriate amount (25 mM, 
50 mM, 150 mM) of Tween 80 in pH 5.00 acetate buffer. 
Cocrystal synthesis 
Cocrystals were prepared by the reaction crystallization method
20
 at 25°C. The 1:1 
danazol-hydroxybenxoic acid cocrystal (DNZ-HBA) was prepared by adding stoichiometric 
amounts of cocrystal components (DNZ and HBA) to nearly saturated HBA solution in ethyl 
acetate.  The 1:1 danazol-vanillin cocrystal (DNZ-VAN) was prepared by adding stoichiometric 
amounts of cocrystal components (DNZ and VAN) to nearly saturated VAN solution in ethyl 
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acetate.  Prior to carrying out any solubility experiments, solid phases were characterized by 
XRPD and DSC and stoichiometry verified by HPLC.   Full conversion to cocrystal was 
observed in 24 hours. 
Solubility measurements of cocrystal constituents 
Cocrystal constituent solubilities were measured in FeSSIF, Tween 80, and pH 5.00 
acetate buffer (FeSSIF without NaTC and lecithin or Tween 80).  The solubilities of the cocrystal 
components were determined by adding excess solid to 3 mL of media (FeSSIF, Tween 80, or 
buffer). Solutions were magnetically stirred and maintained at 25 ±  0.1°C using a water bath for 
up to 96 h. In 24 hr intervals, 0.30 mL of samples were collected, pH of solutions measured, and 
filtered through a 0.45 µm pore membrane.   After dilution with mobile phase, solution 
concentrations of drug or coformer were analyzed by HPLC. The final solid phases were 
characterized by XRPD and DSC.  
Cocrystal solubility measurements 
Cocrystal equilibrium solubilities were measured in FeSSIF, Tween 80, and pH 5.00 
acetate buffer (FeSSIF without NaTC and lecithin) at the eutectic point, where drug and 
cocrystal solid phases are in equilibrium with solution. The eutectic point between cocrystal and 
drug was approached by cocrystal dissolution (suspending solid cocrystal (~100 mg) and drug 
(~50 mg) in 3 mL of media (FeSSIF or buffer)) and by cocrystal precipitation (suspending solid 
cocrystal (~50 mg) and drug (~100 mg) in 3 mL of media (FeSSIF or buffer) nearly saturated 
with coformer).  Solutions were magnetically stirred and maintained at 25 ± 0.1°C using a water 
bath for up to 96 h. At 24 hr intervals, 0.30 mL aliquots of suspension were collected, pH was 
measured, before filtration through a 0.45 µm pore membrane.   Solid phases were also collected 
at 24 hr intervals to ensure the sample was at the eutectic point (confirmed by presence of both 
 162 
 
drug and cocrystal solid phases and constant [coformer] and [drug] solution concentrations).  
After dilution of filtered solutions with mobile phase, drug and coformer concentrations were 
analyzed by HPLC. The equilibrium solid phases were characterized by XRPD and DSC. 
The stoichiometric solubility of the cocrystals (cocrystal equilibrium solubility in the 
absence of excess coformer) is calculated by the following equations for 1:1 cocrystals
15
: 
1:1 cocrystal
T T,eu T,euS = [drug] [coformer]         (5.30) 
X-ray powder diffraction 
X-ray powder diffraction diffractograms of solid phases were collected on a benchtop 
Rigaku Miniflex X-ray diffractometer (Rigaku, Danverse, MA) using Cu Kα radiation (λ= 
1.54Å), a tube voltage of 30 kV, and a tube current of 15 mA. Data were collected from 5 to 40° 
at a continuous scan rate of 2.5°/min.  
Thermal analysis 
Solid phases collected from the slurry studies were dried at room temperature and 
analyzed by differential scanning calorimetry (DSC) using a TA instrument (Newark, DE) 
2910MDSC system equipped with a refrigerated cooling unit. DSC experiments were performed 
by heating the samples at a rate of 10 °C/min under a dry nitrogen atmosphere. A high purity 
indium standard was used for temperature and enthalpy calibration.  Standard aluminum sample 
pans were used for all measurements.  
High performance liquid chromatography 
Solution concentrations were analyzed by a Waters HPLC (Milford, MA) equipped with 
an ultraviolet-visible spectrometer detector.  For the DNZ-HBA and DNZ-VAN cocrystals and 
their components, a C18 Waters Atlantis (Milford, MA) column (5 µM 250 x 6 mm) at ambient 
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temperature was used.  The injection volume was 20 µL in FeSSIF and Tween 80 experiments, 
and 100 µL in buffer experiments due to the extremely low solubility of DNZ in aqueous 
solutions.  Analysis was conducted using an isocratic method composed of 80% methanol and 
20% water with 0.1% trifluoroacetic acid and a flow rate of 1 mL/min.  Absorbance of DNZ was 
monitored at 285 nm, HBA at 242 nm, and VAN at 300 nm.  For all cocrystals, the Waters’ 
operation software Empower 2 was used to collect and process data. 
Results 
Cocrystal component solubilization in multiple surfactants 
To determine if Tween 80 and FeSSIF mix ideally, the solubilization of cocrystal 
constituents by Tween 80 in pH 5.00 blank aqueous buffer was compared to their solubilization 
by Tween 80 in the presence of FeSSIF.  Drug and coformer solubilities were measured in 
increasing concentrations of Tween 80 either in buffer with Tween 80 or in Tween 80 + FeSSIF.  
Figure 5.2 and Table 5.1 show the measured DNZ solubility in 25, 50 and 150 mM Tween 80 in 
buffer and FeSSIF. 
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Figure 5.2.  Influence of Tween 80 on the solubility of DNZ in pH 5.00 buffer and in FeSSIF.  
Symbols represent experimentally measured solubility values in Tween 80 in pH 5.00 buffer () 
and in Tween 80 + FeSSIF ().  Lines are drawn according to equations obtained from linear 
regression of the data: y = (2.00±0.03)x + 0.008±0.003 for Tween 80 in buffer (blue) and y = 
(1.87±0.01)x + 0.008±0.001 for Tween 80 + FeSSIF (red).  Errors on regression parameters 
represent the 95% confidence interval.   
Table 5.1.  Influence of Tween 80 on the solubility of DNZ in pH 5.00 buffer and FeSSIF. 
Media [Tween 80] (mM) SDNZ (mM) pH 
Buffer 
0 (1.6±0.2)x10
-4
 4.96±0.01 
25 0.61±0.02 4.97±0.02 
50 1.15±0.06 4.99±0.01 
150 3.05±0.02 5.02±0.01 
FeSSIF 
0 0.11±0.01 5.01±0.05 
25 0.54±0.04 5.04±0.01 
50 1.00±0.05 5.06±0.01 
150 2.90±0.02 5.07±0.02 
 
DNZ solubilization by Tween 80 is not significantly affected by the presence of FeSSIF.  
The linear regression parameters for the measured DNZ solubility in buffer + Tween 80 are not 
significantly different from the data in FeSSIF + Tween 80.  In buffer, the linear regression 
equation is y = (2.00±0.03)x + 0.008±0.003 and in FeSSIF, the equation is y = (1.87±0.01)x + 
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0.008±0.001).  Similar behavior is seen for the solubilization of coformers HBA and VAN by 
Tween 80 in buffer and FeSSIF as shown in Figure 5.3 and Table 5.2. 
(a)       (b) 
 
Figure 5.3.  Influence of Tween 80 on the solubility of HBA (H) (a) and VAN (b) in pH 5.00 
buffer and in FeSSIF.  Symbols represent experimentally measured solubility values in Tween 80 
in pH 5.00 buffer () and Tween 80 + FeSSIF ().  Lines are drawn according to equations 
obtained from linear regression of the data: for (a) y = (1.38±0.02)x + 82±2 for Tween 80 in 
buffer (blue) and y = (1.45±0.06)x + 87±5 for Tween 80 + FeSSIF (red), for (b) y = (1.53±0.03)x 
+ 57±2 in Tween 80 in buffer (blue) and  y = (1.52±0.03)x + 55±3 in Tween 80 in FeSSIF (red).  
Errors on regression parameters represent the 95% confidence interval.  HBA (H) represents the 
monohydrate form of HBA which is the stable form in aqueous solution. 
Table 5.2.  Influence of Tween 80 on the solubility of HBA (H) and VAN in pH 5.00 buffer and 
FeSSIF. 
Media 
[Tween 80] 
(mM) 
SHBA (H) (mM) Final pH SVAN (mM) Final pH 
Buffer 
0 84±2 4.41±0.04 54.3±0.1 4.94±0.01 
25 113±5 4.40±0.01 96.6±0.2 4.98±0.01 
50 153±3 4.39±0.01 130±10 4.98±0.01 
150 289±2 4.34±0.01 286±8 5.02±0.01 
FeSSIF 
0 96.4±0.6 4.45±0.02 63.7±0.2 4.99±0.01 
25 120±4 4.42±0.01 105±6 5.06±0.02 
50 149±2 4.43±0.02 139±8 5.07±0.01 
150 310±20 4.39±0.03 290±10 5.08±0.02 
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As was observed for DNZ, HBA (H) and VAN solubilization by Tween 80 were similar 
in buffer and in FeSSIF.  The linear regression equations for the solubility of each coformer in 
Tween 80 are very similar in FeSSIF and buffer.  For HBA (H), y = (1.38±0.02)x + 82±2 in 
buffer and  y = (1.45±0.06)x + 87±5 in FeSSIF.  For VAN, y = (1.53±0.03)x + 57±2 in buffer 
and  y = (1.52±0.03)x + 55±3 in FeSSIF.  From the linear regression equations for DNZ, HBA 
(H), and VAN, solubilization constants (Ks
drug
 and Ks
coformer
) can be calculated to further assess 
the solubilization of each component by Tween 80 in buffer and by Tween 80 in FeSSIF.  
 For nonionizable drug DNZ, the linear regression equation takes the form 
 T 0 sS =S 1+K [M]           (5.31) 
where the slope is equal to Ks/S0.  For monoprotic weakly acidic coformers HBA and VAN,  
 pH-pKa TT 0 sS =S 1+10 +K [M]         (5.32) 
where the slope is equal to Ks
T
/S0.  S0 is equal to the measured intrinsic (nonionized) solubility in 
blank aqueous buffer or FeSSIF.  The Ks and Ks
T
 values for DNZ, HBA (H) and VAN obtained 
from linear regression are shown in Figure 5.1. 
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Table 5.3.  Ks
T
 in Tween 80 calculated from linear regression analysis of measured solubility 
values of DNZ, HBA (H), and VAN in increasing concentrations of Tween 80 in buffer and 
FeSSIF 
 DNZ HBA (H) VAN 
Media Slope Ks
T
 (mM
-1
)
a
 Slope Ks
T
 (mM
-1
)
b
 Slope Ks
T
 (mM
-1
)
c
 
Tween 80 pH 
5.00 buffer 
2.00±0.03 125±16 1.38±0.02 0.031±0.001 1.53±0.03 0.028±0.001 
Tween 80 + 
FeSSIF 
1.87±0.01 121±14 1.45±0.06 0.032±0.001 1.52±0.03 0.028±0.001 
(a) Calculated using equation (5.31), S0 = (1.6±0.2)x 10
-4
 mM and CMC of Tween 80 = 0.01 
mM
-1
 from reference 
21
. 
(b)  Calculated using equation (5.32)and S0 = 45±2 mM and CMC of Tween 80 = 0.01 mM
-1
 
(reference 
21
). 
(c) Calculated using equation (5.32) and S0 = 54±1 mM and CMC of Tween 80 = 0.01 mM
-1
 
(reference 
21
). 
 
DNZ is highly solubilized by Tween 80 as shown by Ks
T
 values of 125 and 121 mM
-1
.  This is 
not surprising as DNZ is a very hydrophobic drug with a log P of 4.53 and micellar solubilization 
of drugs has been shown to correlate with log P
7, 22, 23
.  Comparatively, the hydrophilic coformers 
HBA (H) (log P = 1.60
13
) and VAN (log P = 1.26
13
) are not solubilized significantly, with Ks
T
 
values in the range of 0.028-0.032 mM
-1
.   
Cocrystal constituent solubilization by Tween 80 is very similar in buffer compared to 
FeSSIF.  The similarity of the Ks
T
 values for Tween 80 determined from linear regression 
analysis in buffer and FeSSIF indicates that Tween 80 and FeSSIF can be treated as ideally 
mixing surfactants.  That is, solubilization by Tween 80 is unaffected by the presence of FeSSIF.  
This means that the Ks
T
 values of cocrystal components measured independently (separately) in 
Tween 80 and FeSSIF can be used to predict cocrystal solubility using equation (5.22).  
Assuming ideally mixing surfactants in this way reduces the number of experiments that need to 
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be done because the Ks
T
 values of compounds only need to be measured in separate single 
surfactants and not in surfactant mixtures. 
Cocrystal solubility prediction in multiple surfactants 
Equation (5.22)  can be used to predict the solubility of DNZ-HBA and DNZ-VAN in the 
presence of two surfactants as a function of Ksp, Ka, and measured Ks
T
 values along with 
knowledge of the pH of [M] values of the media of interest.  Table 5.4 shows the measured Ksp 
and reported pKa of the coformers for DNZ-HBA and DNZ-VAN. 
Table 5.4.  Cocrystal Ksp and coformer pKa values at 25°C. 
Cocrystal Ksp (mM
2
)
a
 Coformer pKa
b 
DNZ-HBA (1.1 ± 0.4) x10
-2 
mM
2
 4.48 
DNZ-VAN (3.5 ± 0.5) x10
-3 
mM
2
 7.4 
(a) Ksp was experimentally determined from cocrystal eutectic point measurements as 
described in the Appendix in Chapter 2. 
(b) pKa values reported in reference 12. 
 
The Ks
T
 values calculated from measured cocrystal component solubilities in aqueous buffer, 
FeSSIF, and various concentrations of Tween 80 are shown in Table 5.5. 
Table 5.5.  Ks
T 
values for DNZ, HBA, and VAN in FeSSIF and Tween 80. 
Component Ks
T
 FeSSIF (mM
-1
)
a
 Ks
T
 Tween 80 (mM
-1
)
b
 
DNZ 49±5 125±16 
HBA 0.018±0.001 0.031±0.001 
VAN 0.012±0.001 0.028±0.001 
(a) Calculated from single solubility measurements in FeSSIF and buffer in Table 2.5 as 
described in Chapter 2.  
(b) Calculated from linear regression analysis shown in Figure 5.2, Figure 5.3, and Table 5.3 
and described in the text. 
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The thermodynamic equilibrium constants in Table 5.4 and Table 5.5 can be used to 
predict DNZ cocrystal solubility in aqueous, single surfactant, and two surfactant solutions.  The 
derivation for DNZ cocrystal solubility in the presence of two surfactants is shown in the 
theoretical section and is given by equation (5.22).  The equations to predict cocrystal solubility 
as a function of pH in aqueous solutions and in a single micellar surfactant have been previously 
reported and are 
 pH pKa,coformercocrystal,aq spS K 1 10           (5.33) 
in aqueous buffer
18
 and 
  R pH pKa,coformer coformercocrystal,T sp s sS K 1 K [M] 1 10 K [M]        (5.34) 
in a single micellar surfactant
1
 for a 1:1 cocrystal RHA such as DNZ-HBA and DNZ-VAN.   
Table 5.6 shows the experimentally measured and predicted stoichiometric cocrystal 
solubilities in buffer, Tween 80, and FeSSIF. 
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Table 5.6.  Comparison between predicted and experimentally measured cocrystal solubility 
values. 
  
Scocrystal FeSSIF 
(mM) 
 Scocrystal buffer (mM)  
Cocrsytal 
[Tween 80] 
(mM) 
Pred
a 
Exp
b 
pH
c 
Pred
a 
Exp
b 
pH
c 
DNZ-HBA 
0 4.2 2.8±0.1 4.46±0.06 0.15 0.12±0.01 4.47±0.04 
25 11 9.1±0.3 4.46±0.02 9.6 8.8±0.2 4.45±0.01 
50 17 13.5±0.4 4.43±0.01 16 14.2±0.2 4.43±0.01 
150 38 35.5±0.5 4.41±0.02 37 31.7±0.5 4.42±0.01 
DNZ-VAN 
0 1.7 1.39±0.03 5.00 ± 0.01 0.059 0.057±0.02 4.96 ± 0.01 
25 5.0 4.2±0.2 5.04 ± 0.01 4.4 N/A N/A 
50 7.9 6.6±0.1 5.06 ± 0.01 7.4 N/A N/A 
150 20 16.3±0.3 5.08 ± 0.01 19 17.2±0.2 5.02±0.01 
(a) Predicted from equation (5.33) in aqueous buffer, (5.34) in a single surfactant, and (5.22) 
in two surfactants. 
(b) Calculated from experimentally measured eutectic concentrations using equation (5.30). 
(c) Experimentally measured eutectic point pH values.  
 
To compare to stoichiometric cocrystal solubilities calculated from experimentally 
measured eutectic concentrations, solubilities were predicted at the eutectic pHs indicated in 
Table 5.6 rather than that of the initial FeSSIF and buffer (pH 5.00).  However, the pH values 
only deviated from 5.00 slightly for these cocrystals because the pKa of HBA is 4.48 and the pKa 
of VAN is 7.4.  Solubilities in buffer and a particular Tween 80 concentration did not differ 
significantly from solubility in FeSSIF + that particular Tween 80 concentration.  In other words, 
the solubilizing effect of Tween 80 on cocrystal solubility and stability greatly outweighed that 
of FeSSIF.  While there were significant differences between solubility in blank aqueous buffer 
and FeSSIF, once Tween 80 was added at any concentration, the solubilities were similar in 
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FeSSIF and buffer.  For example, DNZ-HBA solubility in 25 mM Tween 80 in buffer is 88 mM 
and is 91 mM in 25 mM Tween 80 + FeSSIF.  For this reason, DNZ-VAN solubilities at the 
eutectic point were not measured in 25 mM or 50 mM Tween 80 + buffer.  DNZ-HBA and DNZ-
VAN solubilities in buffer, FeSSIF, and Tween 80 separately, and Tween 80 + FeSSIF are 
predicted within a factor of two.  Figure 5.4 shows the good agreement between the predicted 
and experimentally measured values. 
(a)       (b) 
 
Figure 5.4.  Comparison of predicted and observed DNZ-HBA () and DNZ-VAN () in (a) 
buffer (blue symbols), FeSSIF (red symbols), and Tween 80 (green symbols) separately and (b) 
Tween 80 and FeSSIF (purple symbols) at 25°C. Predictions were made using equation (5.33) in 
aqueous buffer, (5.34) in a single surfactant, and (5.22) in two surfactants.  Line indicates the 
function y=x, where the predicted and observed solubilities are equivalent.  Experimental errors 
fit within the size of each symbol. 
 
DNZ-HBA and DNZ-VAN solubility can be predicted over orders of magnitude in buffer, 
FeSSIF, Tween 80, and in Tween 80 + FeSSIF using equations (5.33), (5.34), and (5.22).  This to 
our knowledge the first time that cocrystal solubility has been predicted in the presence of two 
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surfactants using mechanism-based models.  When surfactants can be assumed to mix ideally, 
cocrystal solubility are predicted in two surfactants based on knowledge of the cocrystal Ksp, as 
well as the Ka and Ks
T 
values of the drug and coformer in each surfactant of interest.  When the 
surfactants or solubilizing agents of interest do not mix ideally, interaction or nonideality terms 
must be included, which is beyond the scope of this work. 
The stoichiometric solubility of the cocrystals was calculated from measured total 
eutectic concentrations of drug and coformer ([drug]eu and [coformer]eu) according to the 
following equations for a 1:1 cocrystal: 
1:1 cocrystal
T T,eu T,euS = [drug] [coformer]         (5.35) 
Table 5.7 shows the measured DNZ-HBA solubilities at the eutectic point in increasing 
concentrations of Tween 80 in FeSSIF and buffer. 
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Table 5.7.  Measured DNZ and HBA eutectic concentrations used to calculate stoichiometric 
cocrystal solubility (Scocrystal), Keu, and Scocrystal/Sdrug. 
 
[Tween 80] 
(mM) 
pH [DNZ]eu (mM) 
[HBA]eu 
(mM) 
Scocrystal 
(mM)
a 
Scocrystal/Sdrug
b
 Scocrystal/Sdrug
c 
Keu 
d 
Buffer 
0 4.47±0.04 (2.0±0.4)x10
-4
 79±4 0.12±0.01 770±90 660±50 440,000±67,000 
25 4.45±0.01 0.75±0.02 103±2 88±2 14.3±0.6 11.7±0.1 138±8 
50 4.43±0.01 1.49±0.04 136±1 142±2 12.4±0.2 9.6±0.2 92±3 
150 4.42±0.01 4.25±0.06 236±6 317±5 10.4±0.2 7.5±0.1 56±2 
FeSSIF 
0 4.46±0.06 (9.9±0.8)x10
-2
 78±1 28±1 25±3 28±4 790±60 
25 4.46±0.02 0.71±0.07 113±5 91±3 17.0±0.5 12±1 160±30 
50 4.43±0.01 1.26±0.06 144±2 135±4 13.5±0.4 10.7±0.2 115±4 
150 4.41±0.02 4.6±0.2 273±5 355±5 12.2±0.2 7.7±0.2 59±3 
(a) Calculated from equation (5.35) as described in the text. 
(b) Calculated from Scocrystal measured at the eutectic point in Table 5.7 and Sdrug measured in 
the absence of coformer in Table 5.9. 
(c) Calculated from Keu using equation (5.27). 
(d) Calculated from ratio of [HBA]eu/[DNZ]eu. 
 
Highly soluble cocrystals require high [coformer]eu to reach the eutectic point.  [HBA]eu values 
were orders of magnitude larger than [DNZ]eu values at all surfactant concentrations, indicating 
that the cocrystal maintained a solubility advantage over the drug in all conditions.  At high 
Tween 80 concentrations (150 mM), however, the difference between [HBA]eu and [DNZ]eu was 
dampened due to preferential solubilization of DNZ.  This corresponded to a dramatic reduction 
in Scocrystal/Sdrug calculated from Keu from 660 in buffer to 7.7 in 150 mM Tween 80.   
As described in the theoretical section, (Scocrystal/Sdrug)aq greatly impacts the ability of a 
cocrystal to be stabilized in surfactants.  Since (Scocrystal/Sdrug)aq is 660 in the pH conditions 
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studied, DNZ-HBA was not stabilized at any Tween 80 concentration, regardless if FeSSIF was 
present or not.  Scocrystal/Sdrug was also calculated from the measured Scocrystal and Sdrug measured 
in the absence of coformer (not at the eutectic point).  Differences between Scocrystal/Sdrug 
calculated from measured eutectic concentrations and Scocrystal/Sdrug calculated using Sdrug 
measured in the absence of coformer are due to differences in Sdrug in these conditions.  
Comparison of Sdrug in the presence of and in the absence of coformer will be discussed in more 
detail in a subsequent section.  In general, Sdrug was slightly higher in the presence of coformer 
which lead to lower Scocrystal/Sdrug values calculated from the measured eutectic concentrations 
compared to those values calculated using Sdrug measured in the absence of coformer.  This was 
observed at all surfactant concentrations except for pure FeSSIF. 
DNZ-VAN solubility behavior in Tween 80 and FeSSIF was similar to DNZ-HBA.  
Table 5.8 shows the measured DNZ-VAN solubilities at the eutectic point in increasing 
concentrations of Tween 80 in FeSSIF and buffer. 
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Table 5.8.  Measured DNZ and VAN eutectic concentrations used to calculate stoichiometric 
cocrystal solubility (Scocrystal), Keu, and Scocrystal/Sdrug. 
 
[Tween 80] 
(mM) 
pH [DNZ]eu (mM) 
[VAN]eu 
(mM) 
Scocrystal (mM)
a 
Scocrystal/Sdrug 
b
 Scocrystal/Sdrug 
c 
Keu 
d 
Buffer 
0 4.96±0.01 (2.1±0.1)x10
-4
 16±3 (5.7±0.2)x 10
-2
 370±70 280±6 78,000±4.000 
25 ---- ---- ---- ----- ---- ---- ----- 
50 ----- --- ---- ----- ---- ----- ----- 
150 5.02±0.01 3.27±0.03 90±2 17.2±0.2 5.6±0.1 5.3±0.1 27±1 
FeSSIF 
0 5.00±0.01 0.10±0.02 19.4±0.8 1.39±0.03 13±1 14.0±0.3 195±9 
25 5.04±0.01 0.52±0.03 34±4 4.2±0.2 7.8±0.3 8.0±0.7 64±11 
50 5.06±0.01 1.0±0.2 43±1 6.6±0.1 6.6±0.1 6.5±0.1 43±2 
150 5.08±0.01 3.05±0.04 87±2 16.3±0.3 5.6±0.1 5.3±0.1 29±1 
(a) Calculated from equation (5.35)  as described in the text. 
(b) Calculated from Scocrystal measured at the eutectic point in Table 5.7 and Sdrug measured in 
the absence of coformer in Table 5.9. 
(c) Calculated from Keu using equation (5.27). 
(d) Calculated from ratio of [VAN]eu/[DNZ]eu. 
 
[VAN]eu values were orders of magnitude larger than [DNZ]eu values at 0-25 mM Tween 80; 
however, at 50 mM and 150 mM Tween 80, [VAN]eu was only one order of magnitude larger 
than [DNZ]eu due to preferential solubilization of DNZ.  This corresponded to a dramatic 
reduction in Scocrystal/Sdrug calculated from Keu from 280 in buffer to 5.3 in 150 mM Tween 80.  
Scocrystal/Sdrug of DNZ-VAN was reduced more than DNZ-HBA since (Scocrystal/Sdrug)aq is 280, or 
about half that of DNZ-HBA (660).  As described earlier, due to the overpowering solubilizing 
power of Tween 80, DNZ-HBA and DNZ-VAN did not show large differences in Scocrystal, Keu, 
or Scocrystal/Sdrug in buffer or FeSSIF at a particular Tween 80 concentration. 
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As for DNZ-HBA, Scocrystal/Sdrug was also calculated from the measured Scocrystal and Sdrug 
measured in the absence of coformer (not at the eutectic point).  Similar to the trend observed for 
DNZ-HBA, Sdrug was slightly higher in the presence of coformer which led to lower Scocrystal/Sdrug 
values; however, this was only observed for measurements in the presence of Tween 80 only, 
and the difference in Scocrystal/Sdrug by the two methods in the presence of FeSSIF and Tween 80 
was not significant. 
Drug solubility in the presence of and in the absence of coformer 
The drug concentration at the eutectic point also serves as a measure of the equilibrium 
solubility of the drug in the presence of coformer in solution since the solution is saturated with 
drug as well as cocrystal phases.  Table 5.9 shows the comparison of DNZ solubility measured in 
the absence of coformer (independently measured) to the solubility measured at the eutectic 
point in the presence of coformer (either HBA or VAN).  
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Table 5.9.  Comparison of DNZ solubilities in increasing concentrations of Tween 80 in buffer 
or FeSSIF measured in the absence of and in the presence of coformer at the eutectic point 
(either DNZ-HBA or DNZ-VAN eutectic point). 
Media 
[Tween 
80] (mM) 
SDNZ (mM)
a 
pH 
SDNZ HBA 
eutectic 
(mM)
b 
pH 
SDNZ VAN 
eutectic (mM)
b pH 
Buffer 
0 (1.6±0.2)x10
-4
 4.96±0.01 (2.0±0.4)x10
-4
 4.47±0.04 (2.1±0.1)x10
-4
 4.96±0.01 
25 0.61±0.02 4.97±0.02 
0.75±0.02 4.45±0.01 ---- ---- 
50 1.15±0.06 4.99±0.01 
1.49±0.04 4.43±0.01 --- ----- 
150 3.05±0.02 5.02±0.01 
4.25±0.06 4.42±0.01 3.27±0.03 5.02±0.01 
FeSSIF 
0 0.11±0.01 5.01±0.05 (9.9±0.8)x10
-2
 4.46±0.06 0.10±0.02 5.00±0.01 
25 0.54±0.04 5.04±0.01 
0.71±0.07 4.46±0.02 0.52±0.03 5.04±0.01 
50 1.00±0.05 5.06±0.01 
1.26±0.06 4.43±0.01 1.0±0.2 5.06±0.01 
150 2.90±0.02 5.07±0.02 
4.6±0.2 4.41±0.02 3.05±0.04 5.08±0.01 
(a) Measured with only drug solid phase in equilibrium with solution.  
(b) Measured at the eutectic point with drug and cocrystal solid phases in equilibrium with 
solution. 
 
DNZ solubility values are consistenly slightly higher at the eutectic point compared to 
those values measured in the absence of coformer in solution.  This is likely due to 
supersaturation caused by cocrystal dissolution (and subsequent drug precipitation to reach the 
eutectic point).  While the eutectic point was approached from both cocrystal dissolution and 
cocrystal precipitation (to avoid supersaturated drug values), the very high cocrystal solubilities 
of DNZ-HBA and DNZ-VAN compared to drug likely resulted in supersaturated drug 
concentrations.  These higher drug values could also be due to solution complexation between 
DNZ and the coformers, but the difference between DNZ solubility measured independently and 
the values measured at the eutectic point did not increase as coformer concentrations increased, 
so this is probably not the case. 
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Scocrystal/Sdrug and cocrystal dissolution in the presence of multiple surfactants 
Figure 5.5 shows Scocrystal/Sdrug calculated from Keu for DNZ-HBA and DNZ-VAN in 
buffer and FeSSIF as a function of Tween 80 concentration. 
 
Figure 5.5.  Scocrystal/Sdrug for DNZ-HBA (
_____
) and DNZ-VAN (----) predicted using equation 
(5.24) for increasing concentrations of Tween 80 in pH 5.00 buffer (blue lines) and equation 
(5.25) for increasing concentrations of Tween 80 in FeSSIF (red lines).  Values used for 
predictions are Ksp values from Table 5.4, Ks
T
 and pKa values from Table 2.5, and measured 
value of SDNZ,aq
0
 = 1.6 x 10
-4
 mM.  Symbols represent experimentally measured values for DNZ-
HBA in buffer () DNZ-HBA in FeSSIF (), DNZ-VAN in buffer () and DNZ-VAN in 
FeSSIF () at 0, 25, 50, and 150 mM Tween 80. 
 
Scocrystal/Sdrug decreases dramatically in the presence of Tween 80.  However, the ability of Tween 
80 to decrease the solubility advantage is dampened in the presence of FeSSIF.  In buffer, 
Scocrystal/Sdrug of DNZ-HBA drops by orders of magnitude from 660 to 7.5 from 0 to 150 mM 
Tween 80.  In FeSSIF, this decrease is only from 28 to 7.7 from 0 to 150 mM Tween 80.  Similar 
behavior is seen for DNZ-VAN in buffer and FeSSIF at increasing concentrations of Tween 80.  
Since the (Scocrystal/Sdrug)aq of DNZ-HBA and DNZ-VAN are relatively high (660 and 280 at the 
eutectic point pH), neither cocrystal is stabilized in FeSSIF + 150 mM Tween 80.  DNZ-VAN 
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exhibited the lowest Scocrystal/Sdrug of 5.3 in FeSSIF + 150 mM Tween 80, so these conditions 
were selected for a preliminary powder dissolution study of DNZ-VAN to assess the impact of 
the decrease in Scocrystal/Sdrug in two surfactants on the cocrystal dissolution profile. 
 Figure 5.6 shows the powder dissolution profile of DNZ-VAN in FeSSIF and FeSSIF + 
150 mM Tween 80. 
(a)       (b) 
 
Figure 5.6.  DNZ-VAN dissolution in FeSSIF () and FeSSIF + 150 mM Tween 80 () at 
25°C.  (a) [DNZ]T vs time profile and (b) supersaturation generated by DNZ-VAN during 
dissolution ([DNZ]T/SDNZ,T.  The pH of both media had an initial and final pH of 5.00. 
 
DNZ-VAN achieves a higher peak concentration in the presence of 150 mM Tween 80 + FeSSIF 
compared to FeSSIF.  In the presence of 150 mM Tween 80, DNZ-VAN achieves a peak 
concentration of 24±3 mM and a peak supersaturation of 8.6±0.9 at 15 minutes, which are 
slightly higher than the measured solubility of 16.3±0.3 mM and measured Scocyrstal/Sdrug of 
5.3±0.1.  The disagreement between the equilibrium studies and dissolution conditions may be 
due to underestimation of DNZ-VAN by eutectic point measurement or the preliminary nature of 
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this dissolution experiment. Only one repetition of the study was completed and error values on 
concentrations represent the error due to sampling by HPLC (different injections).  Further 
repetitions of this experiment would elucidate if the disagreement is due to large variability in 
solution concentration during dissolution or if the solubility measurement method needs to be 
examined.  After 15 minutes, solution-mediated transformation to DNZ occurs.  [DNZ]T 
decreases rapidly to the solubility of DNZ and supersaturation decreases to 1.1±0.1 which is 
maintained from 50 minutes for the remainder of the experiment.   
The solid phase at the end of the experiment is a mixed phase of DNZ and DNZ-VAN, 
confirming that conversion occurred.  This conversion is further confirmed by the high 
concentration of VAN, which is shown in Figure 5.7b for FeSSIF + 150 mM Tween 80. 
  (a)      (b) 
 
Figure 5.7.  Concentrations of DNZ () and VAN () during DNZ-VAN dissolution in FeSSIF 
(a) and FeSSIF + 150 mM Tween 80 (b) at 25°C.  The pH of both media had an initial and final 
pH of 5.00. 
As shown in Figure 5.7b, VAN concentrations continue to increase as DNZ concentrations 
decrease during solution-transformation to drug.  The pH of the dissolution media does not 
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change significantly despite these high VAN concentrations because the pKa of VAN is 7.4 
while the dissolution media is 5.00 so no large decrease in pH is observed.  The supersaturation 
behavior in Figure 5.6b is similar to the reported supersaturation behavior of DNZ-VAN 
observed when the cocrystal is formulated with the solubilizing agent TPGS and the precipitation 
inhibitor HPMC
6
.  In that study, a peak supersaturation of 5.6 was observed at around 15 minutes 
during powder dissolution of the formulated cocrystal in FaSSIF followed by conversion to 
DNZ.  
In FeSSIF, a DNZ concentration of 0.24 mM is obtained and maintained for the duration 
of the experiment, which is less than the measured solubility of 1.39 mM.  The final solid phase 
was a mixed phase of DNZ and DNZ-VAN, indicating that solution-mediated transformation to 
drug had occurred.  Results in Figure 5.7a confirm the instantaneous conversion of the cocrsytal 
to drug based on the high VAN concentrations compared to DNZ concentrations for the duration 
of the experiment.  However, the cocrystal maintained a supersaturated state with [DNZ]T/ST,DNZ 
of around 2.4 for the duration of the 240 minute experiment, which is similar to what others have 
reported for DNZ-VAN dissolution in FaSSIF
6
.  FaSSIF and FeSSIF contain the same 
solubilizing agents (sodium taurocholate and lecithin), though FeSSIF has a five-fold higher 
concentration of them compared to FaSSIF.  Based on the literature and observed dissolution 
behavior of DNZ-VAN in FeSSIF in Figure 5.6, in the presence of these solubilizing agents and 
VAN, DNZ is able to maintain a moderately supersaturated concentration for hours. Despite this 
supersaturated state, the reduction in Scocrystal/Sdrug from 14.0 in FeSSIF to 5.3 in FeSSIF + 150 
Tween 80 resulted in a higher peak supersaturation for the formulated cocrystal. 
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Conclusions 
Theoretical relationships that describe cocrystal solubility and thermodynamic stability in 
the presence of multiple surfactants are derived in this work for the first time.  These equations 
are useful to predict the solution behavior of cocrystals as formulated products, where they may 
encounter solubilizing agents in the formulation and/or endogenous surfactants in vivo.  
Surfactants are assumed to mix ideally, which is a valid assumption for the Tween 80 and 
FeSSIF concentrations studied in this work.  Experimentally measured cocrystal solubilities are 
in excellent agreement with the proposed models. The solubility of DNZ-HBA and DNZ-VAN 
in the presence Tween 80 and FeSSIF is quantitatively predicted from cocrystal Ksp (measured in 
aqueous solution) and cocrystal component Ka values reported in the literature and Ks
T
 values 
determined from drug and coformer solubility measurements in Tween 80 and FeSSIF 
independently.   
DNZ is significantly solubilized by FeSSIF and Tween 80 while the hydrophilic 
coformers HBA and VAN are not.  This preferential solubilization of DNZ leads to a dramatic 
decrease in Scocrystal/Sdrug as Tween 80 concentration increases, but this effect is dampened in the 
presence of FeSSIF, particularly at low Tween 80 concentrations.  Decreased Scocrystal/Sdrug for 
DNZ-VAN in FeSSIF + 150 mM Tween 80 results in higher drug concentrations and high 
supersaturations during dissolution compared to FeSSIF alone. 
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CHAPTER 6  
COCRYSTAL TRANSITION POINTS: ROLE OF COCRYSTAL SOLUBILITY, DRUG 
SOLUBILITY, AND SOLUBILIZING AGENTS   
 
Introduction 
Cocrystals are playing an important role in solving many of the challenges related to the 
bioavailability of poorly-water soluble drugs
1-8
.  One of the vital properties of cocrystals is their 
tunable solubility
2, 4, 9-17
 offering dramatic benefits to drug absorption and bioavailability.  
Chemical interactions between cocrystal constituents and dissolution media additives are 
critically important for cocrystals to achieve a wide range of solubility and thermodynamic 
stability behaviors.  
 We recently discovered that the same cocrystal can display higher, equal, or lower 
solubility than the constituent drug, depending on the concentration of drug solubilizing agents
10-
12
.   As a result of this phenomenon, cocrystals can exhibit transition points at which the 
cocrystal solubility advantage over the parent drug is switched by the presence of drug 
solubilizing agents.  The indomethacin-saccharin cocrystal, for example, has a solubility 26 
times higher than indomethacin in pH 2 buffer
16
.  This solubility advantage is however 
eliminated in the presence of drug solubilizing agents and the cocrystal becomes less soluble 
than indomethacin in solutions with SLS or Brij, or Tween 80 among others
18, 19
.  The underlying 
mechanism for this behavior was determined to be the solubilizing agent preferential 
solubilization for the drug, and its indifference for coformer solubilization.  Coformers are much 
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more hydrophilic than the constituent drugs and therefore such selective drug solubilization is 
generally observed with solubilizing agents in aqueous media.   
 The solubilizing agent concentration at the transition point is referred to as the CSC or 
critical stabilization concentration
10-12
.  Studies on carbamazepine and indomethacin cocrystals 
led to the recognition of the transition point and established the factors that determine the value 
of the CSC
10-12, 18, 19
.   CSC was found to decrease with increasing drug solubilization and drug 
selectivity by the additive, and with decreasing cocrystal aqueous solubility (in the absence of 
solubilizing agents).  CSC values for CBZ cocrystals in solutions of sodium lauryl sulfate were 
in the range of 23 to 187 mM
10-12
, which can be encountered in formulation, processing, and 
dissolution media.   
 Cocrystal transition points are not only dependent on the effectiveness of the drug 
solubilizing agent but also on the extent of ionization and solubilization of cocrystal components, 
i.e., drug and coformer
10-12, 18, 19
.   These findings have challenged the traditional notion of 
cocrystal solubility and thermodynamic stability, since not only do cocrystals exhibit transition 
points, but the CSC at the transition points shift with the nature and concentration of solubilizing 
agents.   
 When selecting a cocrystal, designing a pharmaceutical product, and developing 
meaningful characterization methods, it is essential to know how the cocrystal transition point is 
affected.    While the variation of cocrystal transition points with surfactant properties can be 
predicted using theoretical models with the associated equilibrium constants, we wished to 
develop a simplified version of the more rigorous theoretical models and evaluate their 
predictive power for a broad range of cocrystals and drug solubilizing agents. 
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 During these studies we derived simple relationships to quantitatively predict cocrystal 
solubilization by drug solubilizing agents from knowledge of drug solubilization.  We have also 
discovered that (1) the cocrystal transition points are defined by a solubility value (S*) and a 
CSC, and (2) that S* is independent of solubilizing agents as long as coformer solubilization is 
negligible.   An important property of S* is that it is only dependent on cocrystal and drug 
aqueous solubilities in the absence of solubilizing agents.   This means that once cocrystal and 
drug solubilities in aqueous media are known at a particular temperature and pH, then S* can be 
estimated from the equations derived in this work.   Knowledge of S* for a given cocrystal will 
guide the selection and concentrations of solubilizing agents since S* has associated CSCs.    
  The selection criterion for cocrystals and solubilizing agents in this work was that 
cocrystal and drug solubilities be measured under equilibrium conditions. We included cocrystals 
studied in our laboratory as well as reported in the literature.   Solubilities and transition points 
for cocrystals of carbamazepine, indomethacin, danazol, piroxicam, and pterostilbene in the 
presence of a range of drug solubilizing agents comprising surfactants and lipid-based systems 
were analyzed in light of the simple equations and concepts presented here. 
Theoretical 
Calculation of cocrystal solubilization from drug solubilization  
A simplified model that can be used to establish the influence of drug solubilizing agents 
on cocrystal solubility is important to guide cocrystal formulation.  We have found a simple 
mathematical relationship that allows for calculation of cocrystal solubilization ratio (SRcocrystal) 
from knowledge of a common descriptor of drug solubilization, the drug solubilization ratio 
(SRdrug).   For a 1:1 cocrystal, the solubilization ratio is given by 
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cocrystal drugSR = SR           (6.1) 
or 
T T
aq aqcocrystal drug
S S
=
S S
   
      
   
          
 
 
under the condition that coformer solubilization by the additive is negligible.   This relationship 
is of practical importance since drug solubilizing agents such as surfactants, lipids, and 
complexing agents among others are often included or encountered in cocrystal formulations as 
well as in dissolution media.   
 At a specific pH and solubilizing agent concentration, SR is defined as the ratio of the 
total solubility (ST) to the aqueous solubility (Saq)  
T
cocrystal
aq cocrystal
S
SR =
S
 
  
 
         (6.2) 
ST is defined as the sum of the concentrations of all species dissolved (ST = Saq + Ss).  Saq 
represents the cocrystal aqueous solubility at a particular pH in the absence of solubilizing agent 
(Saq = Snonionized,aq + Sionized,aq) and is the sum of the nonionized and ionized contributions to the 
aqueous solubility.  Ss represents the cocrystal solubilized by solubilizing agents (Ss = Snonionized,s 
+ Sionized,s) and contributions from the ionized species as appropriate.   
 Without getting into a lot of detail, the relationship between cocrystal and drug 
solubilization ratios (equation (6.1)) can be found from the equation that describes cocrystal total 
solubility as a function of pH and solubilizing agent
10-12
, by replacing the equilibrium constants 
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for ionization and solubilization with drug and cocrystal solubility terms.  For a 1:1 cocrystal of a 
nonionizable drug and an ionizable (monoprotic) acidic coformer, the cocrystal solubility is  
  drug pH pKa,coformer coformercocrystal,T sp s sS K 1 K [M] 1 10 K [M]        (6.3) 
where Ksp is the cocrystal solubility product, Ks stands for solubilization constants of cocrystal 
constituents, and the term in brackets is the concentration of solubilizing agent, which for a 
micellar surfactant is [M].  Ka represents the dissociation constant of a monoprotic acidic 
coformer.   When solubilizing agents enhance drug solubility and not coformer solubility 
(Ks
coformer
 = 0), the cocrystal solubility equation becomes 
  drug pH pKa,coformercocrystal,T sp sS K 1 K [M] 1 10          (6.4) 
This equation can be expressed in terms of cocrystal and drug solubilities by considering that the 
cocrystal aqueous solubility (nonionized + ionized species) as a function of pH is  
 pH pKa,coformercocrystal,aq spS K 1 10           (6.5) 
 and the drug solubilization ratio is  
 drugT s
aq drug
S
= 1+K [M]
S
 
  
 
         (6.6) 
Substituting equations (6.4) and (6.5) in equation (6.2) gives the relationship between cocrystal 
solubilization ratio and drug solubilization ratio presented in equation (6.1). 
 For the case of a 2:1 cocrystal (drug:coformer) the relationship becomes 
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 
2
3
cocrystal drugSR = SR           (6.7) 
or  
2
3
T T
aq aqcocrystal drug
S S
=
S S
   
      
   
         
The general form of the equation for a cocrystal with stoichiometry AxBy, where A and B are the 
cocrystal constituents, drug and coformer respectively; and x and y are the stoichiometric 
coefficients or molar ratios, is 
 
x
x+y
cocrystal drugSR = SR          (6.8) 
or 
x
x+y
T T
aq aqcocrystal drug
S S
=
S S
   
      
   
         
Solubilizing agents in aqueous media may favor interactions with drugs over coformers, 
since the drug constituents of cocrystals generally are quite hydrophobic whereas coformers are 
hydrophilic.  We have confirmed such behavior for cocrystals of hydrophobic drugs, 
carbamazepine, indomethacin, and danazol with hydrophilic coformers in solutions of synthetic 
and biorelevant solubilizing agents
10-12, 18-23
. 
 The shape of the SRcocrystal versus SRdrug curves (Figure 6.1) reflects the impact of 
different cocrystal stoichiometries on SRcocrystal.  The curvature of the plots is due to preferential 
solubilization of drug over coformer.   SRcocrystal is predicted to be much lower than SRdrug with a 
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1:1 cocrystal being lower than the 2:1.   The plot shows that drug solubilizing agents with SRdrug 
values of 100 and 1000 will result in SRcocrystal values of 10 and 31.6 for 1:1 cocrystals.   SRdrug 
can reach values in the order of 10
6
 with some solubilizing agents, and therefore one would 
expect cocrystals of these drugs to have solubilization ratios that are orders of magnitude lower 
than the drug.  These predictions will be compared with experimental observations for several 
cocrystals and solubilizing agents in the results section. 
 
Figure 6.1.  Dependence of SRcocrystal on SRdrug for cocrystal stoichiometries 1:1 (
_____
) and 2:1  
(----) predicted from equations (6.1) and (6.7) using a typical range of SRdrug values. 
Cocrystal transition points 
Drug solubilizing agents have been shown to switch the cocrystal solubility advantage
10-
12, 18, 19
.  That is, a cocrystal that is more soluble than the drug in aqueous solution can become 
less soluble than the drug depending on the nature and concentration of the solubilizing agent.    
 Cocrystals were shown to possess transition points in the presence of solubilizing agents 
that have selective affinity for the drug.  This behavior was mathematically explained by a drug 
solubility that is linearly dependent on solubilizing agent concentration,  
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 0 drugdrug,T drug,aq sS S 1 K [M]          (6.9) 
and a cocrystal solubility that exhibits nonlinear dependence.  S
0
drug,aq represents the nonionized 
drug aqueous solubility (which for simplicity will be denoted as S
0
drug,aq). Cocrystal solubility 
exhibits a square root dependence on solubilizing agent concentration (equation (6.4)) for 1:1 
cocrystals when coformer solubilization is negligible.  For the case of 2:1 cocrystals, the 
solubility exhibits a 2/3 power dependence.  Theoretical predictions were recently reported to be 
in excellent agreement with experimental observations for carbamazepine and indomethacin 
cocrystals in the presence of several solubilizing agents
10-12, 18, 19, 21, 23
.    
 Figure 6.2 illustrates the concept of cocrystal transition points, indicated by the 
intersection of the cocrystal and drug solubility curves.  The position of the transition point is 
defined by a solubility (S*) and a solubilizing agent concentration (CSC or critical stabilization 
concentration).  Since the transition point that we are referring to is that between cocrystal and 
drug crystalline phases, the solubilities of the drug and the cocrystal are equal at this point.    
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Figure 6.2.  Transition points (S* and CSC) for a cocrystal (
_____
) and its constituent drug (
_____
) 
in two different solubilizing agents, a and b.  S* is constant and CSC varies with the extent of 
drug solubilization by the solubilizing agent.  Drug is solubilized to a greater extent by a than by 
b and thus CSCa < CSCb.  The curves were generated from equations (6.4) and (6.9) under 
nonionizing conditions and the parameter values S
0
drug,aq = 0.5 mM, Scocrystal,aq = 2.4 mM (Ksp = 
5.76 mM
2
), Ks
drug
 = 1.5 mM and 0.5 mM
-1
 for solubilizing agents a and b, respectively.   
 
 The position of the transition point for a given cocrystal and its drug, (depicted in Figure 
6.2) varies with solubilizing agent or with the degree to which the drug is solubilized (Ks
drug
).  
For a given cocrystal and a drug, the transition points exhibit a constant S* but a variable CSC.  
A lower CSC is obtained with a stronger drug solubilizing agent (Ks = 1.5 mM
-1
) than with a 
weaker one (Ks= 0.5 mM
-1
).  In other words, a lower concentration of solubilizing agent is 
required to reach the transition point with a stronger solubilizing agent.   
In contrast to the CSC, whose values differ for both solubilizing agents, the value of S* is 
constant.  This property of S* is found by examining the mathematical models that describe 
cocrystal and drug solubilization as follows.  At the transition point, the solubilities of cocrystal 
and drug are equal 
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cocrystal,T drug,TS = S = S*           (6.10) 
The solubilization ratio equations of cocrystal and drug at the transition point can be written in 
terms of S*, which for a 1:1 cocrystal (from equation ((6.1)) is 
aq aqcocrystal drug
S* S*
=
S S
   
      
   
         (6.11)
 
 
and solving for S* gives 
 
2
cocrystal,aq
drug,aq
S
S*=
S
          (6.12) 
This equation shows that the solubility value at the transition point is governed by two 
fundamental parameters, the aqueous solubilities of cocrystal and of drug.  Saq refers to the 
(unionized + ionized) aqueous solubilities of cocrystal and of drug and therefore equation (6.12) 
applies to a range of ionizing conditions (pH and appropriate solubility values).   
 S* for a 2:1 cocrystal is found by a similar approach and is  
 
 
3
cocrystal,aq
2
drug,aq
S
S*=
S
          (6.13) 
 A plot of equation (6.12) in Figure 6.3 provides some insight about the dependence of S* 
on the corresponding aqueous solubilities, Scocrystal,aq and Sdrug,aq for a 1:1 cocrystal.  Typical 
values for drug and cocrystal solubilities have been used in this example.  S* is shown to 
increase with increasing Scocrystal,aq, and the increase in S* is greater at lower Sdrug,aq.   
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Figure 6.3.  Graphical representation of S* as a function of cocrystal and drug aqueous 
solubilities for a 1:1 cocrystal, according to equation (6.12).  S* is reached at the cocrystal/drug 
transition point.   
For the case of a drug with Sdrug,aq = 0.3 mM and its (1:1) cocrystal with Scocrystal,aq = 3.0 
mM, the transition solubility for this system is then S* =30 mM.  This means that a cocrystal will 
not maintain its solubility advantage over the drug above 30 mM (under the conditions of this 
example) since cocrystal is less soluble than drug at S values above S*.   Another factor that 
influences the value of S* is the solution pH.  For the case of cocrystals with ionizable 
components, pH will determine the drug and coformer ionization and change the aqueous 
solubilities of drug and cocrystal, thereby altering the position the value of S*.  It is therefore 
possible to calculate the influence of pH on the cocrystal transition point.  
Another useful expression of S* is in terms of the cocrystal solubility advantage (SA) 
given by 
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cocrystal
cocrystal,aq
drug aq
S
S*=S
S
 
  
 
          (6.14) 
or 
 cocrystal,aq aqS*=S SA          
 
where 
cocrystal
aq
drug aq
S
SA =
S
 
  
 
          (6.15) 
For a 2:1 cocrystal, the S* expression in terms of solubility advantage becomes: 
 
2
cocrystal,aq aq
S*=S SA           (6.16)
 
Cocrystals with low SAaq will possess low S* values, which means that lower concentrations of 
drug solubilizing agents are required to reach S*.  
Implications of coformer solubilization on SRcocrystal and S* 
The equations presented above assume that coformer solubilization is negligible 
(Ks
coformer
= 0).  Under some conditions this assumption is not justified (Ks
coformer
 > 0) and relevant 
terms need to be included in the SRcocrystal and S* equations to account for the deviations due to 
coformer solubilization.    
 The contribution of coformer solubilization is included in the following equations as a 
factor by which the simpler equations are multiplied.   The cocrystal solubilization ratio of a 1:1 
cocrystal of a nonionizable drug and a monoprotic acidic coformer is 
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T T
aq aqcocrystal drug
S S
= ε
S S
   
      
   
         (6.17)
 
where  
 
 
pH-pKa,coformer cof
s
pH-pKa,coformer
1+10 +K [M]
ε =
1+10
        (6.18) 
It can be seen that when Ks
coformer
 = 0, ε = 1 and the equation is equal to the simple equation (6.1)
.  When Ks
coformer
 > 0, ε > 1 and the coformer solubilization, as well as solubilizing agent 
concentration and coformer ionization must be considered. 
The expression for S* is given by 
 
2
cocrystal,aq
drug,aq
S
S*= ε
S
           (6.19) 
S* equations can also be expressed in terms of cocrystal Ksp.   In terms of the unionized cocrystal 
(solubility product) and drug aqueous solubilities, when Ks
coformer = 0,  
 pH-pKa,coformersp
0
drug,aq
K 1+10
S*=
S
         (6.20) 
When Ks
coformer 
> 0, S* is given by: 
 pH-pKa,coformer coformersp s
0
drug,aq
K 1+10 +K [M]
S*=
S
       (6.21) 
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based on the full solubility equations of cocrystal and drug, (equations (6.3) and (6.9)) and 
nonionized cocrystal and drug solubilities. 
Materials and Methods 
Materials 
Cocrystal components 
Anhydrous carbamazepine form III (CBZ), anhydrous indomethacin form γ (IND) were 
purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  Anhydrous 
piroxicam form I (PXC) was received as a gift from Pfizer (Groton, CT) and used as received.  
Anhydrous danazol was received as a gift from Renovo Research (Atlanta, GA) and used as 
received.   
Anhydrous saccharin (SAC), 4- aminobenzoic acid (4ABA), and salicylic acid (SLC), 
were purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  
Anhydrous hydroxybenzoic acid was purchased from Acros Organics (Pittsburgh, PA) and used 
as received.  Anhydrous vanillin was purchased from Fisher Scientific (Fair Lawn, NJ) and used 
as received. Carbamazepine dihydrate (CBZD) piroxicam monohydrate (PXCH), and 
hydroxybenzoic acid monohydrate (HBAH) were prepared by slurrying CBZ, PXC, and HBA in 
deionized water for at least 24 hours.  All crystalline drugs and coformers were characterized by 
X-ray power diffraction (XRPD) and differential scanning calorimetry (DSC) before carrying out 
experiments. 
Solvents and buffer components 
Ethyl acetate and ethanol were purchased from Acros Organics (Pittsburgh, PA) and used 
as received, and HPLC grade methanol and acetonitrile were purchased from Fisher Scientific 
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(Pittsburgh, PA). Trifluoroacetic acid spectrophometric grade 99% was purchased from Aldrich 
Company (Milwaukee, WI) and phosphoric acid ACS reagent 85% was purchased from Sigma 
Chemical Company (St. Louis, MO).  Water used in this study was filtered through a double 
deionized purification system (Milli Q Plus Water System) from Millipore Co. (Bedford, MA). 
Tween 80 solutions, FeSSIF, and acetate buffer were prepared using Tween 80 purchased 
from Sigma Chemical Company (St. Louis, MO), sodium taurocholate (NaTC) purchased from 
Sigma Chemical Company (St. Louis, MO), lecithin purchased from Fisher Scientific 
(Pittsburgh, PA), sodium hydroxide pellets (NaOH) purchased from J.T. Baker (Philipsburg, NJ), 
and acetic acid and potassium chloride (KCl) purchased from Acros Organics (Pittsburgh, PA).  
Methods 
FeSSIF, acetate buffer, and Tween 80 solution preparation  
FeSSIF and acetate buffer were prepared according to the protocol of Galia and 
coworkers
24
.   Acetate buffer was prepared as a stock solution at room temperature by dissolving 
8.08 g NaOH (pellets), 17.3 g glacial acetic acid and 23.748 g NaCl in 2 L of purified water. The 
pH was adjusted to 5.00 with 1 N NaOH and 1 N HCl.   
FeSSIF was prepared by dissolving 0.41 g sodium taurocholate in 12.5 mL of pH 5 
acetate buffer. 0.148 g lecithin was added with magnetic stirring at 37 °C until dissolved.  The 
volume was adjusted to exactly 50 mL with acetate buffer.  Tween 80 solutions were prepared by 
dissolving an appropriate amount (25 mM, 50 mM, and 150 mM) of Tween 80 in pH 5 acetate 
buffer. 
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Cocrystal synthesis 
Cocrystals were prepared by the reaction crystallization method
25
 at 25°C. The 1:1 
indomethacin-saccharin cocrystal (IND-SAC) was synthesized by adding stoichiometric amounts 
of cocrystal components (IND and SAC) to nearly saturated SAC solution in ethyl acetate.  The 
1:1 carbamazepine saccharin cocrystal (CBZ-SAC) was prepared by adding stoichiometric 
amounts of cocrystal components (CBZ and SAC) to nearly saturated SAC solution in ethanol. 
The 1:1 carbamazepine-salicylic acid cocrystal (CBZ-SLC) was prepared by adding 
stoichiometric amounts of cocrystal components (CBZ and SLC) to nearly saturated SLC 
solution in acetonitrile. The 2:1 carbamazepine-4-aminobenzoic acid monohydrate cocrystal 
(CBZ-4ABA-HYD) was prepared by suspending stoichiometric amounts of cocrystal 
components (CBZ and 4ABA) in a 0.01 M 4ABA aqueous solution at pH 3.9.  The 1:1 
piroxicam-saccharin cocrystal (PXC-SAC) was prepared by adding stoichiometric amounts of 
cocrystal components (PXC and SAC) to nearly saturated SAC in acetonitrile.  The 1:1 danazol-
hydroxybenzoic acid cocrystal (DNZ-HBA) was prepared by adding stoichiometric amounts of 
cocrystal components (DNZ and HBA) to nearly saturated HBA solution in ethyl acetate.  The 
1:1 danazol-vanillin cocrystal (DNZ-VAN) was prepared by adding stoichiometric amounts of 
cocrystal components (DNZ and VAN) to nearly saturated VAN solution in ethyl acetate.  Prior 
to carrying out any solubility experiments, solid phases were characterized by XRPD and DSC 
and stoichiometry verified by HPLC.   Full conversion to cocrystal was observed in 24 hours. 
Drug solubility measurements 
Drug solubilities were either reported in the literature or experimentally determined in 
this work.  When reported values at a specific surfactant concentration were not available, drug 
solubility values at the surfactant concentration of the cocrystal solubility measurements were 
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interpolated from data at other at other surfactant concentrations. Drug solubility values in 
sodium lauryl sulfate (SLS), Myrj 52, Brij 99, Tween 80 (IND only), and a lipid formulation 
were obtained from the literature
12, 19, 26-28
.  Drug solubilities were measured in FeSSIF, Tween 
80, and pH 5 acetate buffer (FeSSIF without NaTC and lecithin or Tween 80).  The solubilities 
of the drugs were determined by adding excess solid to 3 mL of media (FeSSIF, Tween 80, or 
buffer). Solutions were magnetically stirred and maintained at 25 ± 0.1°C using a water bath for 
up to 96 hours. In 24 hour intervals, 0.30 mL of samples were collected, pH of solutions 
measured, and filtered through a 0.45 µm pore membrane.   After dilution with mobile phase, 
drug solution concentrations were analyzed by HPLC. The final solid phases were characterized 
by XRPD and DSC. 
Cocrystal solubility measurements 
Cocrystal equilibrium solubilities were either reported in the literature or experimentally 
determined in this work. Literature cocrystal solubility values were taken from experimentally 
determined values at specific reported surfactant concentrations.  Cocrystal solubility values in 
sodium lauryl sulfate (SLS), Myrj 52, Brij 99, Tween 80 (IND-SAC only), and a lipid 
formulation were obtained from the literature
12, 19, 26-28
.    Cocrystal equilibrium solubilities were 
measured in FeSSIF, Tween 80, and pH 5 acetate buffer (FeSSIF without NaTC and lecithin) at 
the eutectic point, where drug and cocrystal solid phases are in equilibrium with solution. The 
eutectic point between cocrystal and drug was approached by cocrystal dissolution (suspending 
solid cocrystal (~100 mg) and drug (~50 mg) in 3 mL of media (FeSSIF or buffer)) and by 
cocrystal precipitation (suspending solid cocrystal (~50 mg) and drug (~100 mg) in 3 mL of 
media (FeSSIF or buffer) nearly saturated with coformer).  Solutions were magnetically stirred 
and maintained at 25 ± 0.1°C using a water bath for up to 96 hours. In 24 hour intervals, 0.30 mL 
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of samples were collected, pH of solutions measured, and filtered through a 0.45 µm pore 
membrane.   Solid phases were also collected in 24 hour intervals to ensure the sample was at the 
eutectic (confirmed by presence of both drug and cocrystal solid phases).  After dilution with 
mobile phase, drug and coformer solution concentrations were analyzed by HPLC. The final 
solid phases were characterized by XRPD and DSC. 
X-ray powder diffraction 
X-ray powder diffraction diffractograms of solid phases were collected on a benchtop 
Rigaku Miniflex X-ray diffractometer (Rigaku, Wilmington, MA) using Cu Kα radiation (λ= 
1.54Å), a tube voltage of 30 kV, and a tube current of 15 mA. Data were collected from 5 to 40° 
at a continuous scan rate of 2.5°/min.  
Thermal analysis 
Solid phases collected from the slurry studies were dried at room temperature and 
analyzed by differential scanning calorimetry (DSC) using a TA instrument (Newark, DE) 
2910MDSC system equipped with a refrigerated cooling unit. DSC experiments were performed 
by heating the samples at a rate of 10 °C/min under a dry nitrogen atmosphere. A high purity 
indium standard was used for temperature and enthalpy calibration.  Standard aluminum sample 
pans were used for all measurements.  
High performance liquid chromatography 
Solution concentrations were analyzed by a Waters HPLC (Milford, MA) equipped with 
an ultraviolet-visible spectrometer detector. For the IND-SAC and CBZ-SAC, CBZ-SLC, CBZ-
4ABA-HYD cocrystals and their components, a C18 Thermo Electron Corporation (Quebec, 
Canada) column (5µm, 250 x 4.6 mm) at ambient temperature was used. For the IND-SAC 
cocrystal, the injection volume was 20 µl and analysis conducted using an isocratic method with 
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a mobile phase composed of 70% acetonitrile and 30% water with 0.1% trifluoroacetic acid and 
a flow rate of 1 ml/min. Absorbance of IND and SAC were monitored at 265 nm. For the CBZ 
cocrystals, the injection volume was 20 µl and analysis conducted using an isocratic method with 
a mobile phase composed of 55% methanol and 45% water with 0.1% trifluoroacetic acid and a 
flow rate of 1 mL/min.  Absorbance was monitored as follows: CBZ and 4ABA at 284 nm, SAC 
at 265 nm, and SLC at 303 nm. For the PXC-SAC, DNZ-HBA, and DNZ-VAN cocrystals and 
their components, a C18 Waters Atlantis (Milford, MA) column (5 µM 250 x 6 mm) at ambient 
temperature was used.  For PXC-SAC, the injection volume was 20 µL and analysis was 
conducted using an isocratic method with a mobile phase composed of 70% methanol and 30% 
water with 0.3% phosphoric acid and a flow rate of 1 mL/min.  Absorbance of PXC was 
monitored at 340 nm and SAC at 240 nm.  For the DNZ cocrystals, the injection volume was 20 
µL in FeSSIF experiments, and 100 µL in buffer experiments due to the extremely low solubility 
of DNZ in aqueous solutions.  Analysis was conducted using an isocratic method composed of 
80% methanol and 20% water with 0.1% trifluoroacetic acid and a flow rate of 1 mL/min.  
Absorbance of DNZ was monitored at 285 nm, HBA at 242 nm, and VAN at 300 nm.  For all 
cocrystals, the Waters’ operation software Empower 2 was used to collect and process data. 
Results 
Solubilization ratios of cocrystals and drugs  
Figure 6.4 shows the observed and predicted dependence of cocrystal solubilization ratio 
(SRcocrystal) on drug solubilization ratio (SRdrug) for cocrystals of carbamazepine (CBZ), 
piroxicam (PXC), indomethacin (IND), danazol (DNZ) and pterostilbene (PTB) in different 
solubilizing agents. Solubilizing agents included: anionic surfactants (SLS, FeSSIF), nonionic 
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surfactants (Tween 80, Myrj 52, and Brij 99), and a lipid formulation (Captex 355/Capmul MCM 
(1/3): Cremophor EL (3:7)).   
a 
 
b 
 
Figure 6.4.  SRcocrystal dependence on SRdrug for (a) 1:1 cocrystals and (b) 2:1 cocrystals. Lines 
represent theoretical relationships between SRcocrystal and SRdrug according to equation (6.1) for 
1:1 cocrystals and (6.7) for 2:1 cocrystals.  1:1 cocrystals have a slope of ½. 2:1 cocrystals have a 
slope of 2/3. Symbols represent experimentally determined SR values in equilibrium conditions. 
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Logarithmic plots are presented since values range across 6 orders of magnitude for 
SRdrug and 4 orders of magnitude for SRcocrystal.  The cocrystal solubilization ratio for a 1:1 
cocrystal is equal to square root of the drug solubilization ratio  
T T
aq aqcocrystal drug
S S
=
S S
   
      
   
         
which in logarithmic form becomes 
T T
aq aqcocrystal drug
S S1
Log = Log
S 2 S
   
      
   
        (6.22) 
The line in Figure 6.4a has a slope of 1/2.   
Figure 6.4b shows 2:1 cocrystals according to the logarithmic form of 
2
3
T T
aq aqcocrystal drug
S S
=
S S
   
      
   
         
which is 
T T
aq aqcocrystal drug
S S2
Log = Log
S 3 S
   
      
   
        (6.23) 
The line in Figure 6.4b has a slope of 2/3.  
These plots reveal that (1) SRcocrystal is well approximated by SRdrug over a wide range of 
values for different drugs, cocrystals, and drug solubilizing agents assuming coformer 
solubilization is negligible, and that (2) 1:1 cocrystals are solubilized to a lesser extent than the 
2:1 cocrystals for the same value of SRdrug.   
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 Drug solubilizing agents with SRdrug values as high as 12,000 (PTB) and 20,000 (DNZ) 
resulted in SRcocrystal of 102 (1:1 PTB-CAF in lipids), 300 (1:1 DNZ-HBA and DNZ-VAN in 
Tween 80), and 530 (2:1 cocrystal PTB-PIP).  Solubilization ratios of 2:1 cocrystals are well 
predicted for the systems studied, CBZ-SUC and CBZ-4ABA-HYD in SLS, and PTB-PIP in 
lipid-based media (Figure 6.4b).    The positive deviations observed for several 1:1 cocrystals at 
high values of SRdrug appear to be a result of coformer solubilization under the conditions 
studied, which will be examined in a later section.  
These results indicate that if drug solubilization is known then cocrystal solubilization 
can be calculated (under the same experimental conditions).  Although small changes in 
coformer solubilization by the additive can result in deviations from predictions, these 
relationships are very important to guide additive selection for cocrystal formulations and 
dissolution methods. 
Prediction of cocrystal solubility (Scocrystal,T) in the presence of drug solubilizing agents 
From the results of cocrystal and drug SR relationships presented above one can 
anticipate the impact that formulating poorly soluble drugs with very effective solubilizing 
agents may have on cocrystal solubility.  An example of this analysis is applied to understanding 
the solubilization of PTB cocrystals in lipid-based solubilizers
26, 28
 (Table 6.1).    
PTB is poorly water-soluble.  Two cocrystals with caffeine (CAF) and piperazine (PIP) 
were shown to increase its aqueous solubility by orders of magnitude
26, 27
.  However, this 
cocrystal solubility advantage was eliminated when cocrystals were formulated in a lipid 
system
28
.   In fact, the cocrystals became less soluble than PTB in the presence of these lipids.  A 
key question to ask is whether this observation could have been predicted from the simple 
relationships presented here. 
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Table 6.1.  Comparison of experimental and predicted PTB cocrystal solubilities in lipid-based 
formulations. 
Solid phase 
Aqueous 
solubility
 a
  
Saq (mM)
 
Experimental 
Total solubility in lipid
 b
  
ST (mM)
 
Predicted  
Total solubility in 
lipid
 c
 ST (mM)  
PTB 0.0819 1002 ---- 
PTB-CAF (1:1) 2.19  222 242 
PTB-PIP (2:1) 0.492 246 262 
a) From references 24 and 25. 
b) From reference 26. 
c) Calculated from equations (6.24) and (6.25) for 1:1 and 2:1 cocrystals as described in the 
text.  
 
Cocrystal solubility in media containing drug solubilizing agents such as lipid-based 
systems can be obtained by simply solving for Scocrystal,T in equations (6.1) and (6.7), which for a 
1:1 cocrystal becomes     
T
cocrystal,T cocrystal,aq
aq drug
S
S =S
S
 
  
 
         (6.24) 
and for a 2:1 cocrystal, gives 
2
3
T
cocrystal,T cocrystal,aq
aq drug
S
S =S
S
 
  
 
         (6.25) 
 208 
 
Once the cocrystal aqueous solubility and drug solubilization ratio are known then the cocrystal 
solubility in the media containing the solubilizing agents can be readily calculated.   
For PTB-CAF (1:1 cocrystal) the solubility in the lipid formulation, Scocrystal,T is  
4T
cocrystal,T cocrysta,aq
aq drug
S
S = S 2.19 1.22 x10 242 mM
S
 
   
 
 
For PTB-PIP (2:1 cocrystal), Scocrystal,T is 
 
2
23
1 4T 3
cocrystal,T cocrysta,aq
aq drug
S
S = S 4.92x10 1.22x10 262 mM
S

 
   
 
 
The predicted cocrystal solubilities in the lipid formulation are in very good agreement with the 
measured values (222 and 246 mM) shown in Table 6.1.  These simple relationships provide 
quantitative information about cocrystal solubility without the need of more rigorous equations 
(equation (6.3) for example) that require knowledge of equilibrium constants associated with the 
solution processes.  The full equations are however valuable when the assumptions underlying 
the simple relationships are no longer warranted. 
 The PTB cocrystal formulation in lipid-based systems also teaches us about the ability of 
strong drug solubilizing agents to reverse the cocrystal solubility advantage over drug.  The 
particular combination and concentration of lipids/surfactants in this formulation induced this 
reversal. Lower concentrations of these lipids/surfactants would have decreased the cocrystal 
solubility advantage without reversing it.   This switch of cocrystal solubility over drug solubility 
has been shown for other cocrystals with solubilizing agents and indicates the existence of a 
cocrystal transition point.   
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Cocrystal transition points 
Figure 6.5 and Figure 6.6 show the transition points for several CBZ cocrystals in 
aqueous solutions of SLS. It is noted that two parameters characterize the transition point: (1) 
solubility at which both drug and cocrystal exhibit the same solubility (S*) and (2) solubilizing 
agent concentration (CSC).   Our previous work focused on the CSC
10-12, 18, 19
, here we will focus 
on S*.   One important observation that emerged from the present study is that aqueous solubility 
is a key indicator of the transition point.   In fact, S* as described in the theoretical section, is 
independent of the solubilizing agent, and is only determined by the drug and cocrystal aqueous 
solubilities.   
 S* values in the following analysis were obtained by a graphical method from 
experimentally measured cocrystal and drug solubility dependence on solubilizing agent 
concentrations (Figure 6.5and Figure 6.6).  These experimentally determined S* values were 
then compared with those predicted by simple equations based on knowledge of drug and 
cocrystal aqueous solubilities.   
(a)  
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(b) 
 
(c) 
 
Figure 6.5.  Transition points for CBZ cocrystals induced by solubilizing CBZ with SLS for (a) 
CBZ-SAC, (b) CBZ-4ABA-HYD, and (c) (CBZ-SUC) from reference 13.   Transition points are 
characterized by a solubility (S*) and a solubilizing agent concentration (CSC).  Both S* and 
CSC vary with cocrystal aqueous solubility and stoichiometry.  Symbols represent 
experimentally measured cocrystal () and drug () solubility values12.  
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S* 
CSC 
S* 
CSC 
(a)	 (b)	  
Figure 6.6.  Transition points for CBZ and CBZ-SLC induced by solubilizing CBZ with SLS 
from reference 13.  Transition points are characterized by a solubility (S*) and a solubilizing 
agent concentration (CSC).  Both S* and CSC vary with cocrystal aqueous solubility and 
stoichiometry.  SLC was found to influence the CMC of SLS, raising it from 6 mM (a) to 9 mM, 
(b) which had a minor impact on the CSC (20-23 mM) and no impact on S*.  Symbols represent 
experimentally measured cocrystal () and drug ()solubility values12. 
S* values determined graphically from the intersection of solubility vs solubilizing agent 
curves for drug and cocrystal (Figure 6.5 and Figure 6.6) are presented in Table 6.2.  S* is 
observed to increase with cocrystal aqueous solubility and with the molar content of drug in the 
cocrystal.   For this small series of cocrystals the range of S* is 4.6 to 47.6 mM.  S* can play an 
important role in cocrystal selection as it establishes the upper solubility limit at which a 
cocrystal has an advantage over drug in solutions with solubilizing agents.    
S* values were also predicted with the simplified equations under the assumption that 
Ks
coformer 
= 0 according to 
 
2
cocrystal,aq
drug,aq
S
S*=
S
          
for 1:1 cocrystals, and 
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 
 
3
cocrystal,aq
2
drug,aq
S
S*=
S
          
for 2:1 cocrystals at a particular solution pH. 
Scocrystal,aq and Sdrug,aq were measured in aqueous solutions without solubilizing agents at a 
particular pH (as described in the methods section).  Sdrug,aq stands for the CBZ dihydrate 
(CBZD) solubility since this is the thermodynamically stable form of CBZ under the 
experimental conditions studied.  
Results in Table 6.2 indicate that there is excellent agreement between predicted and 
observed S* values.   The largest deviation was observed for the SLC cocrystal, where coformer 
solubilization leads to a positive deviation in predicted S*.  Deviations in S* due to coformer 
solubilization are examined in a subsequent section.  
Table 6.2.  Predicted and observed S* values for CBZ cocrystals in aqueous solutions of SLS. 
a) Solubility values at 25°C from reference 13, in terms of CBZ mM. 
b) Predicted from equations (6.12) and (6.13) for 1:1 and 2:1 cocrystals with SCBZD,aq = 0.53 
mM. 
c) Determined from the intersection of Scocrystal,T and Sdrug,T curves in Figure 6.5 and Figure 6.6. 
Cocrystal pH 
Scocrystal,aq
a 
(mM) 
S*pred
b
 
(mM) 
S* exp
c 
(mM) 
CBZ-SLC (1:1) 3.0 1.32 ± 0.06 3.3 4.6 
CBZ-SAC (1:1) 2.2 2.36 ± 0.05 10.5 12.0 
CBZ-4ABA-HYD (2:1) 4.0 1.83 ± 0.02 21.8 22.0 
CBZ-SUC (2:1) 3.1 2.38 ± 0.02 48.0 47.6 
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It is instructive to apply this analysis to estimate the S* values of PTB cocrystals.  
S* values of 59 mM (PTB-CAF) and 18 mM (PTB-PIP) were predicted, from equations (6.12) 
and (6.13) with values for the aqueous solubilities of drug and cocrystals presented in Table 6.1.    
Comparing the predicted S* values with the PTB solubility in lipid-based media (1 M) reveals 
that the lipid mixture concentration used in the reported study was above the transition point for 
each cocrystal.  This is also consistent with the observed cocrystal solubilities (222 mM and 246 
mM) being lower than the PTB solubility (1 M) in the lipid formulation.    
Comparing the S* values for the CBZ and PTB cocrystals reveals that S* increases with 
cocrystal solubility for the 1:1 and 2:1 cocrystals studied.  S* values are within the range of 4.6 
to 57 mM for both CBZ and PTB cocrystals even though the aqueous solubility of CBZD is 
about 700 times higher than the solubility of PTB.  S* is inversely related to Sdrug,aq and 
proportional to Scocrystal,aq squared or cubed.  PTB cocrystals have aqueous solubilities higher than 
the CBZ cocrystals considered here, and compensate for the low aqueous solubility of PTB. 
Solubilization ratio and cocrystal transition points  
The relationships between cocrystal and drug solubilization ratios presented in equations 
(6.1) and (6.7) and Figure 6.4 are useful to predict the SRcocrystal from knowledge of SRdrug but do 
not provide information about the cocrystal transition point and particularly S*.   The question is 
how to establish where a cocrystal stands with respect to its transition point in a given 
formulation or in the presence of solubilizing agents from knowledge of SRdrug and without 
having to measure SRcocrystal.   
 214 
 
The relationship between solubilization ratio and cocrystal transition point or S* can be 
easily found by rewriting equation (6.1) for 1: 1 cocrystals as  
cocrystal cocrystal T
drug drug aqaq T drug
S S S
=
S S S
     
          
     
        (6.26) 
The criterion for the cocrystal transition point is that Scocrystal,T = Sdrug,T, therefore 
cocrystal
drug T
S
=1
S
 
  
 
           (6.27)  
and equation (6.26) becomes.   
cocrystal T
drug aqaq drug
S S *
=
S S
   
      
   
         (6.28) 
In other words, at the transition point 
drugaq cocrystalSA = SR* =SR*          (6.29)
 
and the cocrystal solubility advantage over drug in aqueous media (SAaq) is equal to the square 
root of the drug solubilization ratio, (SRdrug)
1/2
, and to the cocrystal solubilization ratio 
(SRcocrystal).  
Below the cocrystal transition point S* > Scocrystal,T > Sdrug,T which means that  
cocrystal
drug T
S
> 1
S
 
  
 
          (6.30)
 
Substituting the above equation into equation (6.26) leads to 
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cocrystal T
drug aqaq drug
S S
>
S S
   
      
   
         (6.31) 
or 
aq cocrystalSA > SR
 
which is indicative of a cocrystal that is below its transition point and thus will possess a higher 
solubility than the drug in the solubilizing media at the respective SRdrug or SRcocrystal values.  
For a 2:1 cocrystal equation (6.7) becomes  
1
3
cocrystal cocrystal T
drug drug aqaq T drug
S S S
=
S S S
     
          
     
        (6.32) 
Cocrystal is then at the transition point when  
1
3
cocrystal T
drug aqaq drug
S S *
=
S S
   
      
   
         (6.33) 
Cocrystal is below the transition point when 
1
3
cocrystal T
drug aqaq drug
S S
> 
S S
   
      
   
         (6.34) 
or  
aq cocrystalSA  > SR           (6.35) 
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Applying this analysis to DNZ cocrystals in Tween 80 and PTB cocrystals in lipid-based 
media (Figure 6.7) demonstrates the important role of cocrystal solubility advantage (SAaq = 
(Scocrystal/Sdrug)aq) in determining the position of the cocrystal solubility with respect to the 
transition point and S*.  For instance, it can be seen that both DNZ cocrystals meet the criteria 
for being below the transition point in 150 mM Tween 80 since (SA)aq > SRcocrystal.  SAaq values 
for the two DNZ cocrystals (770 and 370) are greater than their SR values (264 and 300), 
indicating that the DNZ cocrystals are below the transition point (at this concentration of Tween 
80).  PTB cocrystals are however above the transition point in the lipid mixture
28
 since (SA)aq < 
SRcocrystal for the 1:1 cocrystal (26 < 111) and (SA)aq
2
 < SRcocrystal
1/2
 for the 2:1 cocrystal (6 < 23).   
The effect of drug solubilizing agent findings are in excellent agreement with the observed 
cocrystal and drug solubilities with respect to the transition point.  
 
Figure 6.7.  Measured solubilities for DNZ and PTB and their cocrystals in solubilizing agents:  
Tween 80 aqueous solution (150 mM, pH 5.0) for DNZ and lipid mixture for PTB.  How to 
determine where a cocrystal stands with respect to its transition point in a given formulation or in 
the presence of solubilizing agents from knowledge of SRdrug and without having to measure 
SRcocrystal is described in the text.  Numbers in parentheses represent SR values, and numbers 
within the lines represent SAaq.  Transition point solubilities, S*, were calculated from equations 
(6.12) and (6.13) for 1:1 DNZ and PTB cocrystals and the 2:1 PTB-PIP cocrystal with the 
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measured values of Sdrug,aq and Scocrystal,aq presented in the plot.  PTB data obtained from 
references
26-28
. 
S* values were also calculated for the DNZ and PTB cocrystals according to equations 
(6.12) and (6.13).  Whether a cocrystal is above or below the transition point in a given 
formulation can be determined by comparing the S* values with the cocrystal solubilities in the 
drug solubilizing media.  S* values are between 16 and 94 mM indicating the adjustments that 
could be made in drug solubilizing agent concentration to move closer to or further away from 
the transition point.   
Influence of coformer solubilization 
Deviations in SRcocrystal for a 1:1 cocrystal due to coformer solubilization are accounted 
for by a factor ε and equation (6.1) for a 1:1 cocrystal becomes 
 cocrystal drugSR = ε SR          
For a monoprotic weakly acidic coformer, 
 
 
pH-pKa,coformer coformer
s
pH-pKa,coformer
1+10 +K [M]
ε = 
1+10
        
When Ks
coformer
 = 0, ε = 1 and SRcocrystal can be accurately predicted from SRdrug using equation 
(6.1).  However, as shown in Figure 6.4a, the observed SRcocrystal values are higher than those 
predicted from SRdrug using equation (6.1)  for DNZ-HBA and DNZ-VAN in 150 mM Tween 80, 
and IND-SAC at increasing concentrations of Tween 80, Brij 99, Myrj 52.  In these conditions, 
Ks
coformer
 > 0 and ε >1, leading to an underprediction of SRcocrystal when ε is ignored.  
ε can also be obtained from  
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cocrystal,observed
cocrystal,predicted
SR
ε  = 
SR
          (6.36) 
where SRcocrystal is predicted from equation (6.1) assuming Ks
coformer 
= 0.  Table 6.3 shows the ε 
values obtained using equations (6.18) and (6.36). 
Table 6.3.  SRcocrystal deviations due to coformer solubilization. 
Cocrystal pH 
Solubilizing 
agent 
(Ks
coformer
)
a 
(mM
-1
)
 
[solubilizing 
agent]
b
 (mM) 
ε1/2 predc ε1/2 expd 
DNZ-VAN 5.02 Tween 80 0.0283±0.0009 150 2.28 2.14 
DNZ-HBA 4.42 Tween 80 0.031±0.001 150 1.87 1.88 
IND-SAC 2.1 Myrj 52 0.083±0.007 100 1.73 1.72 
IND-SAC 2.1 Tween 80 0.059±0.003 124 1.66 1.69 
IND-SAC 2.1 Brij 99 0.058±0.004 121 1.64 1.70 
IND-SAC 2.1 SLS 0.008±0.002 199 1.18 1.17 
a) Ks
coformer
 for HBA, VAN experimentally measured and SAC reported in reference 21.  
b) Solubilizing agent concentration is the highest concentration studied for each system. 
c) Predicted using equation (6.18) with pKa HBA = 4.48, pKa VAN = 7.4, and pKa SAC = 1.6. 
d) Calculated using equation (6.36).   
 
The ε values from the two methods are in excellent agreement.  Ignoring ε can lead to 
underpredicting SRcocrystal by as much as 2 fold for solubilizing agents and high concentrations 
and/or high Ks
coformer
 values. 
S* is influenced by coformer solubilization to a greater extent than SR.  While SR has a 
square root dependence on ε, S* for a 1:1 cocrystal is proportional to ε, as described by: 
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 
2
cocrystal,aq
drug,aq
S
S* = ε
S
          
where ε has the same definition as in equation (6.18) for a monoprotic weakly acidic coformer.   
 ε can also be obtained from 
observed
predicted
S*
ε = 
S*
           (6.37) 
where S* is predicted using equation (6.12) assuming Ks
coformer
 = 0. Table 6.4 shows the ε values 
obtained using equations (6.18) and (6.37). 
Table 6.4.  S* deviations due to coformer solubilization for CBZ-SLC and CBZ-SAC. 
a) Values reported in reference 13. 
b) Predicted using equation (6.18) and pKa SLC = 3.0 and  pKa SAC = 1.6.  
c) Calculated using equation (6.37). 
 
The sensitivity of S* to ε is shown in Figure 6.8 for CBZ cocrystals.   
 
Cocrystal pH 
(Ks
coformer
)
a 
(mM-1) 
[SLS] at CSC
a 
(mM) 
ε predb ε expc 
CBZ-SLC (1:1) 3.0 0.06 23 1.44 1.40 
CBZ-SAC (1:1) 2.2 0.013 44 1.10 1.14 
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Figure 6.8.  The influence of ε in SLS on S* at varying Scocrystal,aq for CBZ-SLC (), CBZ-SAC 
(), CBZ-4ABA-HYD (), CBZ-SUC ().  S* is simulated using equation (6.19) for 1:1 
(
_____
) and (6.13) for 2:1 (----) cocrystals and Sdrug,aq = 0.53 mM, solubilizing agent is SLS.  ε 
values are 0, 1.10, and 1.44 (calculated values for CBZ-SAC and CBZ-SLC in Table 6.4), and 0 
for 2:1 cocrystals since neither SUC or 4ABA were reported to be solubilized in SLS
12
.  
 
Figure 6.8 reveals the great influence that Scocrystal,aq has on S* for a given drug.  For 
example, for a hypothetical 1:1 cocrystal of CBZ (Sdrug,aq = 0.53) with a Scocrystal,aq of 1 mM, the 
S* is 1.9 mM.  If the Scocrystal,aq is doubled to 2 mM, the S* increases by a factor of 4 and is 7.5 
mM.  For a 2:1 cocrystal, the influence is even greater.  For a hypothetical 2:1 cocrystal of CBZ 
with Scocrystal,aq of 1 mM, S* is 3.6 mM.  For Scocrystal,aq of 2 mM, S* increases by a factor of 8 to 
28 mM. 
Apart from the dependence of S* on Scocrystal,aq, Figure 6.8 also shows the influence of ε 
on S* for CBZ cocrystals.  The S* values for CBZ cocrystals are well predicted when ε is taken 
into account for SAC and SLC which have nonzero Ks
coformer
 values in SLS as shown in Table 
6.4. 
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Conclusions 
In this chapter, we present a theoretical framework that allows for the simple and 
quantitative prediction of cocrystal solubilization ratio from drug solubilization ratio when 
coformer solubilization is negligible.  SRdrug values are commonly measured parameters that can 
help guide cocrystal selection and formulation using the presented equations.  While mechanism-
based models that predict cocrystal solubility in the presence of solubilizing agents from relevant 
equilibrium constants have been previously developed, we present here simplified models that 
allow for the prediction of Scocrystal,T from only SRdrug and Scocrystal,aq.  
The concept of a critical transition point solubility S* is developed, where drug and 
cocrystal have equal solubilities in the presence of an additive.  S* is only dependent on the 
aqueous solubilities of the cocrystal and constituent drug and is independent of the nature and 
concentration of the additive, which to our knowledge has not been presented previously in the 
literature.  S* represents the maximum cocrystal solubility in any formulation, above which the 
cocrystal no longer has a solubility advantage over the drug.  The relationship between 
solubilization ratio, aqueous cocrystal solubility advantage, and transition points is described.  
Whether a cocrystal will be above or below (thermodynamically stable or unstable) in a given 
formulation can be predicted from simple equations that relate the cocrystal aqueous solubility 
advantage to the drug solubilization ratio. 
Lastly, a method of quantifying the deviation in SR and S* due to coformer solubilization 
is derived.  A term (ε) for is described, which can be incorporated into the simple models for SR 
and S* when Ks
coformer
 ≠ 0.  These findings allow for the facile calculation of important 
parameters that can guide cocrystal formulation development using simple equations and 
commonly reported drug solubility descriptors. 
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CHAPTER 7  
CONCLUSIONS AND FUTURE WORK 
This dissertation has explored the mechanisms of cocrystal solubilization by solubilizing 
agents and the impact on cocrystal solubility, Scocrystal/Sdrug, and transition points.  The objectives 
of this work were to (1) understand the effect of solubilization by physiologically relevant 
solubilizing agents on cocrystal solubility, Scocrystal/Sdrug, and dissolution behavior, (2) develop 
mathematical models to describe cocrystal solubility and Scocrystal/Sdrug based on cocrystal 
dissociation and constituent ionization and micellar solubilization solution equilibria, (3) expand 
these models to consider the combined effect of multiple solubilizing agents, and (4) develop 
simplified models that allow for the facile estimation of cocrystal solubilization ratio and 
transition points from commonly reported drug physicochemical and solubility descriptors.  
Overall, this work pursued enhanced understanding of cocrystal solubilization by drug 
solubilizing agents based on equilibria that describe cocrystal constituent interactions in solution. 
A theoretical framework that results in the simple and quantitative prediction of cocrystal 
solubilization ratio (SRcocrystal) from drug solubilization ratio (SRdrug) when coformer 
solubilization negligible was derived.  SRcocrystal was up or orders of magnitude lower than SRdrug 
due to preferential solubilization of the drug constituents over the coformer contituents.  These 
models were validated for a set of seven cocrystals comprised of constituents with diverse 
ionization and micellar soluiblization properties in the presence of fed state simulated intestinal 
fluid (FeSSIF).  Additionally, more rigorous models that consider relevant equilibrium constants 
for the cocrystal, drug and coformer were derived to predict cocrystal solubility in FeSSIF from 
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cocrystal Ksp measured in aqueous buffer, and cocrystal component ionization (Ka) and total 
micellar solubilization constants at a given pH (Ks
T
) for these systems.  These models allow for 
the accurate prediction of SRcocrystal or cocrystal solubility in a solubilizing agent of interest 
without carrying out the experiment, which can be useful if cocrystal material is sparing.   
Cocrystals were discovered to exhibit significantly lower solubility advantages 
(Scocrystal/Sdrug) in FeSSIF compared to aqueous buffer due to preferential solubilization of the 
drug constituent, with cocrystals of more hydrophobic and highly solubilized drugs exhibiting 
the largest decreases in Scocrystal/Sdrug.  Mechanism-based mathematical models to predict 
Scocrystal/Sdrug were in good agreement with the experimentally measured Scocrsytal/Sdrug values for a 
diverse series of cocrystals with Scocrystal/Sdrug ranging from 660 to 3.9 in aqueous buffer.  Up to a 
23 fold decrease in Scocrystal/Sdrug was observed for the danazol-hydroxybenzoic acid cocrystal 
(DNZ-HBA) of the highly solubilized drug danazol (DNZ).  The effect of Scocrystal/Sdrug reduction 
due to preferential solubilization by FeSSIF on cocrystal powder dissolution profile was 
examined for indomethacin-saccharin (IND-SAC) and piroxicam-saccharin (PXC-SAC).  The 
decreased Scocrystal/Sdrug resulted in sustained supersaturated drug concentrations and slower 
transformation to drug in FeSSIF compared to aqueous buffer for both cocrystals. The 
Scocrystal/Sdrug values measured at the eutectic point in FeSSIF and buffer were good indicators of 
the dissolution behavior for these systems.  Scocrystal/Sdrug can be predicted from the presented 
models, and these values can be used to anticipate cocrystal dissolution and transformation 
behavior in a variety of surfactant solutions as long as the drug solubility and the cocrystal Ksp, 
and drug and coformer Ka and Ks
T
 values are known. 
Models that describe the relationship between log SRcocrystal and log SRdrug in FeSSIF for 
the purpose of comparing the correlation between log SR by a solubilizing agent and drug 
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hydrophobicity (as described by octanol-water distribution coefficient log D) for drugs and 
cocrystals were derived.  The log SRcocrystal exhibited a weaker dependence on drug log D 
compared to log SRdrug, which was predicted from the derived models.  Log SRcocrystal can be 
calculated simply from knowledge of drug log D if a robust log SRdrug-log D linear regression 
correlation is calculated from experimentally measured SRdrug values.  These models are valuable 
since SRdrug and log P and/or log D are commonly measured and reported drug properties.   
Theoretical relationships that describe cocrystal solubility and Scocrystal/Sdrug in the 
presence of multiple surfactants assumed to mix ideally were derived for the first time.  The 
solubility of DNZ-HBA and danazol-vanillin (DNZ-VAN) in the presence Tween 80 and FeSSIF 
was quantitatively predicted from cocrystal Ksp and cocrystal component Ka values reported in 
the literature and Ks
T
 values determined from drug and coformer solubility measurements in 
Tween 80 and FeSSIF independently.  Preferential solubilization of DNZ resulted in a dramatic 
decrease in Scocrystal/Sdrug as Tween 80 concentration increases, but this effect was dampened in 
the presence of FeSSIF, particularly at low Tween 80 concentrations.  Decreased Scocrystal/Sdrug 
for DNZ-VAN in FeSSIF + 150 mM Tween 80 resulted in higher drug concentrations and 
metastable high supersaturations during dissolution compared to FeSSIF alone.  These models 
are useful to anticipate the solution behavior of cocrystal drug products, where cocrystalline 
phases are in the presence of multiple additives in solution.   
The concept of a critical transition point solubility S* was developed, where drug and 
cocrystal have equal solubilities in the presence of a solubilizing agent.  It was demonstrated that 
S* is only dependent on the aqueous solubilities of the cocrystal and constituent drug and is 
independent of the nature and concentration of the additive.  The relationship between SRcocrystal, 
Scocrystal/Sdrug, and transition points was investigated.  Simple equations that relate the cocrystal 
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Scocrystal/Sdrug in aqueous solution to SRdrug allow for the facile prediction of a cocrystal’s position 
on a phase diagram relative to the transition point.  A method of quantifying the deviation in SR 
and S* due to coformer solubilization was derived.  A term (ε) for was described, which can be 
incorporated into the simple models for SR and S* when coformer solubilization is not negligible  
These findings allow for the calculation of important parameters that can guide cocrystal 
formulation development using simple equations and commonly reported drug solubility 
descriptors. 
The findings in this work have implications for the development of cocrystals as efficient 
strategies to enhance the oral delivery of water insoluble drugs.  Cocrystal solid and solution 
chemistry provides precise control over solubility and dissolution properties that can be used to 
optimize oral drug absorption.  Quantitative mathematical relationships established in this work 
allow for the preliminary prediction of cocrystal solubility in physiologically relevant and 
synthetic solubilizing agents, but further work is needed to fully realize the potential of 
cocrystals to enhance oral delivery.  Cocrystals are supersaturating drug delivery systems, and 
methods of optimizing their supersaturation and transformation kinetics are still lacking.  Now 
that mechanism-based models describing cocrystal solution behavior in equilibrium conditions 
have been established, predictive models for dissolution in physiologically relevant media, where 
cocrystal may undergo solution-mediated transformation to drug are critical.  The influence of 
cocrystal solution chemistry on drug permeability and absorption also remains to be established, 
and application of this knowledge will allow accurate in vivo absorption and bioavailability 
predictions to be made. 
 Experimentally, the equilibrium cocrystal aqueous solubility of highly soluble cocrystals 
is accessed at the eutectic point in this work.  The presence of excess coformer in solution 
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decreases cocrystal solubility to an experimentally accessible equilibrium point where cocrystal 
and drug solid phases are in equilibrium in solution, from which the stoichiometric solubility in 
the absence of excess coformer can be calculated.  However, the excess coformer in solution can 
result in altered pH conditions and solution nonidealities when concentrations are sufficiently 
high.  The stoichiometric solubility of highly soluble cocrystals can also be accessed by 
measurement in the presence of solubilizing agents.  When solubilizing agents are present in 
concentrations higher than the critical stabilization concentration (CSC), the cocrystal is 
thermodynamically stable and the solubility can be measured by traditional slurry solubility 
measurement methods.  The stoichiometric solubility in the absence of solubilizing agent can be 
calculated from knowledge of drug and coformer solubilization properties in the solubilizing 
agent.  Thorough comparison of these two methods of accessing the equilibrium cocrystal 
solubility of unstable cocrystals is yet to be established.  Knowledge of which method is 
preferable in particular experimental conditions can lead to more accurate cocrystal solubility 
measurement. 
